Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives

ABSTRACT

The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.

FIELD OF THE INVENTION

The present invention relates to pharmaceutical compositions of variouspharmaceutical actives containing Diethylene glycol monoethyl ether orother alkyl derivatives thereof as a primary vehicle and/or topharmaceutical compositions utilizing Diethylene glycol monoethyl etheror other alkyl derivatives thereof as a primary vehicle or as a solventsystem in preparation of such pharmaceutical compositions. The presentinvention especially relates to pharmaceutical compositions oflipophilic and hydrophilic actives containing Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleand/or to pharmaceutical compositions utilizing Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor as a solvent system in preparation of such pharmaceuticalcompositions. The pharmaceutical compositions of the present inventionare safe, non-toxic, exhibits enhanced physical stability compared toconventional formulations containing such pharmaceutical actives and aresuitable for use as injectables for intravenous and intramuscularadministration, as well as for use as a preformed solution/liquid forfilling in and preparation of capsules, tablets, nasal sprays, gargles,dermal applications, gels, topicals, liquid oral dosage forms and otherdosage forms.

BACKGROUND OF THE INVENTION

Formulation of various pharmaceutical actives, especially lipophilicactives is a problem because many such actives are difficult tosolubilize, by virtue of their poor solubility; because manyformulations containing such actives have poor stability and hence aredifficult to manufacture and in many instances require such formulationsto be lyophilized or freeze dried; and because many formulationscontaining such actives are required to be formulated as emulsions andhence difficult to manufacture. This is especially true for formulationsof such actives in the form of injectables, capsules, gargles, solutionsetc and other dosage forms. Preparation of various lipophilic drugs thatare poorly soluble or insoluble in water/other solvents in solublepellucid has been a continuing problem in the art.

Examples of such pharmaceutical actives, useful in various physiologicalconditions to alleviate the pathology caused due to various diseaseconditions are the following, which are not restrictive and a person ofskill in the art may select other compounds which fall into theaforementioned categories:

I) Steroids and Hormones;

II) Antimalarial agents;

III) Proton Pump Inhibitors; IV) Analgesic Agents (NSAIDs and NarcoticAnalgesics); V) COX 2 Inhibitors; VI) Hypnotic Agents; VII) AntifungalAgents; VIII) Oxicams; IX) ACE Inhibitors; X) Muscle Relaxants; XI)Antibiotics; XII) Aldosterone Receptor Antagonists; XIII) CardiovascularAgents; XIV) Calcium Channel Blockers; XV) Anti-arrhythmic Agents;

XVI) Cardiac Glycosides and other Drugs related to CVS;

XVII) Antipsychotic Agents; XVIII) Anticonvulsants; XIX) Diuretics; XX)Anticancer Agents; XXI) Immunosuppressants; XXII) Vitamins and Minerals;and XXIII) Peptides

In the past, numerous agents have been used to solubilize variouscategories of drugs. The use of organic solvents like Acetone, Methanol,Ethyl acetate, Tetrahydrofuran, Chloroform, Hexane, etc., for theirsubsequent use either as oral or injectable (intramuscularly orintravenously) is prohibited.

Use of oil and its derivatives has its limitations as these are derivedfrom plant origin like sesame oil, cottonseed oil etc., which posesstability problems because their quality changes with season, may getunstable/rancid as well as their bulky viscous nature result in pain andfurther complication during application at the injecting site.

Manufacture of injectables using oil and its derivative also leads toproblems from a quality control point of view. The tendencies ofseasonal changes in oil quality (rancidity) and color change wereproblems encountered by manufacturing chemists. The pesticide residuefrom oil of natural origin is a potential risk factor for injectableforms. Further sterilization and difficulties during filtration are theadded secondary problems.

Use of emulsions for solubilizing various drugs was also attempted. Butthe stability of emulsions, its particle size and sterility resulted inhigh cost of production. Moreover, various technologies are developedfor administration in the injectable form and also pose the problems ofpain at the site of the injection.

The abovementioned factors limit the use of oil as well as oil/wateremulsions as solubilizing agents for the preparation of variouscategories of active drugs. Moreover, some of the derivatives of oilcause anaphylactic shocks and histamine release, thus reducing theirusage.

The use of fatty acids and its derivative also requires special qualitycontrol and their therapeutic use in oral and injectable forms aretherefore limited. Use of polyethylene glycol derivatives are quite highbut there are limitations to their use as they can be administered up tocertain levels only and are toxic at higher levels. Thus they becomespecific either for oral or local applications and their use is limitedin injectables.

Further, the problems associated with oil-based injections are many,such as for instance a small test dose prior to actual administration isusually required to confirm tolerability of both active and oilyvehicle; it causes pain, erythema and swelling at the site of injection;it leads to nodule formation at the site of injection; it is associatedwith a risk of damage to nerves, arteries or veins if improperly givenor administered; if side effects occur they would be prolonged untilplasma levels fall—hence the necessity for a test dose; it can takeseveral weeks for plasma levels to reach steady state; injectiontechnique competency, assessment and training are required; there arelogistical difficulties for administering to a patient who is employed;there is a need for stabilizers and preservatives in larger amounts insuch formulations for maintaining stability of the oily injections; somepeople have dislike or phobia of pain from the needles of suchinjectables; there could be staffing and medicine storage issues; it isviewed by some as stigmatizing and coercive, etc.

It is also found that there are some drugs available in the lyophilizedform and the doctor/physician requires other pack of solvents toreconstitute before an administration. The technique of lyophilizationis a costly process and unviable, leading many of such drugsuneconomical to patients.

Many drugs that are oil soluble have limited application as only to beadministered intramuscularly and not used for ocular or intravenouspurpose.

Complications associated with intramuscular injections are also many,such as they cause skin and tissue trauma; muscle fibrosis andcontracture; nerve palsies, paralysis; anaphylactic shock; formation ofthrombosis in veins; thrombo phlebitis; can involve infectious processesand cause abscesses or gangrene.

The formulation of drugs used for application as “Eye drops” in form ofsuspension/emulsions is limited because of their limited solubility inthe aqueous media. Quality control attributes like stability,particulate matter, particle size etc., for such emulsions andsuspensions, are the problems that are encountered by chemists duringtheir preparation and application as “Eye drops”.

The problems associated with parenteral suspension formulations are alsomany, such as typically they limit the formulator in selecting theingredients, which are parenterally acceptable as suspending agents,viscosity inducing agents, wetting agents and preservatives; they aredifficult to manufacture—special facilities are required to maintainaseptic conditions for manufacturing such as crystallization, particlesize reduction, wetting, sterilization etc.; stability of theformulations during the period between manufacture and use resulting inmany occasions in settlement of solids, caking, causing difficulty inredispersion etc.; difficulty in maintenance of physical stability;non-uniformity of dose at the time of administration; vials to be shakenfor uniformity prior to use; necessity of ensuring or ruling out ofclumping or granular appearance of the suspension before withdrawinginto syringes; after withdrawal, the injections are to be applied assoon as possible before its starts settling in the syringe, with theresult that the entire problems can be an issue for thedoctor/physician.

Many drugs for solubilization require milling or micronization toenhance the solubility in the solubilising agents. For instance,steroids require micronisation to solubilise in oil or its derivativesor in a co-solvent. The use of co-solvents or other additives in oiltype product adds up difficulty in administration due to viscosity andmay also cause hemolysis if not used in appropriate acceptableconcentration in the body particularly for the parenteral preparation.

Thus the formulation of a clear solution of drugs for therapy has alwaysbeen challenge with the need of a solubilizer to give clear solution.

It is known that ethanol is often used in varying amounts upto 50-60%for solubilization of many drugs during their preparation. However, ifit is used for therapeutic application in the concentration throughintravenous, intramuscular or for oral delivery, then it may lead tointoxication leading to its restrictions.

The use of Propylene Glycol is also limited. The safety regarding itsparenteral application is only up to 40%, that too also throughIntramuscular route and is considered as hemolytic and toxic at higherconcentration to the central nervous system. The formulation containing30% Propylene Glycol which has been used is known to cause hemolysis inhumans. Hemolysis, CNS depression, hyperosmolality, and lactic acidosishave been reported after I.V. administration of Propylene glycol[NTP-CERHR Monograph on the Potential Human Reproductive andDevelopmental Effects of Propylene Glycol (March 2004) NIH Pub. No.04-4482 Page II-30] Propylene glycol is viscous with a viscosity of 58.1cps, thus limiting their use in IM/IV formulation and is not known forthe Intravenous administration. (Handbook of Pharmaceutical Excipients,3^(rd) Edition by Dr. Arthur H. Kibbe, Page No. 443)

Cyclodextrins and its advanced derivatives are used in the formulationfor solubilizing by the process of complexation of lipophilic compounds.Because of its toxicity, their use is limited. When administered, it isun-metabolized and accumulates in kidney as the insoluble cholesterolcomplexes resulting in severe nephrotoxicity and hence it has been usedprimarily for oral purpose. Questions always arise on safety whenCyclodextrin derivatives are administered parenterally (Handbook ofPharmaceutical Excipients, 3^(rd) Edition by Dr. Arthur H. Kibbe, PageNo. 165). Also the molecular weight of β-cyclodextrin is more than 1000and hence after administration it could lead to problems of excretionwith or without causing damages to kidney or any functions of the organin the body.

Glycofurol is cyclic glycol derivative used nowadays as solubilisersolvent in parenteral products for intravenous or intramuscularinjection in concentration up to 50% v/v. It has viscosity of 8-18 Cpswhich may also attribute to cloudiness when miscible in water. It isirritant when used undiluted; its tolerability is approximately the sameas propylene glycol. Glycofurol has found to have effect on liverfunction. (Handbook of Pharmaceutical Excipients, Raymond C. Rowe, 5thEdition Page. No. 313). Central nervous system toxicity was alsoobserved when given by intravenous (I.V.) injection. Necrosis of tissuewas even observed when it was given intramuscularly (I.M.) ChremophorEl® (Trademark for a polyoxy-ethylene castor oil derivative), asurfactant was also used to solubilize poorly soluble drugs, which wasfound to have acute anaphylactoid reaction after initiation ofintravenous fusion. It was a result due to improper mixing of thisvehicle in parenterals and hence different mixing techniques were usedto assess their effect on the distribution of Chremophor EL in thesolution. This led to problem in parenteral formulation of variousactives with this solubilizer and time is required for developing aproper technique for mixing of this solubilizer which limits its use inparenterals with non-safe toxic profile. Due to safety issues, it isused carefully as exceptional use and last resort as drug solubilisingagent (eg. Pacltaxel injection, where balance of convenience suggestsits use for terminal therapy of cancer verses anaphylaxis).

Ethyl oleate/Oleic acid ethyl ester is used nowadays for lipophiliccompounds and for steroids as vehicle in certain parenteral preparationsintended for intramuscular and subcutaneous administration. It is anoily liquid with viscosity of 3.9 Cps at 25° C., less viscous than fixedoils. It is found that it remains clear at 5° C., but darkens in coloron standing, so antioxidants are to be added frequently to extend shelflife. Thus addition of group of antioxidants as well as use of amberbottle is required to protect it from light. This increases the cost offormulation by taking control on above factor of packing, stability(Handbook of Pharmaceutical Excipients, Raymond C. Rowe, 5th EditionPage. No. 274).

U.S. Pat. No. 4,628,053 relates to stabilized injection solutions ofPiroxicam in which propylene glycol, ethanol and water as the solventfor parenteral administration, which might be viscous and painful at thesite of injection.

U.S. Pat. No. 4,824,841 relates to a process for the transformation ofPiroxicam into an hydrated form suitable for Oral, topic or parenteraladministration.

U.S. Pat. No. 4,942,167 discloses aqueous pharmaceutical formulationcontaining lyophilized Piroxicam in Glycine as vehicle which is nottransparent solution and stability can be issue.

U.S. Pat. No. 5,420,124A relates to an injectable Piroxicam potassiumcomposition which contains triethyleneglycol as a solvent andstabilizer.

WO/1996/041646 disclose a pharmaceutical composition in the form of anaqueous solution or in the form of a product for reconstitution as anaqueous solution, for parenteral administration or ophthalmicadministration, comprising Lornoxicam or a pharmaceutically acceptablesalt thereof and a cyclodextrin selected from the group consisting ofhydroxypropylated or sulphoalkylated derivatives of alpha, beta or gammacyclodextrin.

Chinese Patent No. CN 101327193 relates to Lornoxicam freeze-driedpowder injection and a preparation method thereof. The freeze-driedpowder injection comprises Lornoxicam, mannite, tromethamine, EDTA andpH regulator.

From all the above limitations, it is apparent that there is need for asolvent, which is safe and non-toxic, which can be employed as a vehiclefor preparation of pharmaceutical compositions in an efficient waythrough an economical process and being beneficial in treating mammals.

The present inventors have surprisingly found that most, if not all ofthe limitations/problems/concerns associated with the conventionalformulations of various pharmaceutical actives, especially lipophilicactives can be overcome by employing Diethylene glycol monoethyl etheror other alkyl derivatives thereof as a primary vehicle or as a solventin formulation of pharmaceutical compositions containing suchpharmaceutical actives. Diethylene glycol monoethyl ether or other alkylderivatives thereof are versatile enough to be accepted as vehicles foruse in various drug delivery systems. It has been tested for its safetyand toxicity and is reported to be safe for its therapeutic use throughvarious routes of administration. Presently the ethyl derivative is invogue, but use of methyl or any other alkyl derivatives may also beused.

The structure of Diethylene glycol monoethylether is as given below:

It is less viscous and safe. It has inherent viscosity of about 3.11cps. It is soluble in water. The density of Diethylene glycol monoethylether is 0.985 to 0.991. Diethylene glycol monoethyl ether is less densethan water thereby making it easily flowable. As the compound has lessviscosity it can be used for preparations of compositions which arehaving an easy syringability and thus advantageous to withdraw fromvials or ampoules by the healthworkers. Further the same advantageoffers doctors with its less painful impact and also less volume ofliquid could be administered for the drug products in the therapeuticconcentration through parenteral routes.

U.S. Pat. No. 5,837,714 discloses solid pharmaceutical dispersionscomprising a poorly soluble drug substance, as SR48692 or Naproxen,Xylitol and Diethylene glycol monoethyl ether, and a method of preparingsuch dispersions comprising the steps of dissolving the poorly solubledrug substance in Diethylene glycol monoethyl ether and adding thesolution to Xylitol. The dispersions exhibit good pharmaceuticalproperties and reduced levels of impurities and degradation products.

U.S. Patent Application No. 20100056982A1 teaches the photodynamictreatment of acne vulgaris. The method involves the topicaladministration of a photosensitizer composition comprising hydrophobicgreen porphyrins such as Lemuteporfin, Polyethylene glycol and skinpenetration enhancers such as Oleyl alcohol and Transcutol™ toacne-affected skin and subsequent exposure of that skin to energy of awavelength of activating the photosensitizer.

U.S. Patent Application No. 20100010059A1 teaches partially based on adiscovery that an oral formulation containingN-(3-methylisothiazol-5-yl)-2-[1-(3-methylisoxazol-5-ylmethyl)-1H-indol-3-yl]-2-oxoacetamideunexpectedly enhances the oral bioavailability of the compound. In oneaspect, this invention features an anticancer formulation, whichcontains d-alpha-Tocopheryl Polyethylene glycol 1000 succinate (“TPGS”),2-(2-ethoxyethoxy)ethanol (“Transcutol”); and an effective amount of acompound of formula

WO 97/03698 teaches for Transdermal therapeutic system (TTS) having abacking film, having an acrylate-based pressure sensitive adhesivehaving a hormone content and a content of absorption accelerators andhaving a protective film, wherein the hormone content is provided by acontent of an oestrogen and/or gestagen and/or androgen, and wherein theabsorption accelerators are the two substances Oleic acid and2-(2-ethoxyethoxy)-ethanol.

U.S. Pat. No. 5,552,153 teaches a pharmaceutical composition fortransdermal delivery comprising an effective amount of an activeingredient selected from a Benzodiazepine and a Benzodiazepineantagonist; Ethanol; Caprylic acid; and Oleic acid. Additionally, thecomposition may contain Silicon fluid, Benzyl alcohol, and Diethyleneglycol monoethyl ether or Dimethyl sulfoxide.

U.S. Pat. No. 5,998,392 teaches about the improved compositions ofBenzoyl peroxide and methods of processing Benzoyl peroxide. Moreparticularly, the invention relates to the use of a composition such asTranscutol®. Diethylene glycol monoethyl ether as a processing aid formaking a new benzoyl peroxide premixture which can be admixed with anaqueous medium to make a new benzoyl peroxide flocculent composition.

U.S. Pat. No. 5,741,512 teaches with the Pharmaceutical compositionscomprising Cyclosporin, e.g. Cyclosporin as “microemulsionpre-concentrate” and microemulsion form. The compositions typicallycomprise a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether ofa low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol orGlycofurol, as hydrophilic component. Compositions are also providedcomprising a cyclosporin and, suitably, also a saccharide monoester,e.g. raffinose or saccharose monolaurate. Dosage forms include topicalformulations and, in particular, oral dosage forms.

Objects of the Invention

An object of the present invention is to provide pharmaceuticalcompositions of various pharmaceutical actives containing Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent.

Another object of the present invention is to provide pharmaceuticalcompositions of various lipophilic and hydrophilic actives containingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent.

Yet another object of the present invention is to provide use ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or as a solvent in preparation of pharmaceuticalcompositions containing various pharmaceutical actives.

Still another object of the present invention is to provide use ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or as a solvent in preparation of pharmaceuticalcompositions containing various lipophilic and hydrophilic actives.

Another object of the present invention is to utilize Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor solvent for formulation of pharmaceutical actives which are difficultto solubilize in physiologically acceptable solvents.

Yet another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of lipophilic and hydrophilic activeswhich are difficult to solubilize in physiologically acceptablesolvents.

Still another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of pharmaceutical actives whichexhibit instability when compounded with an aqueous phase.

Another object of the present invention is to utilize Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor solvent for formulation of lipophilic and hydrophilic actives whichexhibit instability when compounded with an aqueous phase.

Yet another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of pharmaceutical actives which aredifficult to solubilize in physiologically acceptable solvents andrequire to be formulated as oily injections.

Still another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of lipophilic and hydrophilic activeswhich are difficult to solubilize in physiologically acceptable solventsand require to be formulated as oily injections.

Another object of the present invention is to utilize Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor solvent for formulation of pharmaceutical actives which are difficultto solubilize in physiologically acceptable solvents and require to beformulated as emulsions.

Yet another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of lipophilic and hydrophilic activeswhich are difficult to solubilize in physiologically acceptable solventsand require to be formulated as emulsions.

Still another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of pharmaceutical actives which arefree from oil and related matters.

Another object of the present invention is to utilize Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor solvent for formulation of lipophilic and hydrophilic actives whichare free from oil and related matters.

Yet another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of pharmaceutical actives which areless viscous, less dense and more transparent than oily injectionscontaining such pharmaceutical actives.

Still another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of lipophilic and hydrophilic activeswhich are less viscous, less dense and more transparent than oilyinjections containing such lipophilic actives.

Another object of the present invention is to utilize Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor solvent for formulation of pharmaceutical actives which results inless pain when injected compared to that caused by administration ofoily injections containing such pharmaceutical actives.

Yet another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of lipophilic and hydrophilic activeswhich results in less pain when injected compared to that caused byadministration of oily injections containing such lipophilic actives.

Still another object of the present invention is to utilize Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent for formulation of pharmaceutical actives which canbe easily administered by doctors/physicians/nurses.

Another object of the present invention is to utilize Diethylene glycolmonoethyl ether or other alkyl derivatives thereof as a primary vehicleor solvent for formulation of lipophilic and hydrophilic actives whichcan be easily administered by doctors/physicians/nurses.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which are easy to manufacture, do notinvolve any lengthy and tedious manufacturing steps, which are viableand economical.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which are easy tomanufacture, do not involve any lengthy and tedious manufacturing steps,which are viable and economical.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which do not cause side effects; which donot cause pain, erythema, swelling at the site of injection; which donot cause damage to nerves, arteries or veins; and which does notrequire a test dose to be given to the patient prior to actualadministration.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause sideeffects; which do not cause pain, erythema, swelling at the site ofinjection; which do not cause damage to nerves, arteries or veins; andwhich does not require a test dose to be given to the patient prior toactual administration.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause logisticaldifficulties when administered to a patient who is in employment; whichdoes not have staffing and medicine storage issues; and which is notstigmatizing or coercive to a patient.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause logisticaldifficulties when administered to a patient who is in employment; whichdoes not have staffing and medicine storage issues; and which is notstigmatizing or coercive to a patient.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which do not contain stabilizers orpreservatives in large amounts for maintaining the stability of thecompositions.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which do notcontain stabilizers or preservatives in large amounts for maintainingthe stability of the compositions.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which do not cause skin and tissue trauma;muscle fibrosis and contracture; nerve palsies; paralysis; anaphylacticshock; formation of thrombosis in veins; thrombo phlebitis; andabscesses or gangrene, when administered intramuscularly.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause skin andtissue trauma; muscle fibrosis and contracture; nerve palsies;paralysis; anaphylactic shock; formation of thrombosis in veins; thrombophlebitis; and abscesses or gangrene, when administered intramuscularly.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which does not require specialfacilities to maintain aseptic conditions for manufacturing such ascrystallization, particle size reduction, wetting, sterilization etc.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which does not require specialfacilities to maintain aseptic conditions for manufacturing such ascrystallization, particle size reduction, wetting, sterilization etc.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, wherein the stability of the compositionsduring the period between manufacture and use does not result insettlement of solids, caking, difficulty in redispersion etc.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, wherein thestability of the compositions during the period between manufacture anduse does not result in settlement of solids, caking, difficulty inredispersion etc.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, wherein there is uniformity of dose at thetime of administration and vials need not be shaken for uniformity priorto use.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, wherein there is uniformity ofdose at the time of administration and vials need not be shaken foruniformity prior to use.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which need not be applied assoon as possible to avoid settling in the syringe and do not cause anissue for the doctor/physician/nurse.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which need not be applied assoon as possible to avoid settling in the syringe and do not cause anissue for the doctor/physician/nurse.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which exhibit enhanced physical stabilityin comparison to conventional compositions containing suchpharmaceutical actives.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which exhibitenhanced physical stability in comparison to conventional compositionscontaining such lipophilic and hydrophilic actives.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which are versatile enough to be acceptedas vehicles for use in various drug delivery systems.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which are versatile enough tobe accepted as vehicles for use in various drug delivery systems.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which are safe and non-toxicfor various routes of administration.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which are safe and non-toxicfor various routes of administration.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, for use in parenteral, oral, dermal,nasal, and other dosage forms.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, for use inparenteral, oral, dermal, nasal, and other dosage forms.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, for use of administration via I.M and/orI.V route, oral, dermal, nasal, optic, and other routes ofadministration.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, for use of administration viaI.M and/or I.V route, oral, dermal, nasal, optic, and other routes ofadministration.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which also provides thefunction of a permeation enhancing agent.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which also provides thefunction of a permeation enhancing agent.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which provides ease of application of thesaid pharmaceutical actives comparatively reduced pain at the site ofinjection via I.M and I.V route.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which provides easeof application of the said lipophilic and hydrophilic activescomparatively reduced pain at the site of injection via I.M and I.Vroute.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which exist in different dosage forms withdesired quality control and are especially free from toxicity problemsencountered due to solvents.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which exist in different dosageforms with desired quality control and are especially free from toxicityproblems in the therapeutic dose of drugs and encountered due tosolvents.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which can be formulated intodifferent dosage forms such as capsules, nasal sprays, gargles, dermalgels, and others, which, moreover, can be made into a soluble pellucidsolution.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which can be formulated intodifferent dosage forms such as capsules, nasal sprays, gargles, dermalgels, and others, which, moreover, can be made into a soluble pellucidsolution.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which are comparatively less toxic and atthe same time would be excreted out easily without causing damage to anyorgan, especially kidney, as well as would not get accumulated in anypart of the body.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which are non-toxicand at the same time would be excreted out easily without causing damageto any organ, especially kidney, as well as would not get accumulated inany part of the body.

Another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which provides transparent and lessviscous parenteral solutions.

Yet another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which provides transparent andless viscous parenteral solutions.

Still another object of the present invention is to providepharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which exhibit betterbioavailability in comparison to conventional compositions containingsuch pharmaceutical actives.

Another object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which exhibit betterbioavailability in comparison to conventional compositions containingsuch lipophilic and hydrophilic actives.

Yet another object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, wherein the said pharmaceutical activesare not milled or micronized.

Still another object of the present invention is to providepharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, wherein the saidlipophilic and hydrophilic actives are not milled or micronized.

A further object of the present invention is to provide pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which preferably contains preservativesand buffers to maintain its pH.

Yet further object of the present invention is to provide pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which preferably containspreservatives and buffers to maintain its pH.

SUMMARY OF THE INVENTION

In accordance with the need for a vehicle or solvent, which is safe andnon-toxic for formulation and preparation of pharmaceuticalcompositions, containing pharmaceutical actives, especially lipophilicand hydrophilic actives belonging to diverse pharmacological andtherapeutic classes and which, moreover, can be manufactured in anefficient way through an economical process and being beneficial intreating mammals and, which, further, is free from most, if not all ofthe limitations/problems/concerns associated with the conventionalformulations of such pharmaceutical actives the present inventors havefound that Diethylene glycol monoethyl ether or other alkyl derivativesthereof, especially the former, is the vehicle or solvent of choice.

The present inventors have found Diethylene glycol monoethyl ether,otherwise known as 2-(2-Ethoxyethoxy)ethanol, CARBITOL™, DE Solvent,Diethylene glycol ethyl ether, Ethyldiglycol or Transcutol and havingthe structure shown below,

is versatile enough to be accepted as a vehicle for use in various drugdelivery systems. It has been tested for its safety and toxicity and isreported to be safe for its therapeutic use through various routes ofadministration. Presently the ethyl derivative is in vogue, but use ofmethyl or any other alkyl derivatives after its safety evaluation may beused.

The use of Diethylene glycol monoethyl ether or other alkyl derivativesthereof in formulation or manufacture of pharmaceutical compositions ofpharmaceutical actives, especially lipophilic actives belonging todiverse pharmacological and therapeutic categories results in manyadvantages, such as:

-   (a) It has great solubilizing power and can easily solubilize    various pharmaceutical actives, belonging to diverse pharmacological    and therapeutic classes as listed in Categories (I) to (XXII)    described in the BACKGROUND OF THE INVENTION section of this    Application, which other solvents/vehicles known in the art are not    completely capable of;-   (b) It is versatile enough to be accepted as a vehicle or solvent    for use in various drug delivery systems for use in parenteral (both    intramuscular and intravenous), oral, dermal, nasal, optic, ocular    and otic other routes of administration, especially as injectables,    capsules, nasal sprays, gargles, dermal gels etc.;-   (c) It is a highly versatile vehicle or solvent for formulation of    pharmaceutical actives, especially lipophilic actives, which are    difficult to solubilize and require to be formulated as oily    injections or as emulsions, or which exhibit instability when    compounded with an aqueous phase;-   (d) It is safe for various routes of administration and is less    toxic from toxicity and quality control problems encountered with    other solvents known in the art;-   (e) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent exhibit enhanced    physical stability in comparison to convention compositions of such    pharmaceutical actives;-   (f) Its use as a vehicle or solvent results in formulation of    pharmaceutical compositions of pharmaceutical actives, which are    easy to manufacture; do not involve and lengthy and tedious    manufacturing steps; which are viable and economical; and which do    not require special facilities to maintain aseptic conditions for    manufacturing such as crystallization, particle size reduction,    wetting, sterilization etc.;-   (g) Its use as a vehicle or solvent results in formulation of    pharmaceutical compositions of pharmaceutical actives, which will    have a better bioavailability;-   (h) Its use as a vehicle or solvent results in formulation of    pharmaceutical compositions of pharmaceutical actives, which are    more transparent, less viscous, and less dense than oily injections    containing such pharmaceutical actives and can be made into a    soluble pellucid solution;-   (i) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent are free from oil and    objectionable/problematic matters and hence more stable;-   (j) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent cause less pain when    injected compared to that caused by injection of oily injections    containing such pharmaceutical actives;-   (k) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent are easy to administer    and thereby useful for doctors/physicians/nurses;-   (l) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent are free of side    effects associated with conventional formulations and most    importantly do not require a test dose to be given to the patient    prior to actual administration;-   (m) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent do not cause pain,    erythema, swelling at the site of injections; do not cause damage to    nerves, arteries or veins; do not cause skin and tissue trauma;    muscle fibrosis and contracture; nerve palsies; paralysis;    anaphylactic shock; formation of thrombosis in veins; thrombo    phlebitis; abscesses or gangrene; do not have staffing and medicine    storage issues; is not stigmatizing or coercive to a patient; and do    not cause logistical difficulties when administered to a patient who    is in employment;-   (n) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent which do not exhibit    instability during the period between manufacture and use; do not    result in settlement of solids, caking, difficulty in redispersion    etc.; do not result in non-uniformity of dose at the time of    administration and vials need not be shaken for uniformity prior to    use;-   (o) It also functions as a permeation enhancing agent;-   (p) The pharmaceutical compositions of various pharmaceutical    actives containing it as a vehicle or solvent do not require    stabilizers or preservatives in large amounts for maintaining the    stability of the compositions; and-   (q) It is excreted easily without causing damage to any organ,    especially kidney, as well as would not get accumulated in any part    of the body; and-   (r) Its use obviates the need for the pharmaceutical actives or    lipophilic actives to be milled or micronized prior to use.    Typically, the pharmaceutical or lipophilic actives, embraced within    the scope of the present invention, which however, should be    construed as non-limiting can be classified in to the following    three categories, viz.-   1) Those which are difficult to solubilize and often require toxic    vehicles for solubilization and may further require unwanted    excipients for formulation into suitable dosage forms;-   2) Those which have stability issues and often require complex and    expensive technology for formulation of such actives into suitable    stable dosage forms; and-   3) Those which are available in the form of suspensions and are very    difficult to be solubilized into a solution form.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injections for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,nasal sprays, gargles, gels, topical, ocular, otic, oral dosage formsetc. The solution may additionally contain preservatives and buffers formaintenance of pH. The solutions exhibit enhanced stability compared andare less toxic.

In accordance with the above:

In one embodiment the present invention provides pharmaceuticalcompositions of various pharmaceutical actives containing Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent.

In another embodiment the present invention provides pharmaceuticalcompositions of various lipophilic and hydrophilic actives containingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent.

In yet another embodiment the present invention relates to use ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or as a solvent in preparation of pharmaceuticalcompositions containing various pharmaceutical actives.

In still another embodiment the present invention relates to use ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or as a solvent in preparation of pharmaceuticalcompositions containing various lipophilic and hydrophilic actives.

In another embodiment the present invention relates to utilization ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent for formulation of pharmaceutical activeswhich are difficult to solubilize in physiologically acceptablesolvents.

In yet another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which are difficult to solubilize in physiologicallyacceptable solvents.

In still another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of pharmaceuticalactives which exhibit instability when compounded with an aqueous phase.

In another embodiment the present invention relates to utilization ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which exhibit instability when compounded with anaqueous phase.

In yet another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of pharmaceuticalactives which are difficult to solubilize in physiologically acceptablesolvents and require to be formulated as oily injections.

In still another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which are difficult to solubilize in physiologicallyacceptable solvents and require to be formulated as oily injections.

In another embodiment the present invention relates to utilization ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent for formulation of pharmaceutical activeswhich are difficult to solubilize in physiologically acceptable solventsand require to be formulated as emulsions.

In still another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofis employed in an amount of 1% to 100% by volume of the pharmaceuticalactive.

In yet another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which are difficult to solubilize in physiologicallyacceptable solvents and require to be formulated as emulsions.

In still another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of pharmaceuticalactives which are free from oil and related matters.

In another embodiment the present invention relates to utilization ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which are free from oil and related matters.

In yet another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of pharmaceuticalactives which are less viscous, less dense and more transparent thanoily injections containing such pharmaceutical actives.

In still another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which are less viscous, less dense and moretransparent than oily injections containing such lipophilic andhydrophilic actives.

In another embodiment the present invention relates to utilization ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent for formulation of pharmaceutical activeswhich results in less pain when injected compared to that caused byadministration of oily injections containing such pharmaceuticalactives.

In yet another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which results in less pain when injected compared tothat caused by administration of oily injections containing suchlipophilic and hydrophilic actives.

In still another embodiment the present invention relates to utilizationof Diethylene glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or solvent for formulation of pharmaceuticalactives which can be easily administered by doctors/physicians/nurses.

In another embodiment the present invention relates to utilization ofDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent for formulation of lipophilic andhydrophilic actives which can be easily administered bydoctors/physicians/nurses.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which are easy to manufacture, do notinvolve any lengthy and tedious manufacturing steps, which are viableand economical.

In still another embodiment the present invention providespharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which are easy tomanufacture, do not involve any lengthy and tedious manufacturing steps,which are viable and economical.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which do not cause side effects; which donot cause pain, erythema, swelling at the site of injection; which donot cause damage to nerves, arteries or veins; and which does notrequire a test dose to be given to the patient prior to actualadministration.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause sideeffects; which do not cause pain, erythema, swelling at the site ofinjection; which do not cause damage to nerves, arteries or veins; andwhich does not require a test dose to be given to the patient prior toactual administration.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause logisticaldifficulties when administered to a patient who is in employment; whichdoes not have staffing and medicine storage issues; and which is notstigmatizing or coercive to a patient.

In another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause logisticaldifficulties when administered to a patient who is in employment; whichdoes not have staffing and medicine storage issues; and which is notstigmatizing or coercive to a patient.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which do not contain stabilizers orpreservatives in large amounts for maintaining the stability of thecompositions.

In still another embodiment the present invention providespharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which do notcontain stabilizers or preservatives in large amounts for maintainingthe stability of the compositions.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which do not cause skin and tissue trauma;muscle fibrosis and contracture; nerve palsies; paralysis; anaphylacticshock; formation of thrombosis in veins; thrombo phlebitis; andabscesses or gangrene, when administered intramuscularly.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which do not cause skin andtissue trauma; muscle fibrosis and contracture; nerve palsies;paralysis; anaphylactic shock; formation of thrombosis in veins; thrombophlebitis; and abscesses or gangrene, when administered intramuscularly.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which does not require specialfacilities to maintain aseptic conditions for manufacturing such ascrystallization, particle size reduction, wetting, sterilization etc.

In another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which does not require specialfacilities to maintain aseptic conditions for manufacturing such ascrystallization, particle size reduction, wetting, sterilization etc.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, wherein the stability of the compositionsduring the period between manufacture and use does not result insettlement of solids, caking, difficulty in redispersion etc.

In still another the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, wherein the stability of thecompositions during the period between manufacture and use does notresult in settlement of solids, caking, difficulty in redispersion etc.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, wherein there is uniformity of dose at thetime of administration and vials need not be shaken for uniformity priorto use.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, wherein there is uniformity ofdose at the time of administration and vials need not be shaken foruniformity prior to use.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which need not be applied assoon as possible to avoid settling in the syringe and do not cause anissue for the doctor/physician/nurse.

In another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which need not be applied assoon as possible to avoid settling in the syringe and do not cause anissue for the doctor/physician/nurse.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which exhibit enhanced physical stabilityin comparison to conventional compositions containing suchpharmaceutical actives.

In still another embodiment the present invention providespharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which exhibitenhanced physical stability in comparison to conventional compositionscontaining such lipophilic and hydrophilic actives.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which are versatile enough to be acceptedas vehicles for use in various drug delivery systems.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which are versatile enough tobe accepted as vehicles for use in various drug delivery systems.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which are safe and less toxicfor various routes of administration.

In another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which are safe and non-toxic inthe desired dose for various routes of administration.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, for use in parenteral, oral, dermal,nasal, and other dosage forms.

In still another embodiment the present invention providespharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, for use inparenteral, oral, dermal, nasal, and other dosage forms.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, for use of administration via I.M and/orI.V route, oral, dermal, nasal, optic, and other routes ofadministration.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, for use of administration viaI.M and/or I.V route, oral, dermal, nasal, optic, and other routes ofadministration.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which also provides thefunction of a permeation enhancing agent.

In another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which also provides thefunction of a permeation enhancing agent.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which provides ease of application of thesaid pharmaceutical actives comparatively reduced pain at the site ofinjection via I.M and I.V route.

In still another embodiment the present invention providespharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which provides easeof application of the said lipophilic and hydrophilic activescomparatively reduced pain at the site of injection via I.M and I.Vroute.

In Another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which exist in different dosage forms withdesired quality control and are especially free from toxicity problemsencountered due to solvents.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which exist in different dosageforms with desired quality control and are especially free from toxicityproblems in the therapeutic dose of drugs and encountered due tosolvents.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which can be formulated intodifferent dosage forms such as capsules, nasal sprays, gargles, dermalgels, and others, which, moreover, can be made into a soluble pellucidsolution.

In Another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which can be formulated intodifferent dosage forms such as capsules, nasal ocular, otic deliveries,gargles, dermal gels, and others, which, moreover, can be made into asoluble pellucid solution.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which are comparatively less toxic and atthe same time would be excreted out easily without causing damage to anyorgan, especially kidney, as well as would not get accumulated in anypart of the body.

In still another embodiment the present invention providespharmaceutical compositions of lipophilic and hydrophilic activescontaining or utilizing Diethylene glycol monoethyl ether or other alkylderivatives thereof as a primary vehicle or solvent, which are non-toxicand at the same time would be excreted out easily without causing damageto any organ, especially kidney, as well as would not get accumulated inany part of the body.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which provides transparent and lessviscous parenteral solutions.

In yet another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which provides transparent andless viscous parenteral solutions.

In still another embodiment the present invention providespharmaceutical compositions of pharmaceutical actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which exhibit betterbioavailability in comparison to conventional compositions containingsuch pharmaceutical actives.

In another embodiment the present invention provides pharmaceuticalcompositions of lipophilic and hydrophilic actives containing orutilizing Diethylene glycol monoethyl ether or other alkyl derivativesthereof as a primary vehicle or solvent, which exhibit betterbioavailability in comparison to conventional compositions containingsuch lipophilic and hydrophilic actives.

In yet another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, wherein the said pharmaceutical activesare not milled or micronized. In still another embodiment the presentinvention provides pharmaceutical compositions of lipophilic andhydrophilic actives containing or utilizing Diethylene glycol monoethylether or other alkyl derivatives thereof as a primary vehicle orsolvent, wherein the said lipophilic and hydrophilic actives are notmilled or micronized.

In another embodiment the present invention provides pharmaceuticalcompositions of pharmaceutical actives containing or utilizingDiethylene glycol monoethyl ether or other alkyl derivatives thereof asa primary vehicle or solvent, which preferably contains preservativesand buffers to maintain its pH. In yet another embodiment the presentinvention provides pharmaceutical compositions of lipophilic andhydrophilic actives containing or utilizing Diethylene glycol monoethylether or other alkyl derivatives thereof as a primary vehicle orsolvent, which preferably contains preservatives and buffers to maintainits pH.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1 shows the operator simply wears a special force sensor on thumband measures the force which elicit the animal response.

DETAILED DESCRIPTION OF THE INVENTION

As mentioned hereinbefore, the primary object and embodiment of thepresent invention lies in providing pharmaceutical compositions ofpharmaceutical or lipophilic/hydrophilic actives in desired pellucidclear solution form for their use in formulation of various dosageforms, which includes parenteral/injectable form for use asintramuscular and/or intravenous administration, as well as for use as apreformed solution/liquid for filling in and preparation of capsules,tablets, nasal sprays, gargles, ocular delivery, otic deliveryapplications and other dosage forms.

Further, as mentioned hereinbefore, the primary object and embodiment ofthe present invention is realized through utilization of Diethyleneglycol monoethyl ether or other alkyl derivatives thereof as a primaryvehicle or solvent in the formulation of pharmaceutical compositionscomprising such pharmaceutical or lipophilic actives. By definition, apharmaceutical active, referred to herein in the specification is asubstance that is biologically active. It is also commonly referred toas a Pharmaceutically Active Ingredient (API), a Drug Substance or aBulk Active. It is the active ingredient which is utilized informulation of pharmaceutical compositions or Drug Products of suchactives. By definition, a lipophilic active, referred to herein in thespecification are compounds which exhibit “Lipophilicity”, meaning theability of such compounds to dissolve in fats, oils, lipids, andnon-polar solvents such as hexane or toluene. Such compounds generallyare poorly soluble or insoluble in water and therefore “Hydrophobic”.Barring a few exceptions the terms “Lipophilic” and “Hydrophobic” aresynonymous.

By definition, a hydrophilic active, referred to herein in thespecification are compounds which exhibit “hydrophilicity”, meaning theability of such compounds to dissolve in water and polar solvents.

The pharmaceutical and/or lipophilic/hydrophilic actives of the presentinvention are drug substances belonging to various pharmacological ortherapeutic classes. By way of illustration, which, however, isnon-limiting and should not be construed as limiting the scope of theinvention, such pharmacological or therapeutic classes can be selectedfrom:

-   1. Gastrointestinal and Hepatobiliary System Drugs:    -   This can include Antacids, Antireflux Agents, Antiulcerants, GIT        Regulators, Antiflatulents, Anti-inflammatories, Antispasmodics,        Antidiarrheals, Laxatives, Purgatives, Digestives, Cholagogues,        Cholelitholytics, Hepatic Protectors, Anorectal Preparations,        Antiemetics and other Gastrointestinal Drugs.-   2. Cardiovascular and Hematopoietic System Drugs:    -   This can include Cardiac Drugs, Anti-anginal Drugs, ACE        Inhibitors/Direct Renin Inhibitors, Beta Blockers, Calcium        Antagonists, Angiotensin II Antagonists, Diuretics,        Antidiuretic, Peripheral Vasodilators and Cerebral Activators,        Vasoconstrictors, Dyslipidaemic Agents, Haemostatics,        Anticoagulants, Other Antihypertensives and other Cardiovascular        Drugs.-   3. Respiratory System Drugs:    -   This can include Antiasthmatic and COPD Preparations, Cough and        Cold Preparations, Nasal Decongestants and other Respiratory        System Drugs-   4. Central Nervous System (CNS) Drugs:    -   This can include Anxiolytics, Hypnotics and Sedatives,        Antidepressants, Antipsychotics, Anticonvulsants,        Antiparkinsonian Drugs, Analgesics (Opioid & Non-Opioid) and        Antipyretics, Non Steroidal Anti Inflammatory Drugs (NSAIDs) and        other CNS Drugs.-   5. Musculo-skeletal System Drugs-   6. Hormones, Steroids and Contraceptive Agents-   7. Anti-infective Drugs:    -   This can include Systemic Antibiotics, Antifungals, Antivirals,        Antimalarials, Antiamoebics, Antiprotozoal agents,        Anti-tuberculars, Antibacterial Combinations, Macrolides and        other anti-infectives-   8. Oncology Drugs-   9. Genito-urinary Drugs-   10. Endocrine and Metabolic System Drugs-   11. Vitamins and Minerals-   12. Nutritional Drugs-   13. Ophthalmic (Eye) Drugs-   14. Drugs for Ear, Nose, Mouth/Throat-   15. Dermatological Drugs-   16. Anesthetics—Local and General-   17. Allergy and Immune System Drugs-   18. Antidotes, Detoxifying agents and Drugs used in Substance    Dependence-   19. Intravenous and other Sterile Solutions-   20. Miscellaneous Drugs and Compounds

As per the embodiments of the present invention, the followingpharmaceutical and/or lipophilic actives or drugs or compounds, which,however, is non-limiting and should not be construed as limiting thescope of the invention, belonging to various pharmacological ortherapeutic classes can be solubilised in Diethylene glycol monoethylether or other alkyl derivatives thereof to provide pharmaceuticalcompositions, which exhibit good physical stability.

-   1. Gastrointestinal and Hepatobiliary System Drugs:    -   a) Antacids, Antireflux agents and Antiulcerants: Famotidine,        Misoprostol, Pantoprazole, Rabeprazole, Domperidone, Omeprazole,        Lansoprazole Dexlansoprazole etc.    -   b) GIT Regulators, Antiflatulents and Anti-inflammatories:        Mesalazine, Metoclopromide, Mosapride etc.    -   c) Antispasmodics: Drotaverine    -   d) Antidiarrheals: Loperamide    -   e) Laxatives and Purgatives: Bisacodyl    -   f) Cholagogues, Cholelitholytics and Hepatic Protectors:        Metadoxine    -   g) Antiemetics: Domperidone    -   h) Other Gastrointestinal Drugs: Trifluoperazine-   2. Cardiovascular and Hematopoietic System Drugs:    -   a) Cardiac Drugs: Adenosine, Digoxin, Lidocaine, Propafenone        etc.    -   b) Anti-anginal Drugs: Diltiazem HCl, Nicorandil, Nifedipine        etc.    -   c) ACE Inhibitors/Direct Renin Inhibitors: Captopril, Enalapril,        Fosinopril, Lisinopril, Losartan, Ramipril etc.    -   d) Beta Blockers: Labetelol, Sotalol, Nebivolol, Amplodipine        etc.    -   e) Calcium Antagonists: Amplodipine Besylate, Lacidipine    -   f) Diuretics: Acetazolamide, Spironolactone, Torasemide etc.    -   g) Peripheral Vasodilators and Cerebral Activators: Isoxsuprine,        Nimodipine etc.    -   h) Dyslipidaemic Agents: Bezafibrate, Atorvastatin, Bezafibrate,        Rosuvastatin, Lovastatin, Simvastatin, Somatostatin etc.    -   i) Anticoagulants: Cilostazol    -   j) Other Antihypertensives and other Cardiovascular Drugs:        Doxazocin, Prazocin, Reserpine etc.-   3. Respiratory System Drugs:    -   a) Antiasthmatic and COPD Preparations: Beclomethazone,        Beclonetasone, Budesonide, Fluticazone, Ipratomium Bromide etc.    -   b) Cough and Cold Preparations: Codeine, Dextromethorphan, Mesna        etc.    -   c) Nasal Decongestants and other Respiratory System Drugs:        Oxymetazoline-   4. Central Nervous System (CNS) Drugs:    -   a) Anxiolytics: Alprazolam, Buspirone, Chlordiazepoxide,        Clobazem, Clonazepam, Diazepam, Lorazepam, Hydroxyzine,        Pregabalin etc.    -   b) Hypnotics and Sedatives: Midazolam, Nitrazepam etc.    -   c) Antidepressants: Bupropion Hydrochloride, Clomipramine,        Doxepin, Fluoxetine, Mianserin etc.    -   d) Antipsychotics: Clozapine, Lamotrigine, Olanzapine,        Quetiapine, Valproic acid etc.    -   e) Anticonvulsants: Carbamazepine, Clonazepam, Clobazam,        Diazepam, Lamotrigine, Levetiracetam Phenyloin, Pregabalin,        Dimenhydrinate etc.    -   f) Analgesics (Opioid & Non-Opioid) and Antipyretics:        Buprenorphine, Pentazocin etc.    -   g) Non Steroidal Anti Inflammatory Drugs (NSAIDs):        Buprenorphine, Pentazocine, Aceclofenac, Indometacin, Ibuprofen,        Ketorolac, Lornoxicam, Mefenamic acid, Nimesulide, Piroxicam,        Tenoxicam, Flunarizine, Citicoline, Mecobalamin, Pyritinol,        Piracetam, Leflunomide, Celecoxib, Eterocoxib, Tilmacoxib,        Acetaminophen, Levosulpiride etc.-   5. Musculo-skeletal System Drugs: Chloroquine, Allopurinol,    Baclofen, Glycopyrronium Bromide, Thiocolchicoside Tizanidine,    Neostigmine, Diacerein, Tolperisone, Eperisone etc.-   6. Hormones, Steroids and Contraceptive Agents: Testosterone,    Estradiol, Ethinyl estradiol, Mesterolone, Allylestrenol, Estrdiol,    Hydroxy-Progesterone Caproate, Medroxy-Progesterone, Norethisterone,    Progesterone, Betamethasone, Hydrocortisone, Methyl Prednisolone,    Prednisolone, Triamcinolone, Clomifene, Octreotide, Nandrolone,    Levonorgestrel etc.-   7. Anti-infective Drugs:    -   Systemic Antibiotics, Antifungals, Antivirals, Antimalarials,        Antiamoebics, Antiprotozoal agents, Anti-tuberculars,        Antibacterial Combinations, Macrolides and other        anti-infectives: Fluconazole, Voriconazole Tobramycin,        Cefoperazone, Cefotaxime, Cefprozil, Erthyromycin,        Ciprofloxacin, Ofloxacin, Tetracycline, Metronidazole,        Ornidazole, Rifampicin, Vancomycin, Cycloserine, Protionamide,        Isoniazide, Clotrimazole, Fluconazole, Itraconazole,        Griseofulvin, Ketoconazole, Terbinafine, Ketoconazole,        Acyclovir, Ganciclovir,Levamisole, Mebendazole, Artemether,        Artesunate, Hydroxy-chloroquine, Mefloquine, Metronidazole,        Furazolidine, Artesunate, Arteether, Artemether etc.-   8. Oncology Drugs: Dacarbazine, Doxorubicin, Vinblastine Sulphate,    Bleomycin, Etoposide, Melphalan, Paclitaxel, Vincristine sulfate,    Amifostine, Anastrazole, Leuprolide etc.-   9. Genito-urinary Drugs: Miconazole, Methylergometrine, Tadalafil,    Tamsulosin, Calcitriol etc.-   10. Endocrine and Metabolic System Drugs: Orlistat, Alfacalcidol    etc.-   11. Vitamins and Minerals: Vitamin K, Cholecalciferol, Retinol,    Other Vitamins A, D & E.-   12. Miscellaneous Drugs and Compounds: Aldosterone receptor    Antagonists—Eplerenone, Spironolactone etc

As mentioned hereinbefore, the aforementioned pharmaceutical orlipophilic actives can be solubilised into Diethylene glycol monoethylether or other alkyl derivatives thereof to provide a clear andtransparent stable liquid solution, which can be used as such directlyfor formulation of injectable solutions for parenteral delivery; orwhich can be matrixed with pharmaceutically acceptable adjuvants into atablet form for oral administration; or else which can be use as apreformed solution/liquid for filling in and preparation of capsules,tablets, nasal sprays, gargles, dermal applications ocular, otic andother dosage forms. In such cases, the clear and transparent stableliquid solution can be either used as a single drug preparation or canbe given in combination with other suitable drugs for the requisitepharmacological actions.

While the invention is primarily illustrated with respect to Diethyleneglycol monoethyl ether, otherwise known also as2-(2-Ethoxyethoxy)ethanol, CARBITOL™, DE Solvent, Diethylene glycolethyl ether, Ethyldiglycol or Transcutol and having the structure shownbelow,

however, other alkyl derivatives can also be equally utilized in thepresent invention and a person skilled in the art would have nodifficulty in embracing the other alkyl derivatives for working of theinvention. Typical examples of other alkyl derivatives are Diethyleneglycol monomethyl ether, Diethylene glycol mono-n-propyl ether,Diethylene glycol mono-iso-propyl ether, Diethylene glycol mono-n-butylether, Diethylene glycol mono-iso-butul ether, and Diethylene glycolmono-n-hexyl ether.

Diethylene glycol monoethyl ether is less viscous and safe. It hasinherent viscosity of about 3.11 cps. It is soluble in water. Thedensity of Diethylene glycol monoethyl ether is 0.985 to 0.991.Diethylene glycol monoethyl ether is less dense than water therebymaking it easily flowable. As the compound has less viscosity it can beused for preparations of compositions which are having an easysyringability and thus advantageous to withdraw from vials or ampoulesby the healthworkers. Further the same advantage offers doctors with itsless painful impact and also less volume of liquid could be administeredfor the drug products in the therapeutic concentration throughparenteral routes.

Of the various vehicles known in the art including various organicsolvents, oils and oil-water mixtures for solubilizing theaforementioned pharmaceutical actives including lipophilic actives andpoorly water soluble drugs and steroids, Diethyleneglycol monoethylether provides an efficient solubilizing activity and drug permeationactivity which can avoid most, if not all thelimitations/problems/concerns associated with utilization of the saidvehicles known in the art for formulation of pharmaceuticalcompositions.

The wide range of pharmaceutical or lipophilic actives, describedhereinbefore, namely the following—Antacids, Antireflux agents andAntiulcerants, GIT Regulators, Antiflatulents, Anti-inflammatories,Antispasmodics, Antidiarrheals, Laxatives, Purgatives, Cholagogues,Cholelitholytics, Hepatic Protectors, Anorectal Preparations,Antiemetics, and Other Gastrointestinal Drugs; Cardiac Drugs,Anti-anginal Drugs, ACE Inhibitors/Direct Renin Inhibitors, BetaBlockers, Calcium Antagonists, Angiotensin II Antagonists, OtherAntihypertensives, Diuretics, Antidiuretics, Peripheral Vasodilators andCerebral Activators, Vasoconstrictors, Dyslipidaemic Agents,Haemostatics, Anticoagulants and Other Cardiovascular Drugs;Antiasthmatic and COPD Preparations, Cough and Cold Preparations, NasalDecongestants and other Respiratory System Drugs; Anxiolytics, Hypnoticsand Sedatives, Antidepressants, Antipsychotics, Anticonvulsants,Antiparkinsonian Drugs, Analgesics (Opioid & Non-Opioid) andAntipyretics, NSAIDs and Other CNS Agents, Musculo-skeletal SystemDrugs, Hormones, Steroids and Contraceptive Agents, Antibiotics,Antifungals, Antivirals, Antimalarials, Antiamoebics, Antiprotozoalagents, Anti-tuberculars, Antibacterial Combinations, Macrolides andother Anti infectives, Oncology Drugs, Drugs related to Genito-urinary,Endocrine & Metabolic System Drugs, Vitamins and Minerals, NutritionDrugs belonging to Eye, Nose, Ear & Mouth/Throat, Dermatologicals,Anesthetics—Local and General, Drugs belonging to Allergy and ImmuneSystem, Antidotes, Detoxifying Agents & Drugs used in SubstanceDependence, Intravenous and other Sterile Solutions and variousMiscellaneous Therapeutic Category Drugs—showed highly selectivesolubility in the vehicle or solvent, Diethyleneglycol monoethyl etheror other alkyl derivatives thereof.

The selective vehicle or solvent, Diethylene glycol monoethyl ether orother alkyl derivatives thereof is typically employed in an amount of25% to 30% by weight of the pharmaceutical composition containing theaforementioned pharmaceutical or lipophilic actives. The penetrating cumsolubilisation activity of Diethylene glycol monoethyl ether is veryeffective when such pharmaceutical compositions are used for theirtherapeutic use. The pharmaceutical compositions comprising Diethyleneglycol monoethyl ether or other lakyl derivatives are found to providebetter chemical and biological stability to the said compositions.

The pharmaceutical compositions containing the aforementionedpharmaceutical or lipophilic actives may in addition to Diethyleneglycol monoethyl ether or other alkyl derivatives contain buffers, formaintenance of pH. Examples of suitable buffers that can be employed are0.1 N Sodium hydroxide, Acetic acid, Sodium citrate, Potassium chloride,Sodium chloride, Citric acid, Sodium bicarbonate, L-Arginine, Trisbuffers, Cholic acid Derivatives, Amino acid Derivatives etc.

The pharmaceutical compositions containing the aforementionedpharmaceutical or lipophilic actives may in addition to Diethyleneglycol monoethyl ether or other alkyl derivatives contain preservatives,which are typically employed in an amount of 0.001% to 2% by weight ofthe composition. Examples of preservatives that can be used are Benzylalcohol, Methyl paraben, Propyl paraben, Thiomerosol, Phenyl mercuricsalts (acetate, borate, nitrate), Chlorobutanol, Meta-cresol etc.Typically Benzyl alcohol is employed in an amount of 0.01% to 2% byweight of the composition, Methyl paraben is employed in an amount of0.18% to 0.2% by weight of the composition, Propyl paraben is employedin an amount of 0.01 to 0.02% by weight of the composition, andThiomerosol is employed in an amount of 0.001% to 0.01% by weight of thecomposition. The preservatives also help in maintenance of the stabilityof the compositions.

The pharmaceutical compositions containing the aforementionedpharmaceutical or lipophilic actives may in addition to Diethyleneglycol monoethyl ether or other alkyl derivatives contain antioxidantsor chelating agents or stabilizers. Examples of antioxidants that can beemployed are Ascorbic acid, Ascorbyl palmitate, Thioglycerol and itsderivatives, Sodium bisulphate, Sodium metabisulphite, Sodiumformaldehyde sulphoxylate, Thiourea, Ascorbic acid ester, BHT (Butylatedhydroxyl toluene), Tocopherols etc. Typically Ascorbic acid is employedin an amount of 0.02% to 0.1% by weight of the composition, Ascorbylpalmitate is employed in an amount of 0.5% to 2% by weight of thecomposition, Sodium bisulphate is employed in an amount of 0.1% to 0.15%by weight of the composition, Sodium metabisulphite is employed in anamount of 0.1% to 0.15% by weight of the composition, Sodiumformaldehyde sulphoxylate is employed in an amount of 0.1% to 0.15% byweight of the composition, Thiourea is employed in an amount of 0.004%to 0.005% by weight of the composition, Ascorbic acid ester is employedin an amount of 0.1% to 0.15% by weight of the composition, BHT isemployed in an amount of 0.005% to 0.02% by weight of the composition,and Tocopherols are employed in an amount of 0.05% to 0.075% by weightof the composition. Chelating agents like Ethylene diamine tetraaceticacid in an amount of 0.01% to 0.075% by weight of the composition aretypically employed and stabilizers like Maleic acid or Malate salts maybe employed.

The pharmaceutical compositions containing the aforementionedpharmaceutical or lipophilic actives may in addition to Diethyleneglycol monoethyl ether or other alkyl derivatives contain otherappropriate adjuvants or excepients, based on the dosage forms.

The pharmaceutical compositions containing the aforementionedpharmaceutical or lipophilic actives may in addition to Diethyleneglycol monoethyl ether or other alkyl derivatives contain otherpharmaceutically acceptable co-solvents. Water can also be added inminimal quantity to make the compositions more fluidic.

The versatility of the selective solubilizing agent diethylene glycolmonoethyl ether and alike solvent enables formulation for lipophilicactives which could be used as injectable both intravenously andintramuscularly use as well as for application in various pharmaceuticaldosage compositions thereby providing for its diverse application ofthis drugs for treating diverse diseases and for alleviating thesickness of mammals effectively.

The wide range of the drugs that can be effectively solubilized byDiethylene glycol monoethyl ether or other alkyl derivatives andformulated into suitable pharmaceutical compositions or dosage forms arethe following, which, however, is non-limiting as far as the scope ofthe invention, is concerned.

Class I: Pharmaceutical Actives or Drugs which are Difficult toSolubilize

As mentioned hereinbefore, there are certain pharmaceutical actives ordrugs, which are difficult to solubilize and often require toxicvehicles for solubilization and may further require unwanted excipientsfor formulation into suitable dosage forms.

Such pharmaceutical actives or drugs can be effectively solubilised byutilization of Diethylene glycol monoethyl ether or other alkylderivatives as a primary vehicle or solvent, to provide clear,transparent, non hazy solutions of the said pharmaceutical actives ordrugs in the said vehicle or solvent, which are further less viscous andare ‘ready to use’ for parenteral administration through I.V., I.M. orother routes of injection or can be used for formulation of variousother dosage forms of the pharmaceutical actives or drugs, such as forexample, capsules, tablets, nasal sprays, gargles, dermal applications,gels, ocular, otic, liquid oral dosage forms and other dosage forms.Further, when administered parenterally, the solutions are easilyflowable, easily syringable, easy to inject and cause less pain at thesite of the injection and are therefore, beneficial not only to thepatients bit also to the doctors/physicians/nurses. Furthermore, thepharmaceutical compositions are safe and less toxic, when administeredthrough various routes, especially if administered parenterally. Inaddition, utilization of Diethylene glycol monoethyl ether or otheralkyl derivatives enhances the chemical and biological stability of thepharmaceutical actives or drugs and also offers a better permeation ofsuch actives or drugs.

Diethylene glycol monoethyl ether or other alkyl derivatives offerscomparatively less viscosity (of less than 7-8 cps if used alone in thecomposition and less than 15 cps if used as co solvents in few examples)if administered through parenteral routes.

The various pharmaceutical actives or drugs, belonging to this class, toname a few are the following, which again to reiterate is non-limitingas far as the scope of the invention, is concerned.

I.1) Progesterone (Steroids & Hormones)

Progesterone also known as P4 (pregn-4-ene-3,20-dione) is a C-21 steroidhormone involved in the female menstrual cycle, pregnancy (supportsgestation) and embryogenesis of humans and other species. Progesteronebelongs to a class of hormones called progestogens, and is the majornaturally occurring human progestogen. The molecular structure ofprogesterone is as:

It is white crystalline powder insoluble in water. The solubilityprofile of Progesterone in water is <0.1 g/100 ml at 19° C. It is freelysoluble in dehydrated alcohol, sparingly soluble in vegetable oils andacetone. It is available in micronized form as an oily intramuscularinjection prepared in sesame oil according to USP which is viscous innature and can be painful at the site of injection. It differs fromother commonly used steroids in that it is irritating at the place ofinjection.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injections for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,gels, topical gels, vaginal suppository, liquid oral dosage forms etc.The solution may additionally contain preservatives and buffers formaintenance of pH.

I.2_(A)) Nandrolone Decanoate (Steroids & Hormones)

Nandrolone (19-nortestosterone, I.2) is an anabolic steroid that may bepresent naturally in the human body. Nandrolone is most commonly soldcommercially as its decanoate ester and as a phenyl propionate ester.

Nandrolone decanoate (D1) is synthetic derivative of testosteroneindicated for the management of the anemia of renal insufficiency andhas been shown to increase hemoglobin and red cell mass. The chemicalformula of Nandrolone decanoate is asEstr-4-en-3-one,17-[(1-oxodecyl)oxy]-,(17b)-17b-Hydroxyestr-4-en-3-onedecanoate The molecular formula of decanoate ester is C₂₈H₄₄O₃ and themolecular structure is given as:

Nandrolone decanoate (C₂₈H₄₄O₃) occurs as a fine, white to creamy white,crystalline powder. It is odorless, or may have a slight odor.Nandrolone decanoate is soluble in chloroform, in alcohol, in acetone,and in vegetable oils. It is practically insoluble in water. AsNandrolone decanoate, it is available as a sterile oleaginous solutionin which sesame oil is administered. It is available in dose of 100mg/ml in which upto 10% of benzyl alcohol is used as solubilizer as wellas preservative. While, benzyl alcohol can be used in 2% to 4% aspreservative in parenterals but at 10% of concentration it showsanesthetics effect. While sesame oil makes the injection more viscous,this can be painful at the site of injection.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. bolus injection or Depot I.M. injection forrapid onset of action when required to provide earliest result into thepatient as well as can be used for formulation of different dosage formslike capsules, nasal sprays, gargles, gels, topical, liquid oral dosageforms etc. The solution may additionally contain preservatives andbuffers for maintenance of pH.

I.2_(B)) Nandrolone Phenyl Propionate (Steroids & Hormones)

Nandrolone phenyl propionate is an I.M. injectable form of the anabolicsteroid Nandrolone. It is chemically designated as17b-hydroxyestr-4-en-3-one 17-(3-phenylpropionate) and the chemicalstructure is given as:

It is a white to creamy white, crystalline powder, practically insolublein water. Nandrolone phenyl propionate is active for about a week.Esterified steroids are less polar than free steroids, and are absorbedmore slowly from the area of injection. Once in the bloodstream, theester is removed to yield free (active) 37aphtha37ol. Esterifiedsteroids are designed to prolong the window of therapeutic effectfollowing administration, allowing for a less frequent injectionschedule compared to injections of free (unesterified) steroid.Nandrolone is not C-17 alpha alkylated, and not known to havehepatotoxic effects in healthy subjects. Nandrolone Phenyl Proprionateis available in select human human drug markets in compositions anddosage containing 25 mg/mL or 50 mg/ML of the steroid dissolved in oil.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injections for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,nasal sprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

I.3, I.3_(A), I.3_(B)) Testosterone and its Salt Forms i.e. TestosteroneEnanthate and Testosterone Cypionate (Steroids & Hormones)

Testosterone is an anabolic steroid hormone which is also used inprevention of Osteoporosis. Its molecular formula is C₁₉H₂₈O₂(M.W=288.4) with the following structure as:

It is white crystalline or yellowish white crystals, practicallyinsoluble in water, and fatty oils. It has low bioavailability withhalf-life of 2 to 4 hrs and metabolism occurs in liver, testis andprostate. It is useful in testosterone replacement therapy in male hypogonadal disorders, and also improves type 2 diabetes.

Testosterone enanthate is a derivative of the primary endogenousandrogen testosterone, for intramuscular administration. In their activeform, androgens have a 17-beta-hydroxy group. Esterification of the17-beta-hydroxy group increases the duration of action of testosterone;hydrolysis to free testosterone occurs in vivo.

Testosterone enanthate (C₂₆H₄₀O₃) (M.W. 400.60) is a white or creamywhite, crystalline powder. It is odorless or has a faint odorcharacteristic of heptanoic acid. It is insoluble in water, very solublein ether and soluble in vegetable oils. Testosterone Enanthate Injectionis a clear, colorless to pale yellow sterile oleaginous solution oftestosterone enanthate for intramuscular use. Each mL contains:Testosterone Enanthate 200 mg, Chlorobutanol (Chloral derivative) 0.5%in Sesame Oil q.s.

Testosterone cypionate is the lipophilic active17(beta)-cyclopentylpropionate ester of the androgenic hormonetestosterone. It is a white or creamy white crystalline powder freelysoluble in ether with the chemical formula is androst-4-en-3-one,17-(3-cyclopentyl-1-oxopropoxy)-, (17β)-. Its molecular formula isC₂₇H₄₀O₃ with the molecular weight 412.61.

The structural formula is represented below:

It is available in parenteral form in two strengths, 100 mg/ml and 200mg/ml. It is recommended to inject the drug in the buttocks after every7-12 days for maximum results. At a time, whole of testosterone willremain bound to the protein while only 2% will be available and issecreted in to the blood. It is indicated for replacement therapy in themale in conditions associated with symptoms of deficiency or absence ofendogenous testosterone.

The ester forms are available as oil based depot type parenteralpreparation in which sesame oil or cottonseed oil is used, which mightcause pain as well as allergic reaction This may lead to abscessformation, sores and some skin infections. Moreover, a single sitecannot be used for injection every time. Due to their bulkiness/viscousnature it may be difficult to syringe it.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injection for rapid onset ofaction when required to provide earliest result into the patient. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

I.4) Norethisterone Enantate (Steroids & Hormones)

Norethisterone enantate is a synthetic progestin, contraceptive usuallygiven through intragluteal route as a single injection in strength of200 mg/ml. It continuously releases its progestin into the bloodstreamover a period of eight weeks (2 months). A second and final injectionmay be given eight weeks after the first injection if necessary.Norethisterone enantate is only used as a short-term method ofcontraception in certain circumstances.

It is chemically designated as 17alpha-Ethynyl-19-nortestosterone17-heptanoate and the molecular structure is given as:

It is a white to creamy white, crystalline powder; practically insolublein water; freely soluble in acetone, methanol, dehydrated ethanol,dioxane and ether; slightly soluble in light petroleum. According toU.S. Pat. No. 7,025,979, the invention shows a formulation for malecontraception comprising a progestin possessing both estrogenic andandrogenic properties is remarkably effective for spermatogenesissuppression in males. The progestin Norethisterone (NET), particularlyits derivatives Norethisterone acetate and Norethisterone enanthate insufficient doses induce oligozoospermia or azoospermia in males.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topicals, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

I.5) 17β Estradiol (Steroids & Hormones)

Estradiol (E2 or 17β-estradiol) is a sex hormone which is abbreviated E2as it has two hydroxyl groups in its molecular structure. The chemicalname of this lipophilic active is (17β)-estra-1,3,5(10)-triene-3,17-diolwith molecular formula and molecular structure is as:

It is used, either as an injection or topically, in the treatment ofinflammation, allergy, collagen diseases, asthma, adrenocorticaldeficiency, shock, and some neoplastic conditions. This hormone isavailable as salt form like Estradiol Benzoate, Estradiol Cypionate,Estradiol valerate in parenteral forms which are used in treatment offemale hypogandism. These salts are sparingly soluble in oil like sesameoil so it may be chances of stability problem.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topicals, transdermal discs, intravaginal rings,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

I.6) Fulvestrant (Steroids & Hormones)

Fulvestrant is an estrogen receptor antagonist as a drug for treatmentof hormone receptor-positive metastatic breast cancer in postmenopausalwomen with disease progression following anti-estrogen therapy.

The chemical name is 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]estra-1,3,5-(10)-triene-3,17beta-diol. Themolecular formula is C₃₂H₄₇F₅O₃S and its structural formula is:

Fulvestrant is a white powder with a molecular weight of 606.77. It isavailable as injection for intramuscular administration. The solutionfor injection is a clear, colorless to yellow, viscous liquid.Fulvestrant is soluble in ethanol, DSMO, Dimethyl formamide andpractically insoluble in water.

This injection contains upto 10% of benzyl alcohol which might act asanaesthetic level while castor oil USP is used as release rate modifierwhich can be viscous that can be painful at the time of injection andthe solution might be appear yellowish color too. According to FDA drugapproval summaries, injection site reaction and hot flashes wereobserved.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

In a similar way, Anabolic steroids like Boldenone Undecylanate,Drostanolone propionate, Trenbolone Acetate, Trenbolone Enanthate,Methenolone Enanthate, Methyl Testosterone can also be prepared as I.Mand I.V. injectable forms by utilizing the vehicle or solvent of thepresent invention solvent, Diethylene glycol monoethyl ether or otheralkyl derivatives to give a transparent, non hazy as well as lessviscous solution.

I.7) Artemether (Antimalarial)

It is a methyl ether derivative of artemisinin, which is a peroxidelactone isolated from the Chinese antimalarial plant, Artemisia annua.It is also known as dihydroartemisinin methyl ether, but its correctchemical nomenclature is (+)-(3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepinwith the molecular structure as

It is a white crystalline powder with a bitter taste; practicallyinsoluble in water, soluble in chloroform, acetone, and alcohols. It isa relatively lipophilic and unstable drug. Artemether is highlyeffective against the blood schizonts of both malarial parasites P.falciparum and P. vivax. Its unique features are:

Unlike most other antimalarial, it lacks a nitrogen-containingheterocyclic ring system;

Is equally as effective as quinine in the treatment of severe malaria;and

Is as effective as quinine in the treatment of cerebral malaria.

It is available as I.M injection form at dose of 80 mg/ml. for adult andaccepted as 20 mg/ml for pediatric patients by WHO. The productavailable in the market is prepared in miglycol, Medium chaintriglyceride oils which may be low viscous but are irritant at the siteof injection.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy solution is obtained, which can be useful as I.Mas well as I.V. injections for rapid onset of action when required toprovide earliest result into the patient. The solution may additionallycontain preservatives and buffers for maintenance of pH. The solutioncan also be used for formulation of other dosage forms, such ascapsules, gel, patches, liquid dosage forms etc.

I.8) Arteether (Antimalarial)

Arteether is the ethyl ether derivative of artemisinin, a naturalproduct of the Chinese plant Artemisia annua. It is currently only usedas a second line drug in severe cases of malaria as fast acting bloodschizontocidal agent for P. falciparum malaria at the erythrocyticstage. The molecular formula is C₁₇H₂₈O₅ and molecular weight is 312.4.The molecular formula of Arteether is10-Ethoxydecahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepinwith molecular structure is given as:

It is quite water insoluble, but very soluble in a variety of organicsolvents. It is available in injection form in market as intramuscularapplication at the dose of 150 mg/2 ml.

In one of the parenteral formulation available in the market, it ismanufactured by incorporation of ethyl oleate which is yellow colorliquid, addition of alcohols ethyl alcohol, benzyl alcohol and group ofpreservatives which leads to high cost product as well as viscousformulation which can be irritant at site of injection. This problem canbe solved by using the selected solvent in the present invention toprepare I.V. parenteral.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient. The solutions canbe prepared in concentrations of 150 mg/ml or 75 mg/ml. The solution mayadditionally contain preservatives and buffers for maintenance of pH.The solution can also be used for formulation of other dosage forms,such as capsules.

I.9) Haloperidol (Antipsychotic)

Haloperidol is the first of the butyrophenone series of majorantipsychotics. The chemical designation is4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone and ithas the following structural formula:

The product has very low solubility in water (1.4 mg/100 ml), but it isfreely soluble in chloroform, benzene, methanol, acetone, and diluteacids. It is soluble in 0.1 N hydrochloric acid (3 mg/ml) with heating.

Haloperidol is available as a sterile parenteral form for intramuscularinjection. The injection provides 5 mg haloperidol (as the lactate) andlactic acid for pH adjustment between 3.0-3.6. Haloperidol Injection isrecommended for intramuscular administration only. Skin rash andinjection site reaction has been found by use of this parenteral.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient, but also therashes at the site of injection is prevented. The solution can also beused for formulation of different dosage forms like capsules, tablets,nasal sprays, gargles, gels, topicals, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

I.10) Vitamin D₃ (Vitamins & Minerals)

Presently Cholecalciferol (Vitamin D₃) is available as oily viscousinjectable which is painful when administered and needs to be modifiedinto less viscous and painless injection.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M. injection [of 6, 00,000 IU per ml andoptionally containing preservatives and antioxidants] for rapid onset ofaction when required to provide earliest result into the patient. Thesolution can prevent issue damage and pain at the site of injection,caused by oily injections currently available in the market. I.V.infusion is also possible, since the safety of the same has beenestablished. The solution is easily syringable and can be combined withcalcium salts using water or mixed with co-solvents for combined therapyafter homogenization. The solution can also be used for formulation ofdifferent dosage forms like capsules, tablets, nasal sprays, gargles,gels, topicals, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

A2) Medroxy Progesterone Acetate

Medroxyprogesterone acetate, also known as17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated asMPA, is a steroidal progestin, a synthetic variant of the human hormoneprogesterone. It is used as a contraceptive, in hormone replacementtherapy and for the treatment of endometriosis as well as several otherindications. It is chemically designated as17α-hydroxy-6α-methylpregn-4-ene-3,20-dione acetate and molecularstructure is:

MPA is a more potent derivative of its parent compoundmedroxyprogesterone. It is a white to off-white, odorless crystallinepowder, stable in air, melting between 200° and 210° C. It is freelysoluble in chloroform, soluble in acetone and in dioxane, sparinglysoluble in alcohol and methanol, slightly soluble in ether and insolublein water. It is available as Aqueous Suspension active by the parenteraland oral routes of administration. It is available as intramuscularinjection in which each ml consists of 400 mg/ml MPA. The vehicle usedas parenteral solvent is PEG 3350.

The viscosity of PEG 3350 is about 83 to 130 cps, which is more viscousand may be painful to patient at the time of injection. As it isavailable in suspension form, stability, particle size, and storage ofthe product are critical factors for handling

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injections for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,nasal sprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

I.11) Allyoestrenol (Steroids & Hormones)

It is a synthetic progestogen with progestational activity used toprevent threatened miscarriage, recurrent pregnancy loss and prematurelabor. In men, it has also been studied as a treatment for benignprostatic hyperplasia, with encouraging results. It is chemicallydenoted as (17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol and the molecularstructure is given as:

It is practically insoluble in water. According to U.S. Pat. No.6,696,433, this sex steroid was prepared in injectable form by improvingits solubility using beta cyclodextrin.

It is available in injectable form at dose of 250 mg/ml and as oraldosage form at dose of 5 mg per tablet in the market. By utilizing thevehicle or solvent of the present invention solvent, Diethylene glycolmonoethyl ether or other alkyl derivatives, a transparent, non hazy aswell as less viscous solution is obtained, which can be useful as I.M aswell as I.V. injection for rapid onset of action when required toprovide earliest result into the patient as well as can be used forformulation of different dosage forms like capsules, nasal sprays,gargles, gels, topicals, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

I.12, 1.12_(A)) Etoricoxib and Tilmacoxib (Cox-2 Inhibitors)

Like any other COX-2 selective inhibitor, Eterocoxib selectivelyinhibits isoform 2 of the enzyme cyclooxygenase (COX-2). This reducesthe generation of prostaglandins (PGs) from arachidonic acid. Thechemical name of Etoricoxib is5-chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine withmolecular structure as:

It is very low soluble in water about 3.3 mg/L. According to IndianPatent No. 146674, the invention was related to a clear, stable novelpharmaceutical preparation of selective cyclooxygenase II inhibitors(COX 2) inhibitors preferably in the parenteral form for the treatmentof pain & inflammatory. In this invention, solvent Dimethyl Isosorbide(DMI) is used which was found to be irritant at site of application aswell as during long term storage, there was possible crystal formationof the drug in the liquid.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, gels,patches, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

Other drugs under this category like Firocoxib, Mavacoxib, Robenacoxib,Cimicoxib that are used for veterinary can be also be compounded intoparenteral preparation by utilization the vehicle or solvent of thepresent invention, Diethylene glycol monoethyl ether or other alkylderivatives.

Newer drugs of this category like Tilmacoxib (I.12_(A)) which was foundto be an effective chemo-preventive agent against rat experimental liverfibrosis can also be prepared as parenteral dosage form by usingdiethyleneglycol mono ethyl ether. The chemical name of Tilmacoxib is4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2 fluorobenzenesulfonamidewith molecular structure as:

Tilmacoxib is still new active without any dosage preparation availablein the market.

Here also, by utilizing the vehicle or solvent of the present inventionsolvent, Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, gels,patches, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

I.13) Cyclosporine (Immunosuppressant)

Cyclosporine is an immunosuppressant drug widely used in organtransplantation to prevent rejection. It reduces the activity of theimmune system by interfering with the activity and growth of T cells.Cyclosporine is a cyclic polypeptide immunosuppressant agent consistingof 11 amino acids. It is chemically designated as(E)-14,17,26,32-tetrabutyl-5-ethyl-8-(1-hydroxy-2-methylhex-4-enyl)-1,3,9,12,15,18,20,23,27-nonamethyl-11,29-dipropyl-1,3,6,9,12,15,18,21,24,27,30-undecaazacyclodotriacontan-2,4,7,10,13,16,19,22,25,28,31-undecaoneandmolecular structure is:

The drug exhibits very poor solubility in water, and, as a consequence,suspension and emulsion forms of the drug have been developed for oraladministration and for injection. cyclosporine injection, USP, isavailable in a 5 mL sterile ampoule for I.V. administration in whichEach mL contains: cyclosporine, USP 50 mg, Cremophor® EL(polyoxyethylated castor oil) 650 mg, alcohol about 32.9% by volumewhich must be diluted further with 0.9% Sodium Chloride Injection or 5%Dextrose Injection before use. As discussed earlier, Cremophor® EL wasfound to have acute anaphylactoid reaction and requires administrationof antihistamines prior to the injection and thus the double injectionscause discomfort to the patients.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient, but also doesnot have the safety and toxicity issues associated with Cremophor® EL.The solutions can be prepared in concentrations of 25 mg/ml to 100mg/ml. The solution can also be used for formulation of different dosageforms like capsules, tablets, liquid oral dosage forms etc. The solutionmay additionally contain preservatives and buffers for maintenance ofpH.

I.14) Paclitaxel (Anticancer Agent)

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. When itwas developed commercially by Bristol-Myers Squibb (BMS), the genericname was changed to Paclitaxel and the BMS compound is sold under thebrand name Taxol®. In this formulation, Paclitaxel is dissolved inCremophor EL and ethanol, as a delivery agent. Another formulation, inwhich paclitaxel is bound to albumin, is sold under the brand nameAbraxane®, which is prepared using Nanotechnology and hence a costlytechnique. Paclitaxel is used to treat patients with lung, ovarian,breast, head and neck cancer, and advanced forms of Kaposi's sarcoma.Paclitaxel is also used for the prevention of restenosis.

Paclitaxel is chemically designated as(2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-ylbenzoate and the molecular structure is given as:

The nomenclature for Paclitaxel is structured on a tetracyclic 17-carbon(heptadecane) skeleton. Paclitaxel is a white to off-white crystallinepowder with the empirical formula C₄₇H₅₁NO₁₄ and a molecular weight of853.9. It is highly lipophilic, insoluble in water, and melts at around216-217° C.

Paclitaxel Injection is a slightly yellow viscous solution. It issupplied as a nonaqueous solution intended for dilution with a suitableparenteral fluid prior to intravenous infusion. It is available in 30 mg(5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL ofsterile nonpyrogenic solution contains 6 mg paclitaxel, 527 mg ofpurified Cremophor® EL (polyoxyethylated castor oil) and 49.7% (v/v)dehydrated alcohol, USP. From the above formulation, it is easily toguess that how much painful would be the injection when given to thecancerous patient. It might be surprisingly advantage to prepare theinjection of this highly lipophilic active by it's solubilizing in thepresent permeating enhancer without any reaction that might be possibleto occur by Cremophor® EL.

It is now available and marketed as conjugation as a albumin complex.Thetechnique to prepare the same is costly and is uneconomic and does notcater the need of the poor. Cancer is prevalent is various countries invast majority of global population.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injections for rapid onset of action whenrequired to provide earliest result into the patient, but also does nothave the safety and toxicity issues associated with Cremophor® EL aswell as does not involve the complex and expensive technology involvedfor making albumin based complexes. The solution can also be used forformulation of different dosage forms like capsules, tablets, liquidoral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

I.15) Piroxicam (Antirhuematic Actives for Musculo SkeletalSystem—Oxicams)

Oxicams are members of a class of NSAIDs that bind closely to plasmaproteins. Most oxicams are unselective inhibitors of the cyclooxygenase(COX) enzymes, which includes Piroxicam. Its anti-inflammatory potencyis similar to Indomethacin and analgesic action is greater than Aspirin.It has useful antipyretic property. Piroxicam is chemically designatedas(8E)-8-[hydroxy-(pyridin-2-ylamino)methylidene]-9-methyl-10,10-dioxo-10λ6-thia-9-azabicyclo[4.4.0]deca-1,3,5-trien-7-onewith molecular structure as:

It is a white crystalline solid; sparingly soluble in water (23 mg/L at22° C.), dilute acid and organic solvents; slightly soluble in alcoholsand in aqueous alkalines. It is available as injection in dose of 20mg/2 ml.

In U.S. Pat. No. 4,628,053; Invention relates to stabilized injectionsolutions of Piroxicam in which propylene glycol, ethanol and water asthe solvent for parenteral administration which might be viscous andpainful at the site of injection.

In U.S. Pat. No. 4,824,841, Invention relates to a process for thetransformation of Piroxicam into an hydrated form suitable for Oral,topic or parenteral administration.

In U.S. Pat. No. 4,942,167, Aqueous pharmaceutical formulationcontaining lyophilized Piroxicam in Glycine as vehicle which is nottransparent solution and stability can be issue.

In U.S. Pat. No. 5,420,124A, Invention relates to an injectablePiroxicam potassium composition which contains triethyleneglycol as asolvent and stabilizer.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage

I.16) Clonazepam (Anticonvulsant)

Clonazepam is a benzodiazepine drug having anxiolytic, anticonvulsant,muscle relaxant, sedative, and hypnotic properties.

Clonazepam is classified as a high potency benzodiazepine. Clonazepam isa chlorinated derivative of nitrazepam. It is a light yellow crystallinepowder. It has a molecular weight of 315.72 It is chemically designatedas 5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1,4-benzodiazepin-2-one andthe molecular structure is given as:

It is a light yellow crystalline powder insoluble in water, sparinglysoluble in acetone and chloroform and slightly soluble in alcohol. Ithas a molecular weight of 315.72. Clonazepam was approved in the UnitedStates as a generic drug in 1997 and is now manufactured and marketed byseveral companies. Clonazepam is available as tablets and orallydisintegrating tablets (wafers), oral solution (drops), as well assolution for injection or intravenous infusion. This injection isappearing as lightly greenish yellow solution.

For panic disorder, the initial recommended dose is 0.25 mg twice daily.This dose can be increased every three days in increments of 0.125-0.25mg twice daily. The target dose for panic disorder is 1.0 mg per day,although some people benefit from doses up to a maximum of 4 mg per day.When a person stops taking Clonazepam, the drug should be graduallydiscontinued by decreasing the dose by 0.125 mg twice daily every threedays.

Although, clonazepam is not FDA-approved for the treatment ofpost-traumatic stress disorder, doses in the range of 0.25-3 mg dailyappears to help treat symptoms of this disorder. Daily dosages for thetreatment of social phobia range from 1.0-2.5 mg, while the dosage tocontrol mania may be as high as 10 mg daily.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injections for rapid onset of action whenrequired to provide earliest result into the patient. The solution canalso be used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

I.17) Diazepam (Anticonvulsant)

Diazepam is a benzodiazepine derivative chemically designated as7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. It isa colorless crystalline compound, insoluble in water, with the followingmolecular structure:

Diazepam Injection, USP is a sterile, nonpyrogenic solution intended forintramuscular or intravenous administration. Each milliliter (mL)contains 5 mg diazepam; 40% propylene glycol; 10% alcohol; 5% sodiumbenzoate and benzoic acid added as buffers; and 1.5% benzyl alcoholadded as a preservative. pH 6.6 (6.2 to 6.9). Solution may appear lightyellow. Diazepam Injection is classified by the Drug EnforcementAdministration as a schedule IV controlled substance. The usualrecommended dose in older children and adults ranges from 2 mg to 20 mgIM or IV, depending on the indication and its severity. DiazepamInjection is injected deeply into the muscle while given through I.M.and through I.V., the solution may be injected slowly, taking at leastone minute for each 5 mg (1 mL) given. This might be due to itsviscosity.

Thus it is possible to produce less viscous, clear viable injectablewith Diethylene glycol monoethyl ether.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient. Since thesolution is less viscous, it can be easily filtered aseptically and iseasily syringable. The solution can also be used for formulation ofdifferent dosage forms like capsules, tablets, liquid oral dosage formsetc. The solution may additionally contain preservatives and buffers formaintenance of pH.

Class II: Pharmaceutical Actives or Drugs which have Stability Issues

As mentioned hereinbefore, there are certain pharmaceutical actives ordrugs, which have inherent stability issues i.e. instability and oftenrequire complex and expensive technology for formulation of such activesinto suitable stable dosage forms.

Typical example is that of pharmaceutical actives or drugs that aremarketed as Lyophilized Powders or as a Dry Fill Powder and whichrequires reconstitution while injecting to the patient. The process ofreconstitution in clinical practice is many times cumbersome due to factthat doctor and health workers are always conscious for injecting theclear liquid without leaving the trace of particles remaining asunsolubilized. Further, if the reconstituted clear liquid is kept over ashelf, commonly the drug decomposes due to instability or may increasethe bioburden during storage. Further, compositions containing suchpharmaceutical actives or drugs are costly to manufacture, as theprocesses involve lengthy and tedious technology. Due to the same, it iscost prohibitive and not beneficial to patients.

Such pharmaceutical actives or drugs can be effectively stabilized byutilization of Diethylene glycol monoethyl ether or other alkylderivatives as a primary vehicle or solvent, to provide clear,transparent, non hazy solutions of the said pharmaceutical actives ordrugs in the said vehicle or solvent, which are further less viscous andare ‘ready to use’ for parenteral administration through I.V., I.M. orother routes of injection or can be used for formulation of variousother dosage forms of the pharmaceutical actives or drugs, such as forexample, capsules, tablets, nasal sprays, gargles, dermal applications,gels, topicals, liquid oral dosage forms and other dosage forms. Thesolutions are easy to manufacture, do not involve lengthy and tediousmanufacturing processes and are therefore, economical, viable and hencebeneficial to patients. Further, when administered parenterally, thesolutions are easily flowable, easily syringable, easy to inject andcause less pain at the site of the injection and are therefore,beneficial not only to the patients bit also to thedoctors/physicians/nurses. Furthermore, the pharmaceutical compositionsare safe and less toxic, when administered

The various pharmaceutical actives or drugs, belonging to this class, toname a few are the following, which again to reiterate is non-limitingas far as the scope of the invention, is concerned.

II.1) Hydrocortisone Acetate (Steroids & Hormones)

Hydrocortisone is the main glucocorticoid secreted by the adrenalcortex. Its synthetic counterpart, Hydrocortisone acetate is a hormoneused to treat local pain and swelling (inflammation) due to jointproblems (e.g., arthritis, bursitis) or certain skin conditions (e.g.,keloids, psoriasis). The chemical name for cortisone acetate ispregn-4-ene-3,11,20-trione, 21-(acetyloxy)-17-hydroxy and the molecularweight is 402.49. The structural formula is represented below:

A white or almost white, crystalline powder; odourless, practicallyinsoluble in water; slightly soluble in ethanol (˜750 g/l). It is mostlyavailable as tablet of strength 5 mg or 10 mg and as powder for solutionin the market for I.M as well as I.V. injections as it is an insolublemolecule in water.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, gels,creams patches, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

II.2) 15-me-PGF_(2α): Carboprost (Steroids & Hormones)

15-me-PGF2alpha is as effective as natural PGF2alpha in inducingabortions during very early pregnancy. Carboprost induces contractionsand can trigger abortion in early pregnancy. It also reduces postpartumbleeding. Chemically it is designated(Z)-7-[(3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoicacid and chemical structure is given as:

It is an Off-White Solid. Carboprost is a synthetic prostaglandinanalogue of PGF2α(specifically, it is 15-methyl-PGF2α) with oxytocicproperties.

It is available in market in form of the tromethamine salt of the(15S)-15 methyl analogue of naturally occurring prostaglandin F2α in asolution suitable for intramuscular injection. It contains sodiumchloride and benzyl alcohol as solvent, which can causehypersensitivity. Further, anaphylactic reaction, anaphylactic shock,anaphylactoid reaction and angiodema have been reported in patients.Furthermore, the use of benzyl alcohol in maximum amount in this sterilesolution is associated with fatal “Gasping Syndrome” in prematurepatients.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, vaginaldelivery like sponge bars, suppositories, liquid oral dosage forms etc.The solution may additionally contain preservatives and buffers formaintenance of pH.

II.3) Artesunate (Antimalarial)

Artesunate is an Artemisinin derivative with the antimalarial activityhaving molecular structure (C₁₉H₂₈O₈, M.W 384.4):

The IUPAC name of the drug is as:(3R,5aS,6R,8aS,9R,10S,-12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano-[4,3-j]-1,2-benzodioxepin-10-olhydrogen succinate. It is a white crystalline powder, slightly solublein water.

According to WHO recommendation, Artesunate is the first option for theparenteral treatment of severe falciparum malaria, with the dose of 2.4mg/kg intravenously or intramuscularly, repeated after 12 and 24 hoursand then once daily thereafter.

To overcome the poor solubility of Artesunate in water a number ofdosage forms and routes have been tried.

Several potent derivatives with more suitable pharmaceutical propertieshave been developed in which, the sodium salt of the hemisuccinate esteri.e., sodium Artesunate which is soluble in water but have poorstability in aqueous solutions.

Artesunate is available in form of oral formulation, intramuscularformulation, intravenous formulation and suppositories. It is availableas dry free powder to be reconstituted using sodium bicarbonate andwater to prepare 6 mg/ml of liquid. This can cause problem of adversereactions if not properly constitured with sodium bicarbonate as itleaves particulate matter and slight opalescence if the pharmaceuticalactive or drug is not highly pure.

A systemic review has suggested that intravenous Artesunate should bethe drug of choice in adults with severe malaria, particularly in Asia.

Sodium Artesunate was also found to be used in control ofschistosomaniasis. It is soluble in water but has poor stability inaqueous solution. The limitation of present products its instabilitywhen composition is prepared using alkalinser like sodium bi carbonate

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient. The solution mayadditionally contain preservatives and buffers for maintenance of pH.The solution can also be used for formulation of other dosage forms,such as capsules.

II.4) Ergotamine Maleate (Oxytoxic)

Ergometrine maleate is a medicine which is used in bleeding after labourand inducing or enhancing labour. It is available as Ergometrine 500micrograms/1 ml solution for injection ampoules when used in inducinglabour. It is lipophilic in nature. The formulation is insoluble andoften leads to coloration of liquid with the observed reduction inpotency. It needs to be stabilized with antioxidants.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient. The solutioncan also be used for formulation of different dosage forms likecapsules, tablets, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

II.5, II.5_(A)) Lansoprazole and Dexlansoprazole (Proton PumpInhibitors)

Lansoprazole (II.5) is a Proton Pump Inhibitor (PPI) in the samepharmacologic class as Omeprazole. It is available as 30 mg administerednasogastrically, effectively controls intragastric pH and is analternative to I.V. Pantoprazole in patients who are unable to swallowsolid dosage formulations. Lansoprazole is a racemate [1:1-mixture ofthe enantiomers Dexlansoprazole and Levolansoprazole].

Dexlansoprazole (II. 5_(A)) is an enantiomerically pure activeingredient of a commercial drug as a result of the ‘enantiomeric shift’.Dexlansoprazole was approved by the U.S. Food and Drug Administration(FDA) on Jan. 30, 2009. It's chemical name is(R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazolewith molecular structure of given as:

Dexlansoprazole is a white to nearly white crystalline powder whichmelts with decomposition at 140° C. Dexlansoprazole is freely soluble indimethylformamide, methanol, dichloromethane, ethanol, and ethylacetate; and soluble in acetonitrile; slightly soluble in ether; andvery slightly soluble in water; and practically insoluble in hexane.

Dexlansoprazole is stable when exposed to light. Dexlansoprazole is morestable in neutral and alkaline conditions than acidic conditions.

According to US Patent Application No. US 2011/0028518 A1, Processes forthe preparation of Dexlansoprazole, an amorphous form ofDexlansoprazole, a solid dispersion of amorphous Dexlansoprazole and apharmaceutically acceptable carrier, and processes for their preparationis made. Dexlansoprazole is available as solid dosage form as capsule of30 mg and 60 mg.

The solution of the sodium salt for ready-to-use administration isunstable in nature. This has been overcome by acidifying the solution toconvert into a free acid form and then solubilizing the same inDiethylene glycol monoethyl ether or other alkyl derivatives to providea transparent, non hazy solution is obtained, which can be useful asI.V. injection for rapid onset of action when required to provideearliest result into the patient. The solution may additionally containpreservatives and buffers for maintenance of pH. The solution shows goodstability and can be used directly for parenteral use, obviating theneed for lyophilization when metal salts are used. The solution can alsobe used for formulation of other dosage forms, such as capsules, tabletsetc.

II.6) Fluconazole (Antifungal Agent)

Fluconazole also known as Diflucan®, is a triazole antifungal agentfirst described in UK Patent Application No. 2099818 (Pfizer Limited).It is used worldwide for the treatment of infections due to Candida,Cryptococcus, and other opportunistic yeasts or fungi. The drug isavailable as a tablet (50, 100, or 200 mg), as an oral suspension, andas an intravenous formulation (200 or 400 mg). When used in thetreatment of invasive candidiasis, e.g., bloodstream infections, deeptissue sites, or other normally sterile site infections, Fluconazole isadministered as an initial loading dose of 800 mg (oral or intravenous)followed by a daily maintenance dose of 400 mg (oral or intravenous).Fluconazole is designated chemically2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol with anempirical formula C₁₃H₁₂F₂N₆O and molecular weight 306.3 The structuralformula is given as:

In a bulk powder form, it appears as a white crystalline powder, and itis very slightly soluble in water and soluble in alcohol.

Fluconazole injection, USP in 0.9% NaCl administered as intravenousinfusion, is an iso osmotic solution containing 2 mg/ml of Fluconazole.It is initially administered double dose as loading dose to get earlierplasma steady state. Thus by the present art, this can be solved bymaking the formulation as I.V. bolus injection which may provide earlierplasma steady state concentration without increasing the loading dose.There are also chances of precipitation or cloudy solution formation inI.V. infusion as it is free from preservative can also be prevented bynew formulation using suitable preservative and buffer maintainingstability of the product. Chances of air embolism or moisture may occuras I.V. infusion is packed in plastic container which might be due toplastic leaching.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not onlyall the abovementioned problems are solves, but also a transparent, nonhazy as well as less viscous solution is obtained, which can be usefulas I.V. bolus injection or Depot I.M. injection for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,nasal sprays, gargles, gels, topical, liquid oral dosage forms, oticdelivery systems etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

II.7) Enalapril (ACE Inhibitor)

It is a prodrug that belongs to the angiotensin-converting enzyme (ACE)inhibitor class of medications. It is chemically designated as(2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylicacid with chemical formula C₂₀H₂₈N₂O₅ and molecular structure:

It is available as Enalaprilat (Enalapril Maleate) Injection, 1.25 mgper mL as I.V bolus or infusion.

HeartFailure Adults

PO Initial dosage is 2.5 mg twice daily. Usual dosage is 2.5 to 20mg/day in 2 divided doses (max, 40 mg/day). Titrate doses upward astolerated over a period of a few days or weeks. The max daily dose is 40mg in divided doses.

Hypertension Adults

PO Initial dosage is 2.5 mg (patients on diuretics) to 5 mg (patientsnot on diuretics) per day. Titrate to desired BP control. Usualmaintenance dosage is 10 to 40 mg/day in a single dose or 2 divideddoses.

IV 1.25 mg over a 5-min period every 6 h. For patients at high risk ofexcessive hypotension, the starting dose should be 0.625 mg or lessadministered IV over a period of 5 min or more and preferably longer (upto 1 h).

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. bolus injection for rapid onset of actionwhen required to provide earliest result into the patient as well as canbe used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

II.8) Methocarbamol (CNS Depressant)

Methocarbamol is a carbamate derivative of guaifenesin, is a centralnervous system (CNS) depressant with sedative and musculoskeletalrelaxant properties. Methocarbamol is a white powder, sparingly solublein water and chloroform, soluble in alcohol (only with heating) andpropylene glycol, and insoluble in benzene and n-hexane. The availabledose approved for human dose is Methocarbamol Tablets 500 mg, 750 mg,Methocarbamol Injection 100 mg/ml in 10 ml vials. It is a sterile,pyrogen-free solution intended for intramuscular or intravenousadministration.

Each mL contains: Methocarbamol, USP 100 mg, polyethylene glycol 300, NF0.5 mL, Water for Injection, USP q.s. The pH is adjusted, whennecessary, with hydrochloric acid and/or sodium hydroxide. The chemicalname of Methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol1-carbamate and has the empirical formula of C11H15NO5. Its molecularweight is 241.24. The structural formula is shown below:

This injection consists of polyethylene glycol 300 as solvent.Polyethylene glycol 300 has been noted to increase preexisting acidosisand urea retention in humans with renal impairment. Solutions preparedfor IV infusion should not be refrigerated as a precipitate may form.Because a haze or precipitate may form, all diluted intravenoussolutions should be physically inspected before administration.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not onlythe abovementioned stability issues are solved, but also a transparent,non hazy as well as less viscous solution is obtained, but also thenephrotoxicity associated with the prior art composition is avoided. Thesolutions remain clear without any precipitation even under refrigeratedconditions. The solutions can be useful as I.V. injection for rapidonset of action when required to provide earliest result into thepatient as well as can be used for formulation of different dosage formslike capsules, nasal sprays, gargles, gels, topical, liquid oral dosageforms, otic delivery systems etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

II.9) Lignocaine (Anti-Arrhythmic Drug)

Lignocaine Injection belongs to two groups of medicines known as localanesthetics and antiarrhythmic drugs. It is injected as a dentalanesthetic or as a local anesthetic for minor surgery and it is usedintravenously for the treatment of ventricular arrhythmias

Lignocaine is white crystalline powder, practically insoluble in waterand freely soluble in ether. Lignocaine is chemically known as2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide and the molecularstructure is given as:

One of the injections available in the market contains LignocaineHydrochloride 1% or 2% as the active ingredient and Sodium Chloride andWater for Injections as the excipients. It does not contain apreservative. Lidocaine for infusion packed in PVC container has foundto be having less content of lidocaine as result from ph dependentsorption onto the plastic.

Lidocaine is injected in form of HCl form, and by utilization thevehicle or solvent of the present invention, Diethylene glycol monoethylether or other alkyl derivatives, it is possible to use Lidocaine freebase as such.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,nasal sprays, gargles, gels, topicals, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

II.10) Azithromycin (Antibiotic)

Azithromycin is an azalide, a subclass of macrolide antibiotics.Azithromycin is one of the world's best-selling antibiotics. It isderived from erythromycin, with a methyl-substituted nitrogen atomincorporated into the lactone ring, thus making the lactone ring15-membered. This lipophilic active is chemically designated(3R,4S,5S,6R,7R,9R,11S,12R,13S,14S)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dioneand molecular structure is given as:

It is practically insoluble in water, freely soluble in methylenechloride and ethanol. It is available in Oral (capsule or suspension),intravenous, ophthalmic dosage form. For parenteral administration,Azithromycin (anhydrous) is available as sterile free dried powder (500mg) for reconstitution with sterile water for injection.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient as well as canbe used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

II.11) Cardiac Glycoside: Digoxin (Anti-Arrhythmic Drug)

Digoxin is a purified cardiac glycoside extracted from the foxgloveplant, Digitalis lanata. Its corresponding aglycone is digoxigenin, andits acetyl derivative is acetyldigoxin. Digoxin is widely used in thetreatment of various heart conditions, namely atrial fibrillation,atrial flutter and sometimes heart failure that cannot be controlled byother medication. It is available as tablet form and also available as a0.05 mg/ml oral solution and 0.25 mg/ml or 0.5 mg/ml injectablesolution. Digoxin is described chemically as (3β,5β,12β)-3-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide.Its molecular formula is C₄₁H₆₄O₁₄, its molecular weight is 780.95, andits structural formula is:

It is practically insoluble in water, freely soluble in equal amount ofmethylene chloride and methanol, slightly soluble in ethanol.

I.V. therapy may be better tolerated (less nausea); Digoxin has a verylong distribution half-life into the cardiac tissue, which will delayits onset of action by a number of hours. The half-life is about 36hours; digoxin is given once daily, usually in 125-μg or 250-μg doses.Digoxin is usually given by mouth, but can also be given by I.V.injection in urgent situations. It is available as a sterile solution ofdigoxin for intravenous or intramuscular injection. The vehicle contains40% propylene glycol and 10% alcohol. The injection is buffered to a pHof 6.8 to 7.2 with 0.17% dibasic sodium phosphate and 0.08% anhydrouscitric acid. Each 2-mL ampoule contains 500 mcg (0.5 mg) Digoxin (250mcg [0.25 mg] per mL). Dilution is not required.

Intramuscular injection of Digoxin is extremely painful and offers noadvantages unless other routes of administration are contraindicated.Thus this pain can be prevented by preparing parenteral for I.M/I.V byusing the present selected solvent which will also increase onset ofaction as it will also act as permeation enhancer.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient, but also thepain at the site of injection is prevented. The solution can also beused for formulation of different dosage forms like capsules, tablets,nasal sprays, gargles, gels, topicals, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

II.12) Dicyclomine (Gastrointestinal)

Dicyclomine is used to treat intestinal hypermotility and the symptomsof irritable bowel syndrome

Dicyclomine hydrochloride occurs as a fine, white, crystalline,practically odorless powder with a bitter taste. It is soluble in water,freely soluble in alcohol and chloroform, and very slightly soluble inether.

The solubility of dicyclomine in the present invention vehicle isobserved in range of 1 to 20 mg/ml.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injections for rapid onset of action whenrequired to provide earliest result into the patient, but also the painat the site of injection is prevented. The solution can also be used forformulation of different dosage forms like capsules, tablets, liquidoral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH. It can be also preparedand administered in combination with other drugs. Similarly, differentdrug combination of drug like Diclofenac with Dicyclomine can also beprepared in solution form for therapeutic use in required dose.

II.13) Paracetamol/Acetaminophen (Analgesic & Antipyrretic)

Paracetamol or Acetaminophen has analgesic and antipyretic propertiesand weak anti-inflammatory activity and is used in the symptomaticmanagement of moderate pain and fever. It belongs to class 3 BCS drug.The structural formula of Paracetamol is given as:

It is a white, crystalline powder. Acetaminophen is a synthetic,non-opiate, centrally acting analgesic derived from p-aminophenol. Thefull chemical name is N-acetyl-p-aminophenol. It is stable at a pHbetween 4 and 7 at 25° C. It is available in injection as i.v bolus, i.vinfusion, tablet, syrup, suppository and as oral suspension.

According to U.S. Patent Application No. 2004/0247627 A1, this inventionrefers to ready-to-use highly stable paracetamol injectable solutions,prepared by mixing paracetamol, water, propylene glycol, and a citratebuffer (pH 4.5 to 6.5), and by heating said solution under presetconditions. This injection consists of about 20% of propylene glycolonly co-solvent that shows the high viscous nature of the injectionwhich may be painful for use. At long time period storage, there isformation of paracetamol polymers or benzoquinoneimines providing colorto the solution which is unsafe for use due to decomposition.

In U.S. Application No. 20090215903, aqueous solution of paracetamol isprepared for its use by perfusion with a pH between 4.5 to 6.0. In thisformulation, byproducts of sulfate, gluconate or fufural ions can befound in solution even in presence of antioxidant into the sameformulation.

There is reported death of neonate due to use of preservative likebenzyl alcohol used in Paracetamol injection.

Thus above problems can be obviated by using Diethylene glycol monethylether to provide an alternate stable injection preventing thedevelopment of unwanted color of solution over time and preventingformation of any of byproducts as cited above.

It is possible to add other excipients while compounding in combinationwith other vehicles which are currently used in Paracetamol as infusionliquid to prevent various problems of high viscosity, stability, andimpurity related matters.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. and I.M. injections for rapid onset ofaction when required to provide earliest result into the patient, butalso the pain at the site of injection is prevented. The solution canalso be used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms, oral suspensions, suppositories,buccal delivery systems, sprays etc. The solution may additionallycontain preservatives and buffers for maintenance of pH. It can be alsoprepared and administered in combination with other drugs.

The concentration range and fill volumes can be

50 mg/0.5 ml, 100 mg/0.5 ml, 200 mg/ml, 400 mg/2 ml, 600 mg/3 ml, 1000mg/5 ml filled as ampoules similarly, vials of 5 ml containing 200mg/ml, 10 ml vial containing 100 mg/ml, 20 ml vial containing 50 mg/ml,50 ml vial containing 20 mg/ml, 100 ml vial containing 10 mg/ml dose ofParacetamol may be filled for convenient use of the medicalpractitioner. This ampoule and vial form can offer flexibility tomedical professional for use as this can provide flexibility of dose asper patients need. These forms can be diluted online with salinesolution and can be administered as a drip. A low dose of 50 mg/0.5 mlcan be useful for use in neonates for reduction and monitoring oftemperature in case of fever. Thus, this invention solubiliser canprovide oil free painless low viscosity injectables of Paracetamolfilled in ampoules, vials, blow fill ampoules, Prefilled Syringes forIntravenous and Intramuscular use for the use in Neonatal, Pediatric andAdult Patients.

II.14) Pentazocine (Analgesic Agent)

Pentazocine is a synthetically prepared prototypical mixedagonist-antagonist narcotic (opioid analgesic) drug of the benzomorphanclass of opioids used to treat moderate to moderately severe pain.Pentazocine is sparingly soluble in water. Its salt form Pentazocine HClas well as Pentazocine Lactate are also sparingly soluble in water.While lactate salt is prepared as injectable according USP and BP.Chemically, Pentazocine lactate is1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ollactate, a white, crystalline substance soluble in acidic aqueoussolutions. The molecular structure of Pentazocine is

It is white powder practically insoluble in water; freely soluble inmethylene chloride and soluble in ethanol (almost 96%).

The recommended single parenteral dose is 30 mg by intramuscular,subcutaneous, or intravenous route. This may be repeated every 3 to 4hours. Total daily dosage should not exceed 360 mg. A single,intramuscular 30 mg dose has been most commonly administered. Severeinjection site necrosis and sepsis has occurred with multiple injectionof Pentazocine lactate.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, gels,patches, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

II.15, II.15_(A)) Fentanyl & Fenatyl Citrate (Analgesic Agents)

Fentanyl is a potent, synthetic narcotic analgesic with a rapid onsetand short duration of action. It is a strong agonist at the μ-opioidreceptors. Fentanyl is approximately 100 times more potent thanmorphine. Intravenous fentanyl is extensively used for anesthesia andanalgesia, most often in operating rooms and intensive care units. It ischemically designated asN-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide and molecularstructure is given as:

Fentanyl Citrate Injection, USP is a sterile, nonpyrogenic solution ofFentanyl citrate in water for injection. Fentanyl Citrate is a potentnarcotic analgesic which is administered only by the intravenous orintramuscular routes of injection. Each milliliter contains fentanyl (asthe citrate) 50 mcg (0.05 mg). It may contain sodium hydroxide and/orhydrochloric acid for pH adjustment. pH 4.7 (4.0 to 7.5). It is intendedonly for use as a single-dose injection.

Fentanyl Citrate, a white powder which is sparingly soluble in water, ischemically designated N-(1-phenethyl-4-piperidyl)propionanilide citrate(1:1). The molecular formula is C₂₂H₂₈N₂O.C₆H₈O₇ and the molecularweight is 528.60. Fentanyl Citrate has the following structural formula:

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, gels,patches, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

II.16) Prostaglandin E1/Alprostadil (Steroids & Hormones)

Alprostadil as the naturally occurring form of prostaglandin E1 (PGE1)and is designated chemically as(11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecularweight is 354.49.

Alprostadil is a white to off-white crystalline powder with a meltingpoint between 115° and 116° C. Its solubility at 35° C. is 8000micrograms per 100 milliliter double distilled water.

The structural formula of alprostadil is represented as:

It is available in market as a sterile freeze-dried powder forintracavernosal use in four sizes: 5, 10, 20 and 40 micro-grams pervial—When reconstituted as directed with 1 milliliter of bacteriostaticwater for injection or sterile water, both preserved with benzylalcohol, gives 1.13 milliliters of reconstituted solution. Eachmilliliter of this injection contains 5.4, 10.5, 20.5 or 41.1 microgramsof Alprostadil depending on vial strength, lactose, sodium citrate andbenzyl alcohol. The deliverable amount of Alprostadil is 5, 10, 20 or 40micrograms per milliliter because approximately 0.4 microgram for the 5microgram strength, 0.5 microgram for the 10 and 20 microgram strengthsand 1.1 microgram for the 40 microgram strength is lost due toadsorption to the vial and syringe. When necessary, the pH ofAlprostadil for inject ion is adjusted with hydrochloric acid and/orsodium hydroxide before lyophilization.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy solution is obtained, which can be useful as I.Mas well as I.V. injection for rapid onset of action when required toprovide earliest result into the patient. The solution may additionallycontain preservatives and buffers for maintenance of pH. The solutioncan be filled in FFS or glass disposable syringes as well as there wouldbe no loss of drug from the vial and syringe.

Proton Pump Inhibitors (PPIs)

Generally all the PPIs are manufactured as metal salts, the reason beingfor formation of suitable crystalline forms, ready to be formulated aslyophilized metal salts or by complexing with suitable stabilizingagents to avoid their degradation. The present inventors have found thatif the acid form of the PPIs is isolated during manufacture the sameacid form can be solublised in Diethylene glycol monoethyl ether orother alkyl derivatives, to yield a clear and stable solution, which canbe used directly as injectables or used for preparation of other dosageforms, suitable for oral administration.

The following examples illustrate the abovementioned findings, whichshould be construed as non-limiting and construed as also applicable forother drugs or compounds belonging to the same or different class,having similar stability limitations.

II.17) Omeprazole (Proton Pump Inhibitor)

Omeprazole is one of the most widely prescribed drugs internationally asProton pump inhibitor in the treatment of dyspepsia, peptic ulcerdisease (PUD), gastro esophageal reflux disease (GORD/GERD),laryngopharyngeal reflux (LPR) and Zollinger-Ellison syndrome. Thechemical name of this drug is(RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yf]methylsulfinyl)-1H-benzo[d]imidazoleand molecular structure is as:

Omeprazole is a white to off-white crystalline powder that melts withdecomposition at about 155° C. It is a weak base, freely soluble inethanol and methanol, and slightly soluble in acetone and isopropanoland very slightly soluble in water. The stability of Omeprazole is afunction of pH; it is rapidly degraded in acid media, but has acceptablestability under alkaline conditions.

It is available for use in injectable form (I.V.) in Europe, but not inthe U.S. The injection pack is a combination pack consisting of a vialand a separate ampule of reconstituting solution. Each 10 ml clear glassvial contains a white to off-white lyophilized powder consisting ofOmeprazole sodium 42.6 mg equivalent to 40 mg of Omeprazole.

According to Patent No. KP 1019930009791, an Omeprazole injection ismade by (a) dissolving Omeprazole or non-oral administrating omeprazolesalt and other additives into distilled water; (b) adjusting pH 8.5-9.5with N-methylglucamine or such buffer solution as2-amino-2-hydroxymethyl-1,3-propanediol or the mixture ofN-methylglucamine and potassium hydrogen phosphate in order to make itstable.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy solution is obtained, which can be useful as I.V.injection for rapid onset of action when required to provide earliestresult into the patient. The solution may additionally containpreservatives and buffers for maintenance of pH. The solution shows goodstability and can be used directly for parenteral use, obviating theneed for lyophilization when metal salts are used. The solution can alsobe used for formulation of other dosage forms, such as capsules, tabletsetc.

II.18) Rabeprazole (Proton Pump Inhibitor)

Rabeprazole is an anti-ulcer agent used for Short-term treatment inhealing and symptomatic relief of duodenal ulcers and erosive orulcerative gastroesophageal reflux disease (GERD). The chemical name ofthis lipophilic active is(RS)-2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazolewith the following complex molecular structure that makes it insolublein water:

In market, it is mostly available in enteric coated tablet dosage formin 20 mg and 10 mg dose. The bioavailability is only 51% which can beincreased by preparing its parenteral preparation in I.V formulation.While available I.V preparation consist of Rabeprazole sodium in freezedried powder for reconstitute in 5 ml of sterile water. This availableproduct may be time consuming and costly by process. So it may bepossible to make easier I.V. parenteral preparation by dissolving thissalt in our selected solvent Di ethylene glycol mono ethyl ether andalike solvents with preferable preservatives and tris buffers tomaintain its pH near alkaline nature to maintain its stability insolution.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy solution is obtained, which can be useful as I.V.injection for rapid onset of action when required to provide earliestresult into the patient. The solution may additionally containpreservatives and buffers for maintenance of pH. The solution shows goodstability and can be used directly for parenteral use, obviating theneed for lyophilization when metal salts are used. The solution can alsobe used for formulation of other dosage forms, such as capsules—soft andhard gelating types, tablets, ready to use drops, syrups, buccaldelivery systems, oral liquids etc.

II.19) Pantoprazole (Proton Pump Inhibitor)

Pantoprazole is a PPI with the actions and uses similar to those ofOmeprazole.

It is given as the sodium salt but doses a expressed in terms of base.The molecular name of this drug is C₁₆H₁₄F₂N₃NaO₄S with the molecularstructure is as:

Pantoprazole sodium 11.28 mg is equivalent to about 10 mg ofPantoprazole. It is given intravenously as the sodium salt, over 2 to 15minutes, either as a slow injection or a short term infusion. For pepticulceration or gastro-esophageal reflux disease, the recommended dose is40 mg daily. This sodium salt form is available in form of lyophilizedparenteral which is mostly off white in color.

The solution of the sodium salt for ready-to-use administration isunstable in nature. This has been overcome by acidifying the solution toconvert into a free acid form and then solubilizing the same inDiethylene glycol monoethyl ether or other alkyl derivatives to providea transparent, non hazy solution is obtained, which can be useful asI.V. injection for rapid onset of action when required to provideearliest result into the patient. The solution may additionally containpreservatives and buffers for maintenance of pH. The solution shows goodstability and can be used directly for parenteral use, obviating theneed for lyophilization when metal salts are used. The solution can alsobe used for formulation of other dosage forms, such as capsulescapsules—soft and hard gelating types, tablets, ready to use drops,syrups, buccal delivery systems, oral liquids etc.

II.20) Lornoxicam (Antirhuematic Actives for Musculo skeletalSystem—Oxicams)

It is a Non-steroidal Anti-inflammatory Drug (NSAID of the Oxicam) classwith analgesic (pain relieving), anti-inflammatory and antipyretic(fever reducing) properties. It is available in oral and parenteralformulations. It is chemically designated as(3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2]thiazin-4-one1,1-dioxide with molecular structure as

It is slight yellow crystalline powder hardly soluble in water, slightlysoluble in chloroform and methanol, very lightly soluble in methanol andAcetonitrile, soluble in DMSO.

PCT Application No. WO/1996/041646, discloses a pharmaceuticalcomposition in the form of an aqueous solution or in the form of aproduct for reconstitution as an aqueous solution, for parenteraladministration or ophthalmic administration, comprising lornoxicam or apharmaceutically acceptable salt thereof and a cyclodextrin selectedfrom the group consisting of hydroxypropylated or sulphoalkylatedderivatives of alpha, beta or gamma cyclodextrin.

In Chinese Patent No. CN 101327193 A, the invention relates toLornoxicam freeze-dried powder injection and a preparation methodthereof. The freeze-dried powder injection comprises lornoxicam,mannite, tromethamine, EDTA and pH regulator.

The marketed one vial compositions contains 8 mg Lornoxicam, whichprovides 4 mg Lornoxicam per ml when reconstituted as recommended inwater. It contains Mannitol, trometamol, disodium edentate. Themanufacturing of the powder filling is costly process and reconstitutionis tedious and not friendly process to the doctors.

Freeze dried product needs special care of storage for the stability ofthe product for reconstitute into parenteral solution. While inclusionof Lornaxicam into cyclodextrin can be costly in sense of process andmay be nephrotoxic.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not onlyall the abovementioned problems are solves, but also a transparent, nonhazy as well as less viscous solution is obtained, which can be usefulas I.V. bolus injection or Depot I.M. injection for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,nasal sprays, gargles, gels, topical, liquid oral dosage forms, oticdelivery systems etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

II.21) Etoposide (Anticancer Agent)

Etoposide is a semisynthetic derivative of podophyllotoxin used in thetreatment of certain neoplastic diseases. It is4′-demethylepipodophyllotoxin9-[4,6-0-(R)-ethylidene-β-D-glucopyranoside]. It is very soluble inmethanol and chloroform, slightly soluble in ethanol and sparinglysoluble in water and ether. It is made more miscible with water by meansof organic solvents. It has a molecular weight of 588.58 and a molecularformula of C₂₉H₃₂O₁₃ and the molecular structure is given as:

Etoposide Injection USP is available for intravenous use as 20 mg/mLsolution in 100 mg (5 mL), 500 mg (25 mL), and 1 g (50 mL) sterile,multiple-dose vials. The pH of the clear, nearly colorless to yellowliquid is 3 to 4. Each mL contains 20 mg Etoposide USP, 2 mg citricacid, 30 mg benzyl alcohol, and 80 mg modified polysorbate 80/tween 80,650 mg polyethylene glycol 300, and 30.5 percent (v/v) alcohol.Etoposide Injection available in market is been diluted prior to usewith either 5% Dextrose Injection, or 0.9% Sodium Chloride Injection, togive a final concentration of 0.2 to 0.4 mg/mL If solutions are preparedat concentrations above 0.4 mg/mL, precipitation may occur. Theinjection is viscous and gaives pain at the site of injection. Further,it uses a cocktail of excipients, like PEG and Polysorbate 80, which aretoxic.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, not only atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injections for rapid onset of action whenrequired to provide earliest result into the patient, but also does notresult in pain at the site of injection. The solution can also be usedfor formulation of different dosage forms like capsules, tablets, liquidoral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

II.22) Docetaxel (Anticancer Agent)

It is a semi-synthetic analogue of Paclitaxel (Taxol), an extract fromthe bark of the rare Pacific yew tree Taxus brevifolia. Docetaxel is aclinically well-established anti-mitotic chemotherapy medication. It isused mainly for the treatment of breast, ovarian, prostate, andnon-small cell lung cancer.

Docetaxel is chemically designated as1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl4-acetate2-benzoate13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}and the molecular structure is given as:

According to a 2005 article in the Journal, Drugs, Docetaxel isadministered as a one-hour infusion every three weeks generally over aten cycle course and Docetaxel is considered as more effective thanDoxorubicin, Paclitaxel and Fluorouracil as a cytotoxic antimicrotubuleagent.

Docetaxel is a white to almost-white powder with an empirical formula ofC₄₃H₅₃NO₁₄.3H₂O and a molecular weight of 861.9. It is highly lipophilicand practically insoluble in water.

Docetaxel is a white powder and is the active ingredient available in 20mg and 80 mg Taxotere single-dose vials of concentrated anhydrousdocetaxel in polysorbate 80. It is pale yellow to brownish-yellowsolution at 20 mg/mL concentration. Each mL contains 20 mg docetaxel(anhydrous) in 0.54 grams polysorbate 80 and 0.395 grams dehydratedalcohol solution.

Another formulation made available consist of one vial preparation inwhich all the composition of the above remains the same except thequantity of ethanol is decreased.

From the above marketed formulations, it is seen that it still containshigh concentration of alcohol and Polysorbate 80. To obviate the use ofabove toxic vehicles, a solution prepared using Diethylene glycolmonoethyl ether can be prepared in the suitable concentration and may bediluted to the desired concentration while performing infusion therapy.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injections for rapid onset of action whenrequired to provide earliest result into the patient. The solution canalso be used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

II.23) Leuprolide (Anticancer Agent)

Leuprorelin or Leuprolide acetate is a GnRH analog. Leuprolide acts asan agonist at pituitary GnRH receptors. Leuprolide may be used in thetreatment of hormone-responsive cancers such as prostate cancer orbreast cancer, estrogen-dependent conditions, to treat precociouspuberty, and to control ovarian stimulation in In Vitro Fertilization(IVF).

The chemical name is5oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamideacetate (salt) and the molecular structure is given as:

It is available as a slow-release implant or subcutaneous/intramuscularinjection. It is available in a prefilled dual-chamber syringecontaining sterile lyophilized microspheres which, when mixed withdiluent, become a suspension intended as a monthly intramuscularinjection. Leuprolide acetate is a synthetic nonapeptide analog ofnaturally occurring gonadotropin-releasing hormone (GnRH or LH-RH).

This suspension may have stability issue concern with viscousness thatmay painful too.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient. The solutioncan also be used for formulation of different dosage forms likecapsules, tablets, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

II.24) Clarithromycin (Antibiotic)

It is effective against a broad spectrum of gram-positive andgram-negative bacteria. It is used to treat respiratory tract infectionsand soft tissue infections. It is used to treat duodenal ulcerassociated with Helicobacter pylori infections in combination withomeprazole. One common feature of clarithromycin appears to be thestability against acids. It is absorbed and diffused easily into tissuesand phagocytes without being protected from gastric acids. It is moreeffective against certain gram-negative bacteria, such as Legionellapneumophilae than Erythromycin.

This lipophilic active is chemically designated as(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione(6-O-methylerythromycinA) and molecular structure is given as:

Clarithromycin is a white to off-white crystalline powder; insoluble inwater; soluble in acetone, slightly soluble in alcohol and acetonitrile;administered orally.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

II.25) Voriconazole (Antifungal Agent)

Voriconazole is a triazole antifungal medication that is generally usedto treat serious, invasive fungal infections and it has become the newstandard of care in the treatment of invasive aspergillosis, which mayoccur in immune-compromised patients, including allogeneic BMT, otherhematologic cancers, and solid organ transplants. The systemic name ofthis drug is(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-olwith the molecular structure as:

It is available as a lyophilized powder for solution for intravenousinfusion, film-coated tablets for oral administration, and as a powderfor oral suspension. It is available as I.V. parenteral containing awhite lyophilized powder containing nominally 200 mg voriconazole andsulfobutyl ether beta-cyclodextrin sodium in a 30 mL Type I clear glassvial.

The beta-cyclodextrin derivatives are nephrotoxic. Thus there is alimitation of present formulation. The formulation requires costlytechnique of manufacturing for lyophillisation and requiresreconstitution. The practice to reconstitute is cumbersome to the healthprofessional. Further stability of solution is an issue.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

II.26) Neuromuscular Blocking Agents

Various Neuromuscular agents like Vecuronium, Atracurium isomers likeCisatracurium, Doxacurium, Tubocurarine, Pipecuronium, Rocuronium,Pancuronium etc. are available in market as lyophilized product as wellas ready to use injectables.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

II.27) Ibuprofen (Anti-Inflammatory)

Presently Ibuprofen injections are available as drug with argininecomlexation. as 200 mg/2 ml and 400 mg/4 ml

The use of arginine is very high and the drug to arginine ratio is 1:1which adds up the cost and close monitoring of manufacturing and itstherapeutic effect.

Often the muscular phlebitis is observed after its use in the clinicaltrials.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms etc. Theinjections can be prepared in the desired strengths of 200 mg and 400mg/ml. The solution may additionally contain preservatives and buffersfor maintenance of pH.

Class III: Pharmaceutical Actives of Drugs which are Available in theForm of Suspensions and are Very Difficult to be Solubilized into aSolution Form

As mentioned hereinbefore, there are certain pharmaceutical actives ordrugs, which are very difficult to solubilize into a solution form andhave further stability issues i.e. instability and often require complexand expensive technology for formulation of such actives into suitablestable dosage forms, especially suspension forms.

Drugs that are present in oily or aqueous liquid form have solubilityproblems as well as various physical as well as chemical issues whenincorporated in the formulation. They are also prepared using difficultmanufacturing process. Such formulations are found to cake on standingin addition to phase separation which is common problems of suspensionform. Stabilization of the emulsion formulation is a consistent problemand challenge to pharmaceutical scientists. Currently availableformulations in the market are associated with multitude of problems ascited below.

1) Costly Technology:

The process involved in their preparation uses complex technologies tomaintain it as suspension form. Hence, there are difficulties in theirmanufacturing and maintaining of consistency of the formulation.

The suspensions during the manufacturing requires process controls andchecks to maintain uniformity of the particle size in the preparationsand for their stability for the intended forms during the end use.

2) Manufacturing Problems: Difficulties in Stabilizing the Suspensions.

The suspension should remain homogenous on storage. The suspension oftencauses agglomeration and thus becomes nonhomogenious.

The emulsions are not user friendly to the Doctors. Health professionalsalways prefer clear solution for the parenteral administration.

Such pharmaceutical actives or drugs can be effectively stabilized byutilization of Diethylene glycol monoethyl ether or other alkylderivatives as a primary vehicle or solvent, to provide clear,transparent, non hazy solutions of the said pharmaceutical actives ordrugs in the said vehicle or solvent, which are further less viscous andare ‘ready to use’ for parenteral administration through I.V., I.M. orother routes of injection or can be used for formulation of variousother dosage forms of the pharmaceutical actives or drugs, such as forexample, capsules, tablets, nasal sprays, gargles, dermal applications,gels, topicals, liquid oral dosage forms and other dosage forms. Thesolutions are easy to manufacture, do not involve lengthy and tediousmanufacturing processes and are therefore, economical, viable and hencebeneficial to patients. Further, when administered parenterally, thesolutions are easily flowable, easily syringable, easy to inject andcause less pain at the site of the injection and are therefore,beneficial not only to the patients bit also to thedoctors/physicians/nurses. Furthermore, the pharmaceutical compositionsare safe and less toxic, when administered

The various pharmaceutical actives or drugs, belonging to this class, toname a few are the following, which again to reiterate is non-limitingas far as the scope of the invention, is concerned.

III.1, III.1_(A)) Prednisolone & Prednisolone Acetate (Steroids &Hormones)

Prednisolone is a synthetic glucocorticoid, a derivative of cortisol. Itis used to treat a variety of inflammatory and auto-immune conditions.It is the active metabolite of the drug prednisone.

It is a white, hygroscopic, crystalline powder and it showspolymorphism. It is very slightly soluble in water, soluble in alcoholand sparingly soluble in acetone. The IUPAC name of this drug is(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione and the chemicalstructure is given as:

It is available in various salt forms as Prednisolone acetate,Prednisolone sodium succinate, Prednisolone disodium phosphate,Prednisolone Tebutate. In market, Prednisolone acetate is available asan injectable suspension.

Prednisolone acetate is a white crystalline powder. It is practicallyinsoluble in water and slightly soluble in alcohol. The chemical name ofthis salt is 11β,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetateand the chemical structure is given as:

In the market, Prednisolone acetate is available as 25 mg/ml aqueouswhite suspension for injection which contains water for injection,Sodium chloride for injection, benzyl alcohol, sodiumcarboxymethylcellulose, Polysorbate 80, with sodium hydroxide orhydrochloric acid as pH adjuster.

This suspension requires good micronisation of the drug (thusmaintaining the particle size) and thus in all possibility of caking onstorage particularly at low temperatures. Further phase separation onlong storage can also occur. It is also prepared using costly methods.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy solution is obtained, which can be useful as I.V.injection for rapid onset of action when required to provide earliestresult into the patient. The solution may additionally containpreservatives and buffers for maintenance of pH. The solution shows goodstability and can be used directly for parenteral use, obviating theneed for lyophilization when metal salts are used. The solution can alsobe used for formulation of other dosage forms, such as capsules,tablets, eye drops, ear drops etc.

III.2) Methyl Prednisolone (Steroids & Hormones)

Methylprednisolone is a synthetic glucocorticoid or corticosteroid drug.It is a variant of prednisolone, methylated at carbon 6 of the B ring.The molecular structure of this lipophilic active is as:

Methylprednisolone is typically used for its anti-inflammatory effects.Methylprednisolone occurs as a white to practically white, odorless,crystalline powder. It is sparingly soluble in alcohol, in dioxane, andin methanol, slightly soluble in acetone, and in chloroform, and veryslightly soluble in ether. It is practically insoluble in water.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injection for rapid onset ofaction when required to provide earliest result into the patient as wellas can be used for formulation of different dosage forms like capsules,nasal sprays, gargles, gels, topicals, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

III.2_(A)) Methyl Prednisolone Acetate (Steroids & Hormones)

Methyl Prednisolone acetate is an anti-inflammatory glucocorticoidavailable as intramuscular, intra-articular, soft tissue orintralesional injection. It is available in three strengths: 20 mg/Ml;40 mg/ml; 80 mg/ml. The chemical name for methylprednisolone acetate ispregna-1,4-diene-3,20-dione, 21 (acetyloxy)-11,17-dihydroxy-6-methyl-,(6α, 11β)— and the molecular weight is 416.51. The structural formula isrepresented below:

It is available as sterile aqueous suspension so the stability of suchproduct may be issue for long time storage. Polyethylene glycol used inthe product increases the viscosity of the formulation (Gibaldi's DrugDelivery System in Pharmaceutical Care, Page No. 117) which may be alsoan issue concern with the pain to patient at the site of application.

As it is available in suspension form, stability, particle size, andstorage of the product are critical factors for handling. By utilizingthe vehicle or solvent of the present invention solvent, Diethyleneglycol monoethyl ether or other alkyl derivatives, a transparent, nonhazy as well as less viscous solution is obtained, which can be usefulto use as I.M as well as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

III.3) Medroxy Progesterone Acetate (Steroids & Hormones)

Medroxyprogesterone acetate, also known as17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated asMPA, is a steroidal progestin, a synthetic variant of the human hormoneprogesterone. It is used as a contraceptive, in hormone replacementtherapy and for the treatment of endometriosis as well as several otherindications. It is chemically designated as17α-hydroxy-6α-methylpregn-4-ene-3,20-dione acetate and molecularstructure is:

MPA is a more potent derivative of its parent compoundMedroxyprogesterone. It is a white to off-white, odorless crystallinepowder, stable in air, melting between 200° and 210° C. It is freelysoluble in chloroform, soluble in acetone and in dioxane, sparinglysoluble in alcohol and methanol, slightly soluble in ether and insolublein water. It is available as Aqueous Suspension active by the parenteraland oral routes of administration. It is available as intramuscularinjection in which each ml consists of 400 mg/ml MPA. The vehicle usedas parenteral solvent is PEG 3350.

The viscosity of PEG 3350 is about 83 to 130 cps which is more viscousand is painful to a patient at the time of injection. As it is availablein suspension form, stability, particle size, storage of the product arerequired to be monitored.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful to use as I.M as well as I.V. injection for rapidonset of action when required to provide earliest result into thepatient as well as can be used for formulation of different dosage formslike capsules, nasal sprays, gargles, gels, topical, liquid oral dosageforms etc. The solution may additionally contain preservatives andbuffers for maintenance of pH.

III.4) Triamcinolone Acetonide (Steroids & Hormones)

Triamcinolone acetonide is ester form of triamcinolone, a syntheticglucocorticoid corticosteroid with marked anti-inflammatory action. Thechemical name for triamcinolone acetonide is9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic16,17acetal with acetone. Its structural formula is:

It is white to off-white crystalline powder, practically insoluble inwater but soluble in alcohol and chloroform. It is available in asterile aqueous suspension form in 40 mg dose in the market forintramuscular application. During administration of this product, manyprecautions have to be taken. Before using the vial is to be shaken toensure a uniform suspension. During syringability, ruling out ofclumping or granular appearance of the suspension before withdrawinginto syringe is necessary. After withdrawal, injection is to be appliedas soon as possible before it starts settling in the syringe. The entireproblems are always an issue for a physician.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

III.5) Stanozolol (Steroids & Hormones)

Stanozolol is a synthetic anabolic steroid derived fromdihydrotestosterone. It has been approved by the FDA for human use.Unlike most injectable anabolic steroids, 28aphtha28ol is not esterifiedand is sold as an aqueous suspension, or in oral tablet form. Thus thisaqueous suspension can be prepared as clear viable I.M injectablepreparation by using present art solvent. It is chemically designated as1S,3As,3Br,5As,10As,10Bs,12As)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]79aphtha[1,2-f]indazol-1-olwith chemical structure as:

It is white crystal practically insoluble in water; soluble 1 in 41 ofalcohol, 1 in 74 of chloroform, and 1 in 370 of ether; soluble indimethylformamide; slightly soluble in acetone and ethyl acetate.

It is available as suspension. It is presented most commonly as a 50mg/mL injection or a 5 mg tablet. However, recently 100 mg/mL versionshave become available. A common dosage can be 10-25 mg/day orally and25-50 mg daily injected. The suspension might have stability relatedproblem on long storage; it is also required to maintain the particlesize.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.M as well as I.V. injection for rapid onset ofaction when required to provide earliest result into the patient. Thesolution may additionally contain preservatives and buffers formaintenance of pH. The same solution may be employed for other dosageforms for example, like capsule form.

III.6) Propofol (Hypnotic Agent)

Propofol is a short-acting, intravenously administered hypnotic agent.Its uses include the induction and maintenance of general anesthesia,sedation for mechanically ventilated adults, and procedural sedation.The chemical name of Propofol is 2,6-diisopropylphenol with molecularstructure given as:

It is light yellow liquid, very slightly soluble in water, miscible withhexane and with methanol.

Propofol has been referred to as “milk of amnesia” because of themilk-like appearance of its intravenous preparation. The currentlyavailable preparation is 1% propofol, 10% soybean oil, and 1.2% purifiedegg phospholipid (like LIPOVA-E120) as an emulsifier, with 2.25% ofglycerol as a tonicity-adjusting agent, and sodium hydroxide to adjustthe pH. It also contains EDTA, a common chelation agent, that also actsalone (bacteriostatically against some bacteria) and synergisticallywith some other antimicrobial agents. Newer generic formulations containsodium metabisulfite or benzyl alcohol as antimicrobial agents. Propofolemulsion is a highly opaque white fluid due to the scattering of lightfrom the tiny (˜150 nm) oil droplets that it contains. Thus from theabove problem, milk of amnesia might be removed by using the presentinvention solvent using preferable preservatives and buffer withefficient process without any lyophilization for the drug and makingcost effective product.

Doctors always prefer to use clear liquid to avoid any extraneousmaterial directly injected into veins. The presently available injectionhas a difficulty in maintaining the particle size and also prohibitivefor multiple uses because of the composition is rich in nitrogen tosupport microbial growth.

The cited problems in emusion formulations can be overcome byformulating the drug using Diethylene glycol monoethyl ether in strengthof 1 mg to 500 mg/ml and can administered with suitable adjuvants todirectly infused in the infusion bag after modifying suitably andmodified drug delivery system can be developed.

Viscosity of propofol is less than 5 cps.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. bolus injection or Depot I.M. injection forrapid onset of action when required to provide earliest result into thepatient as well as can be used for formulation of different dosage formslike capsules, nasal sprays, gargles, gels, topical, liquid oral dosageforms etc. The solution may additionally contain preservatives andbuffers for maintenance of pH.

III.7) Clevidipine Butyrate (Calcium Channel Blocker)

It is a dihydropyridine L-type calcium channel blocker. It is used toachieve the desired reduction in blood pressure. It is chemicallydesignated as O3-(butanoyloxymethyl) O5-methyl(4R)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5dicarboxylateand molecular structure is given as

Clevidipine is practically insoluble in water and is generallyformulated in an oil-in-water emulsion. Clevidipine butyrate is rapidlydistributed and metabolized, resulting in an ultra-short half-life. Soit is prepared in form of I.V injection. But the available marketedproduct is a sterile, milky-white opaque emulsion in a vial containing0.5 mg/mL of Clevidipine butyrate for intravenous use as an infusioncentrally or peripherally. The maximum recommended dose is 32 mg/h. Itis a single-use parenteral product that contains phospholipids and cansupport the growth of micro organisms. Thus there are chances ofcontamination as well as stability problem of such emulsion when storedfor a long time. Constant quality check on particle size, microbialload, caking and phase separation are required.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.8) Vitamin K (Vitamins & Minerals)

It belongs to a group of structurally similar, fat-soluble vitamins thatthe human body needs for posttranslational modification of certainproteins required for blood coagulation, and in metabolic pathways inbone and other tissue. They are 2-methyl-1,4-naphthoquinone (3-)derivatives. This group of vitamins includes two natural Vitamins:Vitamin K₁ (Phytomenadione) and Vitamin K₂ (Menaquinone). Vitamin K₁ isavailable as injectable emulsion through I.V., I.M. and S.C.(Subcutaneous) in the market, while Vitamin K₂ (MK) type is made orallyavailable to mammals by natural dietary source.

Vitamin K₁: Phytomenadione is a Vitamin, which is a clear, yellow toamber, viscous, odorless or nearly odorless liquid. It is insoluble inwater, soluble in chloroform and slightly soluble in ethanol. It has amolecular weight of 450.70.

Phytomenadione is 2-methyl-3-phytyl-1,4-naphthoquinone. Its empiricalformula is C₃₁H₄₆O₂ and its structural formula is:

Vitamin K1 Injection (Phytomenadione Injectable Emulsion, USP) is ayellow, sterile, nonpyrogenic aqueous dispersion available for injectionby the intravenous, intramuscular and subcutaneous routes. Eachmilliliter contains phytomenadione 2 or 10 mg, polyoxyethylated fattyacid derivative, dextrose, hydrous in water for injection; benzylalcohol added as preservative. It may contain hydrochloric acid for pHadjustment. pH is 6.3 (range of 5.0 to 7.0).

This is an available emulsion which is yellow in color while it might behigh cost process to provide desired particle size dispersion, thusstability can be issue. Thus a clear pellucid parenteral solution can beprepared by using the present invention solvent diethylene glycolmonoethyl ether with addition of suitable preservatives and antioxidantas Phytomenadione is oxygen sensitive.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient. The solutioncan also be used for formulation of different dosage forms likecapsules, tablets, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

Analgesic Agents: (NSAIDs as Well as Narcotic Analgesics)

The Non-steroidal anti-inflammatory drugs (NSAIDs) has a wide range andthey are available both in non-prescription and prescription mode. Themajor groups of NSAIDs which can be used to prepare parenteral I.V bolusas well as I.M preparations utilizing the vehicle or solvent of thepresent invention, Diethylene glycol monoethyl ether or other alkylderivatives are given below:

Salicylic acid group: Aspirin (acetyl salicylic acid); Choline magnesiumtrisalicylate, Diflunisal and salsalate; Propionic acid group:Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, andOxaprozin; Acetic and acid group: Aceclofenac, Indomethacin, Sulindac,and Tolmetin; Fenamic acid group: Meclofenamate and Mefenamic acid;Napthylalkenone group: Nabumetone; Pyarnocarboxylic acid group:Etodalac; Pyrrole group: Keterolac.

The injections of NSAIDs can be prepared alone or in combination withother drugs for therapeutic purpose i.e, presently approved drugs can bemade available in combination with other drugs combined to produce aclear injectables wherein wholly Diethylene glycol monoethyl ether up to100% by volume can be used in varying concentration with otherco-solvents without causing any physical changes like color change,crystal formation, etc.

Injection form is more advantageous over oral form of the compound asserum concentration of oral NSAID is lesser because of intestinalmetabolism of the drug. Dry powder injectable NSAID needs to belyophilized and then reconstituted before use. The process is costly andcumbersome. So, the present art is helpful to provide clear parenteralsobviating above difficulties.

III.9) Aceclofenac (NSAID)

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) used forthe relief of pain and inflammation in rheumatoid arthritis,osteoarthritis and ankylosing spondylitis. Aceclofenac is the glycolicacid ester of diclofenac. The systemic name of this NSAID is2-[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxyacetic acid with themolecular structure as

It is white crystalline powder practically insoluble in water, freelysoluble in acetone, soluble in alcohol.

Aceclofenac is present as I.V bolus in market as dose of 150 mg per mlin which vehicles like Polyethylene glycol, TCLS01 solvent, Argininesolution for lyophilized Active are used.

In WO 2006054315 B1, the invention relates to nonaqueous liquidparenteral aceclofenac formulation in which propylene glycol was used asinjectable vehicle which is viscous in nature (58.1 cps) that can bepainful at the site of injection.

In Indian Patent Application No. 67/BOM/99, use of dimethyl isosorbideas a parenteral solvent in Aceclofenac injection was found to beirritant and pain full at site of injection.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gels, topicals, liquid oral dosage forms etc. The solution mayadditionally contain preservatives and buffers for maintenance of pH.

III.10) Ethinylestradiol (Steroids & Hormones)

Ethinyl estradiol is a derivative of 17β-estradiol (E2), the majorendogenous estrogen in humans. It is an orally bioactive estrogen usedin many formulations of combined oral contraceptive pills. It is one ofthe most commonly used medications for this purpose.

It is chemically denoted as19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol with molecularstructure as:

It is a white to slightly yellowish white, crystalline powder;odourless, practically insoluble in water; freely soluble in ethanol(˜750 g/l) TS; soluble in acetone and dioxan.

It is available in the market as 0.5 mg and 1 mg of Ethinyl estradioloral tablet. Most combination birth control pills today contain between20 mcg (low dose pills) to 30/35 mcg of Ethinyl estradiol.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, liquidoral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.11) Terbinafine (Antifungal Agent)

Terbinafine hydrochloride is a synthetic allylamine antifungal. It ishighly lipophilic in nature. It prevents conversion of squalene tolanosterol, ergosterol cannot be synthesized. This is thought to changecell membrane permeability; causing fungal cell lysis. Terbinafinehydrochloride is a white fine crystalline powder that is freely solublein methanol and dichloromethane, soluble in ethanol, and slightlysoluble in water. It is chemically designated as[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)(naphthalen-1-ylmethyl)aminewith the molecular structure given as:

As a 1% cream or powder it is used for superficial skin infections. Oral250 mg tablets are often prescribed for the treatment of onychomycosisof the toenail or fingernail due to the dermatophyte Tinea unguium. Itis also available as gel. The drug accumulates in the skin tissues andin nails after ingestion or dermal application to have localized effect.It might be possible to formulate parenteral I.V Bolus for rapid onsetof action by the present art.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. bolus injection for rapid onset of actionwhen required to provide earliest result into the patient as well as canbe used for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

III.12) Roxithromycin (Antibiotic)

Roxithromycin is a semi-synthetic macrolide antibiotic. It is used totreat respiratory tract, urinary and soft tissue infections.

This lipophilic active is chemically designated as(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-d-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-oneand molecular structure is given as:

It is soluble in ethanol and acetone, methanol and ethyl etherdissolved, almost insoluble in water; 2, the water solubility: 0.1 gdissolved in 30 ml water.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient as well as canbe used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

III.13) Spironolactone (Aldosterone Receptor Antagonist)

Spironolactone is a potassium-sparing diuretic (water pill) thatprevents your body from absorbing too much salt and keeps your potassiumlevels from getting too low. It is practically insoluble in water about22 mg/L at 25° C. It is used to diagnose or treat a condition in whichyou have too much aldosterone in your body. It is chemically designatedas 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid,γ-lactone acetate and the molecular structure is:

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.14) Eplerenone (Aldosterone Receptor Antagonist)

Eplerenone is an aldosterone antagonist used as an adjunct in themanagement of chronic heart failure. It is similar to the diureticspironolactone, though it is much more selective for themineralocorticoid receptor in comparison (i.e., does not possess anyantiandrogen, progestogen, or estrogenic effects), and is specificallymarketed for reducing cardiovascular risk in patients followingmyocardial infarction. It is chemically designated aspregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo,≡-lactone, methyl ester (7α,11α,17α) and molecular structure is

Eplerenone is an odorless, white to off-white crystalline powder. It isvery slightly soluble in water, with its solubility essentiallypH-independent. The octanol/water partition coefficient of eplerenone isapproximately 7.1 at pH 7.0. These drugs are mostly available in marketas oral tablet. This both actives are possible to be formulated as aparenteral for unconscious patient.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. or I.M. injections for rapid onset of actionwhen required to provide earliest result into the patient as well as canbe used for formulation of different dosage forms like capsules,tablets, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

III.15) Amlodipine Besylate (Calcium Channel Blocker)

It is a long-acting calcium channel blocker. Amlodipine besylate, USP ischemically described as3-Ethyl-5-methyl(±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate,mono benzene sulphonate. Its molecular formula is C₂₀H₂₅CIN₂O₅.C₆H₆O₃Sand its structural formula is:

It is slightly soluble in water. It is available as oral tablet in doseof 2.5, 5 and 10 mg and as capsule as per USP. According to 14 reportsfrom FDA, it was found to have swelling at site of injection might bedue to use of viscous solvents.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution further avoids swelling atthe site of injection. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.16) Barnidipine Hydrochloride (Calcium Channel Blocker)

It is found to be safer antihypertensive agent used to providehypotension effect in patient. It is chemically designated as3-(3R)-1-benzylpyrrolidin-3-yl 5-methyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate andmolecular structure is

It is a light yellow crystalline powder which is insoluble in waterwhile soluble in DMSO and methanol. This product is available in capsuleform in dose strength of 5, 10, 15 mg.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.17) Benidipine Hydrochloride (Calcium Channel Blocker)

It is a new hypertensive agent i.e., dihydropyridine calcium channelblocker for the treatment of high blood pressure, licensed in Japan fororal administration. It is chemically known as O5-methylO3-[(3R)-1-(phenylmethyl)piperidin-3-yl]2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylateand its molecular structure is given as:

It is occurs as a yellow crystalline powder. It is very soluble informic acid, soluble in methanol, sparingly soluble in ethanol andpractically insoluble in water.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.18) Nifedipine (Calcium Channel Blocker)

Nifedipine is a dihydropyridine calcium channel blocker. Its main usesare as an anti-anginal and antihypertensive, It is chemically designatedas Dimethyl2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate andmolecular structure is.

It has a molecular weight of 346.3, practically insoluble in water. Itis available as capsules are formulated as soft gelatin capsules fororal administration, each containing 10 mg Nifedipine, in which glycerinand PEG is used as inert excipients.

According to Chinese Patent No. 94110139, this invention refers to aNifedipine injection belonged to calcium antagonist. It is prepared, byinvolving Nifedipine, polyvinyl pyrrolidone, alcohol for injection atratio of formulation required to obtain the product.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

III.19) Cilnidipine (Calcium Channel Blocker)

Cilnidipine is the novel calcium antagonist accompanied with L-type andN-type calcium channel blocking function. Due to its N-typecalcium-channel blocking properties, it has more advantages compared toconventional calcium-channel blockers. It has lower incidence of Pedaledema, one of the major adverse effects of other calcium channelblockers. Cilnidipine has similar blood pressure lowering efficacy ascompared to Amlodipine. The chemical name of this active isO3-(2-methoxyethyl)O5-[(E)-3-phenylprop-2-enyl]2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylateand the molecular structure is given as:

It is available in marketed as oral tablet in dose of 5 mg, 10 mg, and40 mg. This medication works by inhibiting the action of angiotensinreceptors, thereby helping to control hypertension.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,liquid oral dosage forms etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

Other Calcium Channel Blockers like Darodipine, Nimodipine, Nisoldipine,Nitrendipine, Felodipine, Nicardipine, and Isradipine can also beformulated into clear pellucid solutions for I.V. or I.M. injectionsutilizing the vehicle or solvent of the present invention, Diethyleneglycol monoethyl ether or other alkyl derivatives.

III.20) Captopril

It is an angiotensin-converting enzyme (ACE) inhibitor used for thetreatment of hypertension and some types of congestive heart failure.Captopril was the first ACE inhibitor developed. It is chemicallydesignated as(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acidand molecular structure is:

It is easily soluble in water but might get converted into salt form soI.V form might be not developed yet till now. Small intravenous bolusinjections of captopril may appear to be effective rapidly and can bewell tolerated in moderate to severe essential hypertension. Short-termintravenous administration seems to predict the response to chronic oralcaptopril therapy. Thus by the present art, I.V bolus parenteral can beprepared by first converting this active into acid form which is thensolubilize in diethylene glycol monoethyl ether.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. bolus injection or Depot I.M. injection forrapid onset of action when required to provide earliest result into thepatient as well as can be used for formulation of different dosage formslike capsules, nasal sprays, gargles, gels, topical, liquid oral dosageforms, otic delivery systems etc. The solution may additionally containpreservatives and buffers for maintenance of pH.

Other commercially available ACE inhibitors like Ramipril, Fosinopril,Zofenopril, Perindopril, Quinapril, Lisinopril etc., which arelipophilic in nature can also be formulated by utilizing the vehicle orsolvent of the present invention solvent, Diethylene glycol monoethylether or other alkyl derivatives, a transparent, non hazy as well asless viscous solution is obtained, which can be useful as I.V. bolusinjection or Depot I.M. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, nasalsprays, gargles, gels, topical, liquid oral dosage forms, otic deliverysystems etc. The solution may additionally contain preservatives andbuffers for maintenance of pH.

III.21) Celecoxib

Celecoxib is a sulfonamide NSAID and selective COX-2 inhibitor used inthe treatment of osteoarthritis, rheumatoid arthritis, acute pain. Thechemical name of celecoxib is with molecular structure as:

It is soluble in DMSO at 200 mg/mL; soluble in ethanol at 100 mg/mL;very poorly soluble in water; Celecoxib is available by prescription incapsule form and as I.V bolus parenteral in market.

The pain relief offered by celecoxib is similar to that offered byparacetamol.

The prior art indicates that such injections are prepared and marketedusing Dimethyl Isosorbide which is painful at the site.

Celecoxib is soluble in Diethylenglycol monoether ether and with othercosolvents like diemthyl isosrbide in minimum quantity

To overcome the problem of pain and irritancy at site of injections theI.V/I.M Injection of Etoricoxib and Celecoxib is prepared by dissolving60, 90, 120 mg/ml solution and 100 mg/ml/200 mg/ml in Diethylene glycolmonoethyl ether with antioxidant and preservative respectively.

It offers an advantage of less painful, less viscous free flowing easilysyringable liquid. It offers a quick onset of action.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as I.V. injection for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, gels,patches, liquid oral dosage forms etc. The solution may additionallycontain preservatives and buffers for maintenance of pH.

III.22) Isoxsuprine Hydrochloride (Anti-Arrhythmic Drug)

It is beta-adrenergic agonist that causes direct relaxation of uterineand vascular smooth muscle. Its vasodilating actions are greater on thearteries supplying skeletal muscle than on those supplying skin. It isused in the treatment of peripheral vascular disease and in prematurelabor. The chemical name of this lipophilic active is4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol hydrochloride.lsoxsuprine hydrochloride occurs as a white odorless, crystallinepowder, having a bitter taste, It has a following structural formula:

It is marketed as Tablet form of dose strength 20 mg and as parenteralinfusion as well as I.M parenteral of 5 mg/ml. An intravenous infusionis prepared by dilution of the injection in an appropriate quantity of5% dextrose injection, 5% dextrose in 0.45% sodium chloride injection,or 5% dextrose in 0.23% sodium chloride injection. Dilution in 0.9%sodium chloride injection is not recommended because of the risk ofpulmonary edema. Because of the risk of hypotension and tachycardia,single intramuscular doses greater than 10 mg are not recommended.

By utilizing the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives, atransparent, non hazy as well as less viscous solution is obtained,which can be useful as injections for rapid onset of action whenrequired to provide earliest result into the patient as well as can beused for formulation of different dosage forms like capsules, tablets,nasal sprays, gargles, gels, topicals, liquid oral dosage forms etc. Thesolution may additionally contain preservatives and buffers formaintenance of pH.

III.23) Drugs Related to Ophthalmic Suspension (Ocular) and OticSuspension

Drugs that are prepared for ophthalmic as well as otic suspensions canalso be formulated as clear pellucic solutions, which are furthertransparent, non hazy and less viscous by utilization of the vehicle orsolvent of the present invention solvent, Diethylene glycol monoethylether or other alkyl derivatives.

In the prior art formulations the particles in the suspension have atendency of sedimentation and aggregation. If administered in to thetissues, often lead to irritation and embolism (e.g. Eye drops havingsuspended particles can cause irritation to mucosal membrane of eyescausing pain and discomfort to the patients, embolism which is causeddue to particles infused as I.V.

The preparations using Diethylene glycol monethyl ether or other alkylderivatives are clear limpid, free from particulate matter and devoid ofparticle agglomeration.

Table-I provides Drugs belonging to different pharmacological ortherapeutic classes which can also be formulated as clear pellucicsolutions, which are further transparent, non hazy and less viscous byutilization of the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives.

TABLE I Drugs Available as Opthalmic Suspensions and Otic SuspensionsDrug & Therapeutic Chemical Structure & Chemical Solubility FormulationsAvailable in the Code Category Name Profile Market & their ProblemsOphthalmic Suspensions III.23_(A) Brinzolamide Carbonic AnhydraseInhibitor

Insoluble in water, very soluble in methanol and soluble in ethanol.Solubility in Diethylene glycol monoethyl ether is 55.55 mg/ml. As aSterile, Aqueous Suspension of Brinzolamide which has been formulated tobe readily suspended and slow settling, following shaking. It has a pHof approximately 7.5 and an osmolality of 300 mOsm/kg. 1% (10 mg/ml)opthalmic suspension Settling Problem of Suspension III.23_(B)Difluprednate Anti- inflammatory Corticosteroid

Very low solubility in water Sterile Preserved Opthalmic Emulsion forthe Treatment of Inflammation and Pain associated with Ocular Surgery.0.05% is a Sterile, Topical Anti- inflammatory Corticosteroid forOphthalmic use. Difluprednate 0.5 mg (0.05%); INACTIVE: Boric acid,Castor oil, Glycerin, Polysorbate 80, Water for injection, Sodiumacetate, Sodium EDTA, Sodium hydroxide (to adjust the pH to 5.2 to 5.8).The emulsion is essentially isotonic with a tonicity of 304 to 411mOsm/kg. PRESERVATIVE: Sorbic acid 0.1%. Settling Problems and UnwantedChemicals like Castor Oil being used III.23_(C) Flurometholone AcetateAnti- inflammatory Corticosteroid

Freely soluble in chloroform and acetone, soluble in ethanol, veryslightly soluble in water Opthalmic Suspension (not for injection)Flarex (Fluorometholone Acetate Ophthalmic Suspension) Sterile Each mLcontains: Active: Fluorometholone acetate 1 mg (0.1%). Preservative:Benzalkonium chloride 0.01%. Inactives: Sodium chloride, Monobasicsodium phosphate, Edetate disodium, Hydroxyethyl cellulose, Tyloxapol,Hydrochloric acid and/or Sodium hydroxide (to adjust pH), and purifiedwater. The pH of the Suspension is approximately 7.3, with an Osmolalityof approximately 300 mOsm/kg. Partile Size Control and Irritation ifAgglomeration occurs. III.23_(D) Loteprednol Anti- inflammatoryCorticosteroid

Soluble in DMSO 34%, in 0.83% ethanol, 0.2241% propylene glycol, 8 μgper 1t in water. Sterile, Topical Anti- inflammatory Corticosteroid Theactive ingredient is Loteprednol Etabonate. Each ml contains 5 mg (0.5%)Loteprednol Etabonate. •The other ingredients are Disodium Edetate,Glycerol, Povidone, Purified Water and Tyloxapol. •Benzalkonium Chloride(0.01%) is added as a preservative. •Sodium Hydroxide and/orHydrochloric Acid are added to adjust the pH. Suspension and ParticleSize Controls. III.23_(E) Besifloxacin Antibacterial

Sparingly soluble in methanol, Sparingly soluble in water (1 mg/mL),DMSO (<1 mg/mL) 0.6% Suspension: Opthalmic Suspension formulated withDuraSite Technology 6.63 mg Besifloxacin Hydrochloride equivalent to 6mg Besifloxacin Base (6 mg/ml) Suspension and Control on ParticlesIII.23_(F) Loteprednol Etabonate + Tobramycin Anti- inflammatoryCorticosteroid + Antibiotic

Solubility of Tobramycin: Soluble in water; very slightly soluble in100% ethanol. Solubility in Diethylene glycol monoethyl ether: 25 mg/mlSolubility in Diethylene glycol monoethyl ether: 3 mg/ml Ocular SteroidSuspension Each mL contains: Actives: Loteprednol Etabonate 5 mg (0.5%)and Tobramycin 3 mg (0.3%). Inactives: Edetate Disodium, Glycerin,Povidone, Purified Water, Tyloxapol, and Benzalkonium Chloride 0.01%(preservative). Sulfric Acid and/or Sodium Hydroxide may be added toadjust the pH to 5.7-5.9. The suspension is essentially isotonic with atonicity of 260 to 320 mOsm/kg. The control on particle size is aconsistent problem for both the drugs III.23_(G) Brimonidine +Brinzolamide Carbonic Anhydrase Inhibitor + Antiglaucoma Agent

 

Brinzolamide: insoluble in water, very soluble in methanol and solublein ethanol. Brimonidine tartarate: soluble in water (34 mg/mL) at pH 6.5Opthalmic Suspension (1%/0.2%) 10 mg/ml Brinzolamide 2 mg/ml BrimonidineTartarate Particle Size Control is essential III.23_(H) RimexoloneGlucocorticoid Steroid

Very slightly soluble in water; freely soluble in chloroform; soluble inethyl acetate and in methanol 1% Opthalmic Suspension Control onParticle Size is essential III.23_(I) Sulfacetamide + PrednisoloneAcetate Antibacterial + Corticosteroid

Sulfacetamide: Water-soluble <0.01 g/100 mL at 16° C. OpthalmicSuspension 10% Sulfacetamide 0.2% Prednisolone Acetate Control onParticle Size III.23_(J) Tobramycin + Dexamethasone Antibiotic + Steroid

3 mg/ml Tobramycin 1 mg/ml Dexamethasone Opthalmic Suspension(0.3%/0.1%) Control on Particle Size III.23_(K) Neomycin Sulphate +Polymixin B Sulphate + Dexamethasone Antibiotic + Glucocorticoid

Each gram contains: Neomycin sulphate: 3.5 mg Polymixin B sulphate:10.000 unit Dexamethasone: 0.1% (1 mg) As an anti-infective Steroidcombination as Sterile Topical Ointment (3.5 g Sterile Ointment in analuminium tube) Control on Particle Size III.23_(L) Nepafenac NSAID

Soluble in DMSO and Methanol Solubility in diethyleneglycol mono ethylether is found upto 2 mg/ml Each mL contains: Active: Nepafenac 0.1%Inactives: Mannitol, Carbomer 974P, Sodium chloride, Tyloxapol, Edetatedisodium, Benzalkonium chloride 0.005% (Preservative), Sodium hydroxideand/or Hydrochloric acid to adjust pH and purified water, USP. Controlon Particle Size III.23_(M) Betaxolol Hydrochloride Beta₁ ReceptorBlocker

Freely soluble in water, ethanol, chloroform, and methanol. OpthalmicSolution/Drops Betaxolol Hydrochloride 0.5% Opthalmic Solution/Drops-Falcon Pharmaceuticals Each 5.6 mg Betaxolol Hydrochloride equivalent toBetaxolol base 5 mg Control on Particle Size Otic Suspensions III.23_(N)Ciprofloxacin & Dexamethasone Antibacterial + Glucocorticoid

Ciprofloxacin: Soluble in water; slightly soluble in methanol R; veryslightly soluble in ethanol (~750 g/l) TS; practically insoluble inacetone R and dichloromethane R. Sterile Otic Suspension (Ciprofloxacin0.3% and Dexamethasone 0.1%) Ciprofloxacin Hydrochloride (equivalent to3 mg Ciprofloxacin Base), 1 mg Dexamethasone Control on Particle Size

Class IV: Drugs Belonging to Other Therapeutic Categories

Table-II provides Drugs belonging to different pharmacological ortherapeutic classes which can also be formulated as clear pellucicsolutions, which are further transparent, non hazy and less viscous byutilization of the vehicle or solvent of the present invention solvent,Diethylene glycol monoethyl ether or other alkyl derivatives. Thesolutions can be useful as I.V. or I.M. injections for rapid onset ofaction when required to provide earliest result into the patient, butalso does not have the safety and toxicity issues associated withCremophor® EL. The solution can also be used for formulation ofdifferent dosage forms like capsules, tablets, liquid oral dosage formsetc. The solution may additionally contain preservatives and buffers formaintenance of pH.

TABLE II Drugs Belonging to Different Pharmacological or TherapeuticClasses Form Drug & Available Therapeutic Chemical Structure & ChemicalIn The Code Category Name Solubility Profile Market IV.1 Vinpocetine Aninhibitor of Ca²⁺/CaM-PDE with Neuroprotective properties

Soluble in DMSO, DMF, ethanol, acetic acid, acetone, and chloroform.Insoluble in water. As an Oral, I.V. as Supplement IV.2 ItraconazoleTriazole Antifungal Agent

Soluble in organic solvents such as DMSO and dimethyl formamide.Insoluble in water. Available as Capsules or as an Oral Solution IV.3Nimodipine Potent L-type Ca2+ Channel Antagonist

Soluble in methanol. Insoluble in water in beta cyclodextrin As FilmCoated Tablet, Intravenous Injection IV.4 Ezetimibe Anti- hyperlipidemic

Freely to very soluble in ethanol, methanol, and acetone and practicallyinsoluble in water. As Tablet of 10 mg. IV.5 Valproic acidAnticonvulsant and Mood- stabilizing Agent

A colorless liquid with a characteristic odor. It is slightly soluble inwater (1.3 mg/mL) and very soluble in organic solvents. As 250 mg ofSoft Elastic Capsule, Enteric Coated Capsule, Syrup Solution, I.V.Injectable Form. IV.6 Bexarotene Antineoplastic Agent

Insoluble in water and slightly soluble in vegetable oils and ethanol,USP As 75 mg of Soft Gelatin Capsule, Topical Soft Gel. IV.7 TretinoinAnti-acne Drug

Insoluble in water As Cream or Gel of 30, 45, 60 mg, 30 ml LiquidSolution; Soft Capsule of 10, 20, 30, 40 mg, Tablet IV.8 LoperamideAnti-diarrheal

Yellow powder insoluble in water A Tablet, Capsule, and Liquid to betaken by mouth IV.9 Melphalan Alkylating Agent

<0.1 g/100 mL at 22° C., 95% ethanol and 1 drop 6 N HCl: 0.05 g/mL 50 MGInjectable Vial, 2 mg Tablet. IV.10 Tadalafil PDE5 Inhibitor

Insoluble in water and very slightly soluble in ethanol As almond shapedTablet. IV.11 Loxapine (Loxapine Succinate) Antipsychotic

Sparingly soluble in H2O, freely soluble in DMS Available as CapsuleIV.12 Amilsulpride Antipshycotic

Practically insoluble in water, sparingly soluble in ethanol, soluble inmethanol and freely soluble in dichloromethane Available as Tablet and100 mg/ml Solution Form. IV.13 Tacrolimus Antibiotic

Insoluble in water, freely soluble in ethanol, and very soluble inmethanol and chloroform. Available as Capsule & 5 mg/ml Injection. IV.14Doxorubicin Anticancer Agent

Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble inwater at 10 mg/mL with slight warming. Available as 2 mg/ml MultidoseVials & as Lyophilized Powder. IV.15 Olanazapine Antipsycotic

Olanzapine is soluble in organic solvents such as ethanol, DMSO, anddimethyl formamide, which should be purged with an inert gas. Thesolubility of olanzapine in these solvents is approx. 1, 16, and 20mg/ml, respectively. As Yellow Lyophilized Powder for Injection. IV.16Fluticasone Propionate Corticosteroid

It is practically insoluble in water, freely soluble in dimethylsulfoxide and dimethylformamide, and slightly soluble in methanol and95% ethanol. Solubility in Diethylene glycol monoethyl ether is 14.7mg/ml. Available as 50 mcg Nasal spray.

In addition to the above, various other drugs for treating AIDS, RareDiseases, Neglected diseases such as Tuberculosis, Malaria etc. can alsobe made into clear, transparent and non hazy solutions by utilizing thevehicle or solvent of the present invention solvent, Diethylene glycolmonoethyl ether or other alkyl derivatives. Such solutions can be usefulas injections for rapid onset of action when required to provideearliest result into the patient. The solution can also be used forformulation of different dosage forms like capsules, tablets, nasalsprays, gels, topics, liquid oral dosage forms etc. The solutions canalso be used for preparation of nano solutions.

EXAMPLES

The following Examples illustrate the invention in detail, which shouldnot be construed as limiting the scope of the invention.

Example 1 Solubility

The solubility of various pharmaceutical actives, belonging to the threeclasses, referred to hereinbefore in Diethylene glycol monoethyl etherare summarized in Table-III.

TABLE III The Solubility of various Pharmaceutical Actives in DiethyleneGlycol Monoethyl Ether Solubility in Diethylene Code PharmaceuticalActive Glycol Monoethyl Ether Class I: Drugs which are Difficult toSolubilize I.1 Progesterone 50 mg/ml 1.2_(A) Nandrolone Decoanate 100mg/ml 100 mg/ml I.2_(B) Nandrolone Phenyl Propionate 71.42 mg/ml 1.3_(A)Testosterone Enanthate 55.50 mg/ml 1.3_(B) Testosterone Cypionate 45.45mg/ml I.6 Fulvestrant 58.80 mg/ml I.7 Artemether 100 mg/ml I.8 Arteether80 mg/ml I.9 Haloperidol 8.30 mg/ml I.10 Vitamin D3 30 mg/ml I.12Etoricoxib 200 mg/ml I.13 Cyclosporine 50 mg/ml I.14 Paclitaxel 23.80mg/ml I.15 Piroxicam 15 mg/ml Class II: Drugs which have StabilityIssues II.3 Artesunate 100 mg/ml II.9 Lignocaine 200 mg/ml II.10Azithromycin 83 mg/ml II.12 Dicyclomine Hydrocloride 20 mg/ml II.13Paracetamol 66.66 mg/ml II.16 Prostaglandin E₁ (Alprostadil) 50 mg/mlII.19 Pantoprazole 80 mg/ml II.21 Etoposide 30 mg/ml II.22 Docetaxel 55mg/ml II.25 Voricanozole 83 mg/ml II.27 Ibuprofen 400 mg/ml Class III:Those which are Available in the Form of Suspensions and are veryDifficult to be Solubilized into a Solution Form III.1 Prednisolone11.11 mg/ml III.2 Methyl Prednisolone 30 mg/ml III.4 TriamcinoloneAcetonide 15 mg/ml III.9 Aceclofenac 150 mg/ml III.11 Terbinafine 16.66mg/ml III.21 Celecoxib 71.42 mg/ml III.23_(A) Brinzolamide 55.55 mg/mlIII.23_(D) Loteprednol 25 mg/ml III.23_(L) Nepafenac 2 mg/ml III.23_(M)Betaxolol Hydrochloride 27.77 mg/ml IV.1 Vinpocetine 12 mg/ml IV.11Loxapine Succinate 31.25 mg/ml IV.12 Amilsulpride 25 mg/ml IV.15Olanazapine 45 mg/ml IV.16 Fluticasone Propionate 14.70 mg/ml

Example 2 Progesterone (I.1)

Sr. No Ingredients Quantity/ml 1 Progesterone 100 mg 2 Benzyl Alcohol20% 3 Diethylene Glycol Monoethyl Ether q.s. up to 1 ml

The maximum solubility of Progesterone in Diethylene glycol monoethylether was found to between 0.1 to 50 mg/ml while its solubility inBenzyl alcohol was found up to 100 mg/ml. Progesterone is dissolved insolution of 20% Benzyl alcohol giving a clear solution and addDiethylene glycol monoethyl ether with constant stirring and make thevolume up to 100 ml with Diethylene glycol monoethyl ether. The clearcolourless liquid has viscosity of 3.86 cps. This solution is filled in3 ml clear glass vial.

Similarly, 2 g to 12 g of drug is dissolved in 100 ml Diethylene glycolmonoethyl ether to give a clear solution for use in therapeuticconcentration as a parenteral form. The same may be filled in vial orampoules, PFS.

Optionally, it can be mixed with preservative like benzyl alcohol in therange of about 2% to 4% for filling in multi dose container or theLiquid prepared can be used for the preparation of pessaries for vaginaldelivery by successfully matrixing with suitable excipients.

Other adjuvant may be used optionally with water in sufficient quantityto keep the solution pellucid as well as physically and chemicallystable.

The non aqueous solution can be filled in capsule or aqueous or nonaqueous liquid can be employed for their use in other oral deliverysystem.

Stability Study Data for Progesterone Injection 100 mg/ml:

40° C./ 40° C./ 25° C./ 30° C./ 40° C./ 25° C./ 30° C./ 40° C./ 25° C./30° C./ Sr. 75% 75% 60% 65% 75% 60% 65% 75% 60% 65% No. TestsSpecification Initial RH/1M RH/2M RH/3M RH/3M RH/3M RH/6M RH/6M RH/6MRH/9M RH/9M 1 Description Clear Colourless Solution Yellowish ClearColourless Colour Solution Clear Solution 2 Assay  92.5 103.00 103.00103.50 101.06 99.90 102.10 102.50 99.30 96.20 100.12 99.37 UV to (%)107.5

The stability study of this formulation containing 100 mg/mlProgesterone and tested by the validated method was found to besatisfactory.

The viscosity of the comparator brand is 4.9 cps

Example 3 Nandralone Decanoate (I.2_(A))

The solubility profile of Nandrolol decanoate with Diethylene glycolmonoethylether is about 1 to 100 mg/ml.

Sr. No. Name of Ingredients Qty/ml Qty/ml Qty/ml 1 Nandrolone 100 mg 25mg  25 mg Decanoate 2 Benzyl Alcohol 2% 2% 2% 3 BHA  1 mg  1 mg 0.3 mg 4BHT  1 mg  1 mg 0.3 mg 5 Vitamin E Acetate  1 mg  1 mg   1 mg 6Diethylene Glycol q.s q.s q.s Monoethyl Ether

Weigh accurately Nandrolone Decanoate under cool & dark place & takeclean vessel. Add Diethylene glycol monoethyl ether into this and stirvigorously to dissolve Nandrolone Decanoate until a clear solution isobtained. Add BHA, BHT & Vit. E. acetate, stir vigorously to dissolve itin Diethylene glycol monoethyl ether.

Make up the volume up to 100 ml. using Diethylene glycol monoethylether. Solution is filtered by 0.45 micron filter 0.22μ & filled in 1 mlclear glass ampoules with nitrogen flushing & stability.

The resultant solution gives a concentration of Nandrolone Decanoate.

The stable solution of Nandrolone Decanoate in the concentration of 25mg and 100 mg/ml can be prepared which has viscosity of 3.485 cps. ascompared to only injection which has more than 19 cps. The newcompsotion solution is painless while administering in the tissues.

Clear solution of Nandrolone decanoate 100 mg/ml injection or 25 mg/mlinjection is obtained. The viscosity of this final solution was foundabout 3.485 cps.

The dispensing & manufacturing process should be completed into cool &dark place because Nandrolone Decoanate is a hormonal drug and sensitiveto light, moisture, & Temperature.

Thus, 1 mg to 100 mg of drug injection can be prepared using Diethyleneglycol monoethyl ether and may be filled in ampoules or vials.

The preservative like benzyl alcohol, solubilisers and antioxidantsadded keeps the solution pellucid, physically and chemically stable.

Stability Study Data for Nandrolone Decanoate Injection 100 mg/ml:

40° C./ 40° C./ 25° C./ 30° C./ 40° C./ 25° C./ 30° C./ 40° C./ Sr.Specifi- 75% 75% RH/ 60% 65% RH/ 75% 60% 65% 75% No. Tests cationInitial RH/1M 2M RH/3M 3M RH/3M RH/6M RH/6M RH/6M 1 Description ClearColourless Solution Slight Pale Yellowish Clear Liquid 2 Assay (%)90-110 100.71 102.81 102.83 102.81 101.22 101.00 99.14 99.25 98.29

Stability Study Data for Nandrolone Decanoate Injection 25 mg/ml:

40° C./ 25° C./ 30° C./ 40° C./ 75% 60% 65% 75% Sr. Specifi- RH/ RH/ RH/RH/ No. Tests cation Initial 1M 3M 3M 3M 1 Descrip- Clear ColourlessSolution tion 2 Assay 90-110 101.95 101.69 103.21 102.79 101.59 (%)

The stability study of Nandrolone Decanoate injection of both dosestrength 25 mg/ml and 100 mg/ml are found to be in the acceptable range.

Example 4 Testosterone Cypionate (I.3_(B))

The solubility of testosterone cypionate in Diethylene glycol monoethylether was found to be 50 mg/ml with viscosity less than 7 cps.

2.5 g to 5 g of drug is dissolved in 100 ml Diethylene glycol monoethylether to give a clear solution.

The stable injections are filled in ampoules or vials or PFS for readyuse.

The final concentration can be given to the doctors after filling inampoules and vials for it therapeutic application to the doctors, forthe parenteral application.

The solution may be optionally filled in the desired concentration incaps for oral delivery or for preparing the composition for applying asgel.

The liquid may optionally have preservative like benzyl alcohol inconcentration of about 2% to 6% antioxidants in butylated hydroxylanisole or butylated hydroxy toluene may be added, which keeps thesolution pellucid as well as physically and chemically stable.

Example 5 Artemether ((I.7)

Example No. Sr. 1 2 3 No. Name of Ingredients Qty/ml Qty/ml Qty/ml 1Artemether   80 mg 80 mg  80 mg 2 Benzyl alcohol 2% v/v 2% 2% 3 BHA —  1mg 0.2 mg 4 BHT —  1 mg 0.2 mg 5 Vitamin E Acetate 0.25 mg  1 mg   1 mg6 Diethylene Glycol Monoethyl Ether Q.s Q.s Q.s 7 Molecular Sieve forDrying — —  25 mg

The viscosity of the final solution of Artemether Injection 80 mg/ml wasfound about 3.322 cps.

4 g to 10 g of drug is dissolved in 100 ml Diethylene glycol monoethylether to give a clear solution.

The necessary antioxidants and preservatives like Butylated hydroxylanisole, Butylated hydroxyl toluene, Tocopherol acetate and Benzylalcohol is added. The solution is found to be stable and can be easilyadministered by I.M. or I.V. route for desired therapeutic purpose.

The achieved concentration may be filled in ampoules, PFS or vials to beused by the doctors.

Suitable preservatives like benzyl alcohol and antioxidants like,thioglycerol and ascorbyl palmitate may be optionally added, which keepsthe solution pellucid physically and chemically stable.

The final clear solution is filled into clear glass vial of 5 ml volumeas well as can be filled into ampoules or prefilled syringes.

Stability Study Data of Artemether Injection 80 mg/ml:

Sr No. Test Initial 1M/40° C. 2M/40° C. 1 Descrpition Clear ColourlessSolution 2 Assay, Limit 104.84 100.35 98 90 to 110%

The Injections can be Administered Through I.M. or I.V. Route

The stability data of Artemether injection prepared using Dietheyleneglycol monoethyl ether solvent was found in the accepted range.

Example 6 Arteether (I.8)

The solubility range for α,β-Arteether in Diethylene glycol monoethylether was observed about 1 to 76.74 mg/ml.

Sr. No Name of Ingredient Qty/ml 1 α, β Arteether 75 mg 2 Benzyl alcohol4% 3 Vitamin E Acetate  1 mg 4 Diethylene Glycol Monoethyl Ether q.s

7.5 g of drug is taken in a flask to dissolve in 100 ml Diethyleneglycol monoethyl ether to give therapeutically suitable preservative andantioxidants are added to give clear solution ready to be used as acomposition after filtering aseptically in an ampoule or vial for use asinjection which can be administered through I.M. and I.V. The viscosityof the liquid is found to be 2.85 cps as compared to oily injectionwhich has more than 39 cps.

Optionally, preservatives like Benzyl alcohol in the concentration from1% to 10% may be added with adding anti oxidants like Vitamin E acetate,BHA, BHT and other available antioxidants in the acceptable range.

Additionally, adjuvants may be added in pharmaceutically acceptableconcentration to stabilize the liquid for its use directly or bymatrixing in the suitable excepients to give suitable oral deliverycomposition.

The final solution of α,β Arteether 75 mg/ml injection have viscosity ofabout 2.85 cps. It can be packed into vials or 2 ml ampoule or prefilledsyringes in therapeutic concentrations and in desired volumes.

As the viscosity is less, same can be administered safely without anypain as compared to presently available oily injection which hasviscosity of more than 35 cps

Stability Study Data for α,β Arteether 75 mg/ml Injection:

40° C./ 40° C./ 25° C./ 30° C./ 40° C./ 25° C./ 30° C./ 40° C./ 25° C./30° C./ Sr. Specifi- 75% 75% 60% 65% 75% 60% 65% 75% 60% 65% No. Testscation Initial RH/1M RH/2M RH/3M RH/3M RH/3M RH/6M RH/6M RH/6M RH/9MRH/9M 1 Descrip- Clear colourless solution tion 2 Assay 90-110 101.10100.84 100.24 101.62 100.91 98.42 98.75 101.13 101.50 99.63 99.86 (%)

Stability study of α,β Arteether 75 mg/ml injection prepared inDiethylene glycol monoethyl ether was performed according to ICHguidelines and all the test were found in acceptable criteria.

Example 7 Etoricoxib (I.12)

Etoricoxib was found to be soluble in Diethylene glycol monoethyl etherin range of 1 to 200 mg/ml.

Sr. No Name of Ingredient Qty/ml 1 Etoricoxib 90 mg 2 Benzyl Alcohol 4%3 Diethylene Glycol Monoethyl q.s Ether

The same is novel delivery otherwise is not available in market asinjections.

1 g to 20 g of drug is dissolved in 100 ml Diethylene glycol monoethylether to give a clear solution. Preservative like Benzyl alcohol invarying concentration can be added.

Herein, the therapeutic concentration of drug is prepared inconcentration of 90 mg/ml in Diethylene glycol monoethyl ether. It hasviscosity 3.70 cps. The injection being less viscous easily syringableand can be easily administered in the tissues through I.M or I.V. route.

The achieved concentration may be useful for its application asinjections filled in ampoules, PFS and or filled in hard filledcaps/soft gel or suitably compounded as Roll On composition or fordermal delivery to give stable formulation. Other additives may be addedto incorporate the same as tablets or for oral liquid with combining inaq liquid with buffering agents and pH adjusting buffers like Trisbuffer, acids or alkali.

Stability Study Data of Etoricoxib Injection 90 mg/ml:

40° C./ 25° C./ 30° C./ 40° C/. 25° C./ 25° C./ 75% 40° C./ 60% 65% 75%25° C./ 30° C./ 40° C./ 60% 30° C./ 60% 30° C./ Sr. Specifi- RH 75% RH/RH/ RH/ 60% 65% 75% RH/ 65% RH/1 65% No. Tests cation Initial

RH/2M

RH/6M RH/6M RH/6M

RH/9M

RH/12M 1 Descrip- Clear Yellow Coloured Solution tion 2 Assav 90-110100.23 99.0 100.60 101.94 102.20 102.80 100.54 99.52 100.23 100.24100.63 100.63 100.55 3 Impurity Single: Not Determined Single: Single:Single: Single: (%) 0.5 0.29 0.298 0.299 0.326 Tot Total Total: Total:Total:

0.7

0.724

indicates data missing or illegible when filed

The stability study was carried out for Etoricoxib injection 90 mg/mland was found to be satisfactory with acceptable. Assay range and noimpurities were detected. Thus, the trial of new formulation ofEtoricoxib injection 90 mg/ml in Diethylene glycol monoethyl etherindicate the solution stability and ready to use for therapy.

The viscosity of the liquid prepared in Diethyelene glycol monoethylether is found to be 3.70 cps.

Etoricoxib gel is prepared with composition as below for dermalapplication.

Composition of Etoricoxib Gel 10 mg

Sr. No Ingredients Qty/ml 1 Etoricoxib IH  10 mg 2 Propylene Glycol IP250 mg 3 Diethylene Glycol 100 mg Monoethyl Ether 4 Ethanol IP 200 mg 5Tocopheryl Phosphate  10 mg Hydrolysate (TPM) IH 6 Sepineo P600 IH  50mg 7 Purified Water IP Qs up to 1.0 gm

Stability Study Data of Etoricoxib Gel 10 mg:

Sr. No Test Initial After 1M 40° C. After 3M 40° C. 1 Description Whiteto off White to off white White to off white colour, colour, semisolid,white colour, semisolid, homogeneous semisolid, homogeneous viscous Gel.homogeneous viscous Gel. viscous Gel. 2 pH 4.09 Not done Not Done 3Viscosity 48614 cps Not done Not Done 4 Assay, 99.83 101.06 97.33 Limits90 to 110% 5 Impurity Not Detected Single: 0.38% Not Detected NMT 2%Total: 0.38%

Example 8 Piroxicam (I.15)

The solubility of Piroxicam in Diethylene glycol monoethyl ether wasfound to be about 0.1 to 35 mg/ml.

Sr. No. Ingredient Qty/ml A) 1 Piroxicam  20 mg 2 Dimethyl Isosorbide15% v/v 3 Diethylene Glycol Monoethyl Ether q.s pH of solution 4.23 B) 1Piroxicam  20 mg 2 Tris Buffer 2.5 mg 3 Diethylene Glycol MonoethylEther q.s pH of solution 5.71

1 g to 5 g of drug is dissolved in 100 ml Diethylene glycol monoethylether to give a clear solution to give 10 mg/ml to 50 mg of Piroxicamper ml with the viscosity 3.365 cps.

Further pH of the solution can be brought to alkaline side usingalkaliser.

The same may be used as injection after aseptic filtration using 0.22μfilter and filled in ampoules or vials as per therapeutic requirements.

The hard filled or soft gelatin caps can be filled in a suitableconcentration for the oral delivery or suitable formulated for thedermal delivery in form of gels or for use as sprays.

Stability Study Data of Piroxicam Injection 20 mg/ml:

40° C./ 40° C./ 75% RH/ 75% RH/ Sr. 1M 1M No. Test Initial A B 1Description Greenish Yellow Colour Liquid 2 Assay, 98.78 97.52 96.28Limit 90% to 110% 3 Related Not Detected Not Detected Single: 0.53%Substances, Limit Total: 0.72% NMT 2%

Stability study was performed for new injectable solution of Piroxicamof dose strength 20 mg/ml. It was found to be in acceptable range andthe formulation was stable at studied accelerated conditions.

Example 9 Vitamin D₃ (I.10)

The solubility of Vitamin D₃ was found upto 0.1 to 33.33 mg/ml inDiethylene glycol monoethyl ether.

Sr. No. Ingredient Qty/ml Qty/ml 1 Vitamin D₃ 15 mg 15 mg 2 BHA  1 mg  1mg 3 Vitamin E Acetate  1 mg  1 mg 4 BHT  1 mg — 5 Diethylene GlycolMonoethyl Ether Q.s Q.s

Weigh accurately 15 mg of Vitamin D3 and add into clean 100 ml glassvessel. Dissolve the drug into Diethylene glycol with addition ofVitamin E acetate, BHA and BHT optionally.

Mix the solution till drug get dissolve to produce final solution. Thesame is filled aspecticvally through 0.22μ filter and filled asepticallyin syringe, PFS or vials for therapeutic use through I.M. or I.V. route.

The solution thus prepared can be made available as injectables as wellas can be used for preparing other dosage forms like filled into capsulewhen matrixed with other excipients and adjuvants

Stability Study Data of Vitamin D₃ Injection 15 mg/ml:

1M 1M 2M 2M 3M 3M Sr. No Test Initial 25° C. 40° C. 25° C. 40° C. 25° C.40° C. 1 Description Clear Colourless Solution 2 Assay, 120.62 108.48110.33 105.46 101.26 105.90 105.90 Limit 90% to 110%

Vitamin D3 Injection 15 mg/ml prepared in Diethylene glycolmonoethylether was kept for stability study. The viscosity of it inDiethylene glycol monoethyl ether is 3.13 cps. The results were found tobe satisfactory.

Example 10 Paclitaxel (I.14)

Trial 1 Trial 2 Trial 3 Sr. No. Ingredients Qty (ml) Qty (ml) Qty (ml) 1Paclitaxel   6 mg   6 mg   6 mg 2 Polysorbate 80 0.15 ml 0.1 ml 0.1 ml 3PEG 400 0.15 ml 0.3 ml 0.2 ml 4 Ethanol  0.4 ml 0.3 ml 0.3 ml 5Diethylene Glycol  0.3 ml 0.1 ml 0.2 ml Monoethyl Ether pH of finalsolution 6.85 6.17 6.26 adjusted with acetic acid

300 mg to 1200 mg of paclitaxel is dissolved in 100 ml Diethylene glycolmonoethyl ether to give a clear solution.

The solution is stable and can be administered directly for itstherapeutic purpose as injectable form by filling in ampoule or vials.

The same can also be prepared in the concentration of 6 mg/ml which istherapeutically recommended concentrations using above compostions. Thesolution is clear and limpid. It is further process under nitrogen tofilter it aseptically through 0.22μ membrane and filled suitably inampoules or vials, PFS for multidose applications for use in infusions.

The same can be administered as bolus or slow infusion.

The trial of Paclitaxel injection prepared in Diethylene glycolmonoethyl ether was kept for stability study and the formulation wasfound to be stable. Viscosity of it in Diethylene glycol monoethyl etherwas found to be 2.967 cps.

Example 11 Artesunate (II.3)

The solubility of Artesunate in Diethylene glycol monoethyl ether wasfound to be from 1 to 100 mg/ml.

Sr. No. Name of Ingredient Qty/ml 1 Artesunate 60 mg 2 Benzyl Alcohol 2%3 Diethylene Glycol Monoethyl ether q.s

5 g to 8 g in acid form of the drug is dissolved in 100 ml Diethyleneglycol monoethyl ether to give a clear, therapeutically acceptableconcentration solution. Preservative like benzyl alcohol can be addedalong with antioxidants like Vit E derivatives, thioglycerol or ascorbylpalmitate can be optionally added which keeps the solution pellucid,physically and chemically stable. Same is filtered aseptically undernitrogen through 0.22μ filter and filled in ampoules, PFS or vials asper therapeutic need and further use.

The injection can be administered as slow infusion or as bolus for safe,for I.V. use for therapeutic action.

The solution of Artesunate in therapeutic dose of 60 mg/ml is preparedusing Diethylene glycol monethyl ether by mixing with 2% Benzyl alcohol.This solution of 60 mg/ml prepared is having the viscosity of about3.466 cps.

Stability Study Data of Artesunate Injection 60 mg/ml:

1M/ 2M/ 3M/ Sr. 40° C./ 40° C./ 40° C./ No Test Initial 75% RH 75% RH75% 1 Description Clear Colourless Solution 2 Assay, Limit 100.23 98.0299.65 99.58 90 to 110%

The stability data of marketed injection and Artesunate injection 60mg/ml were compared and it was found that the new formulation preparedin Diethylene glycol monoethyl ether were stable.

Example 12 Paracetamol (II.13)

The solubility of Paracetamol was found to be about 1 to 66.6 mg per mlof Diethylene glycol monoethyl ether solvent and when mixed withco-solvent, same is increased to 200 mg/ml for preparation oftherapeutic dosage of Paracetamol injection for 1 mg and 225 mg/ml ofParacetamol Injection

Sr. Packing Details No. of Product Ingredients Qty/ml 1 Paracetamol 10mg/ml Paracetamol  10 mg (5 ml clear glass vial) Sodium Chloride  9 mgFor 100 ml infusion Diethylene Glycol 5.0% v/v Monoethyl Ether Water forinjection q.s 2 Paracetamol 20 mg/ml Paracetamol  20 mg (10 ml clearglass vial) Sodium Chloride  9 mg For 50 ml infusion Diethylene Glycol7.5% v/v Monoethyl Ether Water for injection q.s 3 Paracetamol 200 mg/mlParacetamol 200 mg PEG 400 15% Tris Buffer  2.5 mg Diethylene Glycol q.sMonethyl Ether 4 Paracetamol 150 mg/ml Paracetamol 150 mg Benzyl Alcohol 2% Diethylene Glycol q.s Monoethyl Ether 5 Paracetamol 100 mg/mlParacetamol 100 mg Benzyl Alcohol  2% Diethylene Glycol q.s MonoethylEtherFor Sr. No. 1 & 2:

In a suitable vessel, Paracetamol in required quantity is dissolved inDiethylene glycol monoethyl ether with stirring simultaneously. Inanother beaker, sodium chloride is added in water for injection. Then,both the solution are mixed together and final volume is make up withwater for injection to give final solution of 10 mg/ml and 20 mg/mlrespectively. The pH of final solution containing dose strength 10 mg/mlis 5.78 and same for 20 mg/ml is 5.67 respectively.

As the viscosity is very less, the solution can be infused slowly

1 g to 20 g of paracetamol is dissolved in 100 ml Diethylene glycolmonoethyl ether to give a clear solution with addition of suitablepreservative like Benzyl alcohol and adjusting pH with suitablebuffering agent like Tris buffer.

For Sr. No. 3:

Diethylene glycol monoethyl ether is heated upto 80° C. in suitablevessel and Tris buffer is added with stirring till a clear solution isobtained. Then, PEG 400 is added into the solution while dissolving thedrug Paracetamol. Maintain the temperature 80-85° C., a clear solutionis obtained. Then solution is cooled and final volume is make up withDiethylene glycol monoethyl ether in sufficient quantity to give finalsolution of drug, 200 mg/ml. Filter the solution in 0.22μ filter andfill in 2 ml clear ampoule, 5 ml clear ampoule, 5 ml clear vial as wellcan be filled in prefilled syringes or multi dose vials.

Similarly, final solution of 100 mg/ml & 150 mg/ml can also be preparedas given above.

The final solutions of Paracetamol containing 150 mg/ml have viscosityabout 7.34 cps. This solution can be filled into 2 ml clear ampoule, PFSor in multidose vials.

The solution may be used for parenteral as i.v bolus or infusion or oralpurpose after filling in ampoule, vial or in caps forms.

Stability Study Data of Paracetamol Injection 150 mg/ml:

40° C./ 30° C./ 25° C./ 30° C./ 40° C./ 75% 40° C./ 25° C./ 65% 40° C./60% 65% 75% 25° C./ 30° C./ S. Speci- RH/1 75% 60% RH/3 75% RH/6 RH/6RH/6 60% 65% No Tests fication Initial

RH/2M RH/3M

RH/3M

RH/9M RH/9M 1 Descrip- Clear Colourless Solution tion 2 Assay 90-110103.24 105.09 100.76 100.87 100.37 99.16 101.94 99.30 98.99 101.18 99.75(%) 3 Impur- 4 4 4 4 4 4 4 4 4 4 4 4 ities Amino- Amino- Amino- Amino-Amino- Amino- Amino- Amino- Amino- Amino- Amino- Amino- phenol- phenol-phenol- phenol- phenol- phenol- phenol- phenol- phenol- phenol- phenol-phenol- NMT ND ND ND ND ND ND ND ND ND ND ND 0.5% Total Total TotalTotal Total Total Total Total Total Total Total Total impur- impur-impur- impur- impur- impur- impur- impur- impur- impur- impur- impur-ity- ity- ity- ND ity- ity - ity ity- ity- ity- ity-ND ity-ND ity- ND ND0.28% 0.34% 0.128% 0.023% 0.023% 0.57% NMT 2.0%

indicates data missing or illegible when filed

The stability study for Paracetamol Injection 150 mg/ml was performedand was found to be in acceptable range and is satisfactory whencompared with the available marketed product of the same dose strength.

Example 13 Dicyclomine Hydrochloride (II.12)+Diclofenac Sodium Injection

The solubility of Dicyclomine was about 0.1 to 20 mg/ml and ofDiclofenac upto 0.1 to 133 mg/ml in Diethylene glycol monoethyl ether.

Following example is cited to study combination of 20 mg Dicyclomine HClwith 50 mg Diclofenac Sodium using the inventive process which is givingstable injections. Same is easily syringeable and administered in thetissues without causing pain. Viscosity of the solution in Diethyleneglycol monoethyl ether is 5.022 cps.

Example No. Sr. 1 2 3 No. Ingredients Qty/ml Qty/ml Qty/ml 1 DicyclomineHydrochloride 20 mg 20 mg 20 mg 2 Diclofenac Sodium 50 mg 50 mg 50 mg 3Diethylene Glycol Monoethyl Ether Q.s 60% 60% 4 0.1M NaOH Q.s Q.s — 5Sodium Metabisulphite —  1 mg  1 mg 6 WFI — Q.s Q.s 7 Benzyl alcohol — 2%  2%

The Stability study data given below for Diclofenac (50 mg)+DicyclomineHCl (20 mg) injection is of optimized example Nos. 2 & 3.

40° C./ 40° C./ 40° C./ Sr. 75% RH/ 75% RH/ 75% RH/ No Tests Initial 1M2M 3M 1 Description Clear Clear Clear Clear Transparent TransparentTransparent Transparent Liquid Liquid Liquid Liquid 2 Assay of 99.4 99.198.7 100.6 Diclofenac, Limit 90 to 110% 3 Assay of 101.2 100.7 99.9 98.6Dicyclomine hydrochloride Limit 90 to 110% Limit HCL 4 Impurity, Not0.01 0.01 0.01 NMT 2% detected

The combination of Diclofenac (50 mg) and Dicyclomine HCl (20 mg)injection were kept for stability study as per ICH guidelines and werefound to be stable with all the tests in acceptable criteria.

Example 14 Pantoprazole Sodium Injection (II.19)

Pantoprazole Sodium is soluble in Diethylene glycol monoethyl ether from1 to 80 mg/ml.

Examples Sr. 1 2 3 No. Name of Ingredients Qty/ml Qty/ml Qty/ml 1Pantoprazole Sodium 40 mg 40 mg  40 mg 2 BHA  1 mg  1 mg 0.3 mg 3 BenzylAlcohol 2% 2% 2% 4 BHT —  1 mg 0.3 mg 5 Diethylene Glycol MonoethylEther q.s q.s q.s

In the current example, 40 mg/ml of Pantoprazole Sodium stable injectionare prepared by dissolving preferably sodium or its acid salts by taking4 g of the drug in mixture of Diethylene glycol monoethyl ether andBenzyl alcohol in 100 ml vessel. BHA i.e, Butylated Hydroxy Anisole (inExample 1) or in combination of BHA and BHT i.e, Butylated HydroxyToulene (can be added as antioxidant/preservative in Example 2 & 3) orThioglycerol is added into this mixture Finally, the total volume ismake up with Diethylene glycol monoethyl ether in sufficient quantity togive clear colorless solution which is filtered and filled in vials, PFSor ampoules.

It is preferred to bubble the liquid with nitrogen and filled undernitrogen. The viscosity of Pantoprazole Sodium injection 40 mg/ml wasfound to be 3.816 cps.

Similarly, 1 g to 10 g of drug in acid form (Pantaprazole Sodium) isdissolved in 100 ml Diethylene glycol monoethyl ether to give a clearsolution and compounded as above.

The therapeutic concentration is suitably filled in ampoules, PFS orvials for its direct use after, filling aseptically through 0.22μ andfilling suitable antioxidants and preservatives are added to the liquid.

Alternatively, Water for injection q.s and preservative like Benzylalcohol 2 to 4%, buffer agents may be optionally added to maintain pHmore than 8 i.e. 9.5 to 11.5 which keeps the solution pellucid,physically and chemically stable.

Stability Study Data of Pantaprazole Sodium Injection 40 mg/ml:

1M/ 3M/ Sr. No Test Initial 40° C./75% RH 25° C./60% RH 3M/40° C./75% RH1 Description Slight Yellow Colour Solution 2 Assay, 101.36% 95.12%98.43% 95.94% Limit 90 to 110% 3 Impurities, Single: 0.03% Single: 0.42%Single: 0.04% Single: 0.62% single NMT Total: 0.05% Total: 0.55% Total:0.08% Total: 0.81% 1% Total NMT 2%

The stability study of Pantaprazole Sodium injection 40 mg/ml was foundto be satisfactory. Viscosity of the solution in Diethylene glycolmonoethyl ether is 3.816 cps.

Example 15 Voriconazole (II.25)

The solubility profile of Voriconazole is found to be from 0.1 to 83mg/ml in Diethylene glycol monoethyl ether.

Sr. No. Ingredient Qty/ml 1 Voriconazole 10 mg 2 Diethylene GlycolMonoethyl Ether 0.5 ml 3 Water For Injection Q.s

1 g to 10 g of drug is dissolved in 100 ml Diethylene glycol monoethylether to give a physically clear solution. Viscosity of the solution inDiethylene glycol monoethyl ether is 2.977 cps.

The finally achieved therapeutic concentration may be employed forparenteral use as slow infusion or solution so preferred can be used toprepare oral delivery suitably formulated with adjuvants, additives andpreservatives for treating the mammals for therapeutic purpose.

Example 16 Ibuprofen (II.27)

The solubility of Ibuprofen in Diethylene glycol monoethyl ether wasfound to be about 500 mg/ml.

The following formulation can be prepared using Diethylene glycolmonoethyl ether:

Sr. No. Ingredient Qty/ml Qty/ml 1 Ibuprofen 400 mg 200 mg 2 DiethyleneGlycol Monoethyl Ether q.s to 1 ml q.s to 1 ml

10 g to 50 g of Ibuprofen is taken in a vessel and dissolved inDiethylene glycol monoethyl ether to give final solution. Thetherapeutically available and marketed 400 mg/ml and 200 mg/ml ofIbuprofen injectable solution were prepared using the invention solventwhich was found to be colorless and physically stable in nature and theviscosity in Diethylene glycol monoethyl ether is 6.76 cps and 4.51 cpsrespectively.

Example 17 Methyl Prednisolone (III.2)

The solubility of Methyl Prednisolone was found to be about 1 to 30mg/ml in Diethylene glycol monoethyl ether and about 130 mg/ml in benzylalcohol. Hence, formulations were prepared using co-solvents.

Sr. No Ingredients Qty/ml Qty/100 ml Example 1: 1 Methyl Prednisolone 40mg 4 g 2 Benzyl Alcohol 10% v/v 10 ml 3 Dimethyl Isosorbide  2% v/v  2ml 4 Diethylene Glycol Monoethyl Ether q.s q.s Example 2 : 1 MethylPrednisolone 40 mg 4 g 2 Benzyl Alcohol 10% v/v 10 ml 3 DimethylIsosorbide  2% v/v  2 ml 4 Vitamin E  1 mg 100 mg 5 Diethylene GlycolMonoethyl Ether q.s q.s Example 3 : 1 Methyl Prednisolone 40 mg 4 g 2Benzyl Alcohol 10% v/v 10 ml 3 Dimethyl Isosorbide  2% v/v  2 ml 4 BHA(Butylated Hydroanisole)  1 mg 100 mg 5 Diethylene Glycol MonoethylEther q.s q.s

Example 1

In mixture of Diethylene glycol monoethyl ether, benzyl alcohol andDimethyl isosorbide in a vessel, Methyl prednisolone is dissolved andstirs well to get a clear colorless solution. Make up the final volumewith Diethylene glycol monoethyl ether

Example 2/3

A mixture of Diethylene glycol monoethyl ether, Benzyl alcohol andDimethyl isosorbide is prepared in a vessel. Methyl prednisolone isdissolved and stirs well to get a clear colorless solution. Then VitaminE in example 2 and BHA (butylated hydroxy anisole) in example 3 is addedinto the solution respectively and make up the final volume usingDiethylene glycol monoethyl ether.

The viscosity of Methyl Prednisolone Injection 40 mg/ml was measuredabout 3.70 cps which is lesser than the available marketed products.

Similarly, 2 g to 10 g of drug is dissolved in 100 ml Diethylene glycolmonoethyl ether to give a clear solution for therapeutic use asinjectable. Preservative like benzyl alcohol at 2 to 10% may be addedwith antioxidants like Thioglycerol, Sodium Ascorbate, Tocopherols areadded in the desired concentration to give clear, pellucid liquid whichis physically and chemically stable.

After making of volume for the desired strength the liquid is filteredaseptically through 0.22μ filter and filled in ampoules, PFS, vials withnitrogen bubbling.

Above solutions are found to be stable and yields a comfortablysyringable, low viscosity solution which can be easily administered inthe tissues without causing pain.

Stability Study Data of Methyl Prednisolone Injection 40 mg/ml:

Sr. Specifica- No Test tion Initial 1M 40° C. 3M 40° C. 3M 25° C. 6M 25°C. 6M 40° C. 1 Descrip- Clear Colourless Solution tion 2 Assay 90-11099.08 101.49 98.40% 98.39 99.68 98.53 IH (HPLC) 3 RS Single = 1.0%Single = 0.09% Single = 0.33% Single = 0.935% Single = 0.444% Single =0.38% Single = 0.56%  Total = 2.0%  Total = 0.09%  Total = 0.52% Total =1.67% Total = 0.78%  Total = 0.63%  Total = 0.85%

Stability study of Methyl Prednisolone Injection 40 mg/ml was performedand result was obtained in the acceptable range.

Example 18 Triamcinolone Acetonide (III.4)

The solubility of Triamcinolone Acetonide was found upto 1 to 15 mg/mlin Diethylene glycol monoethyl ether.

Sr. No Ingredients Qty/ml Qty/ml 1 Triamcinolone Acetonide 10 mg 20 mg 2Benzyl Alcohol 0.8% 0.8% 3 Diethylene Glycol Monoethyl Ether q.s q.s

While preparation of injection, Diethylene glycol monoethyl ether &Benzyl alcohol are mixed well in a suitable vessel. Triamcinoloneacetonide is added in required dose strength (i.e 1 gm to 5 gm) andstirred till a clear solution is obtained. Final volume of this solutionis made up with Diethylene glycol monoethyl ether. The solution isfiltered aseptically through 0.22μ filter and filled in ampoules, PFSand vials. Optionally, benzyl alcohol can be added which keeps thesolution pellucid as well as physically and chemically stable.

The viscosity of Triamcinolone injection 20 mg/ml was measured about3.036 cps.

Stability Study Data of Triamcinolone Acetonide Injection 20 mg/ml:

40° C./ 25° C./ 30° C./ 40° C./ 25° C./ 30° C./ 40° C./ Sr. 75% 60% 65%75% 60% 65% 75% No. Tests Initial RH/1M RH/3M RH/3M RH/3M RH/6M RH/6MRH/6M 1 Description Clear Complies Complies Complies Complies CompliesComplies Complies colourless solution 2 Assay 103.97% 98.52% 99.93%99.79% 99.83% 99.96% 98.45% 98.87% (90%- 110%) 3 Impurities; Single =Single = Single = Single = Single = Single = Single = Single = single0.12% 0.29% 0.62% 0.52% 0.42% 0.32% 0.28% 0.19% NMT 1%  Total =  Total = Total =  Total =  Total =  Total =  Total =  Total = Total 0.12% 0.52%0.84% 0.80% 0.71% 0.64% 0.63% 0.54% impurities NMT 2%

Stability Study Data of Triamcinolone Acetonide Injection 10 mg/ml:

40° C./ 40° C./ 25° C./ 40° C./ 25° C./ 40° C./ 25° C./ Sr. 75% 75% 60%75% 60% 75% 60% No. Tests Initial RH1M RH/2M RH/3M RH/3M RH/6M RH/6MRH/9M 1 Description Clear Complies Complies Complies Complies CompliesComplies Complies colorless solution 2 Assay 101.30% 101.88% 101.58%101.40% 98.53% 98.34% 96.77% 97.97% (90%- 110%) 3 Impurities; ND Single= Single = Single = Single Single Single = Single = single  0.291% 0.07%  0.24%  0.40%  0.12%  0.33%  0.16% NMT 1% Total = Total = Total =Total Total = Total = Total = Total  0.592%  0.21%  0.37%  0.56%  0.22% 0.76%  0.40% impurities NMT 2%

The stability study of both the dose strength 10 mg/ml and 20 mg/ml ofTriamcinolone acetonide injection was found to be satisfactory as perICH guidelines.

Example 19 Aceclofenac (III.9)

The solubility profile of aceclofenac in Diethylene glycol monoethylether was observed upto 1 to 160 mg/ml.

Example 1: Example 2: Sr Sr no. Ingredient Qty/ml no. Ingredient Qty/ml1 Aceclofenac 150 mg 1 Aceclofenac 150 mg 2 Trisodium citrate q.s 2Benzyl alcohol 2% aqeous solution 3 Triss Buffer 30% 0.026 30% (pH =4.57) aqeous solution ml 3 Diethylene Glycol q.s 4 Diethylene Glycol q.sMonoethyl Ether Monoethyl Ether Example 3: Example 4: Sr. Sr. No.Ingredient Qty/ml No. Ingredient Qty/ml 1 Aceclofenac 150 mg 1Aceclofenac 150 mg 2 Benzyl Alcohol 2% 2 Dimethyl Isosorbide 5% 3 Trisbuffer  8 mg 3 Diethylene Glycol q.s 4 Diethylene Glycol q.s MonoethylEther Monoethyl Ether

5 g to 16 g of drug is dissolved in 100 ml Diethylene glycol monoethylether with other excipients as above to give therapeutically acceptablestable clear solution liquid.

The same may be used therapeutically after aseptically filtering andfilling in ampoule, PFS or vials with use of suitable preservative andantioxidants like benzyl alcohol, other alcohols and butylated hydroxylanisole, sodium metabisulphite, thioacetamide.

Alternatively for an aqueous injection, preservative like benzyl alcohol2 to 4%, buffer agents and pH adjusting agents like NaOH or HCl may beadded which keeps the solution pellucid, physically and chemicallystable.

The viscosity of final solution containing Aceclofenac 150 mg/ml wasfound about 5.11 cps.

Stability Study Data of Aceclofenac 150 mg/ml Injection:

1W 3W 3W 6W 6W 9W 12W 40° C./ 25° C./ 40°/ 40°/ 25° C./ 25° C./ 25° C./Sr. Para- Speci- 75% 60% 75% 75% 60% 60% 60% No meter fication InitialRH RH RH RH RH RH RH 1 Descrip- Light Complies Complies CompliesComplies Complies Complies Complies Complies tion yellow coloured, clearliquid fill in amber coloured 1 ml glass ampoules. 2 Assay (90%- 103.25%102.15% 102.90%  102% 101.8% 102.8% 102.41% 98.25% (By 110%) UV)Aceclofenac 3 Related Diclofenac ND  0.26%  0.23% 0.57%  1.25%  0.57% 0.70%  0.70% Substance impurity NMT 5.0% Single ND ND ND ND ND ND ND NDunknown impurity NMT 1.0% Total ND ND ND ND ND ND ND ND unknown impurityNMT 2.0%

The stability study of Aceclofenac Injection 150 mg/ml was found to bein acceptable criteria. The injectable formulation of Aceclofenac indose strength 150 mg/ml was found to be stable. As the viscosity of theliquid is less it is easily syringable and administered in the tissueswithout causing pain.

Example 20 Nepafenac Eye Drops 0.1% (III.23_(L))

The solubility of Nepafenac in Diethylene glycol monoethyl ether wasfound to be upto 2 mg/ml.

Sr. No. Ingredient Qty/ml 1 Nepafenac 0.1% 2 Sodium Chloride 0.8% 3Benzyl Alkonium Chloride 0.05%  4 Diethylene Glycol Monoethyl Ether  50%5 Water for Injection Q.s 6 Sodium Hydroxide (1N) To adjust pH 7.37

The viscosity of Nepafenac eye drop prepared by using Diethylene glycolmonoethyl ether was found to be 4.137 cps. It was kept for stabilitystudy at 40° C.

Stability Study Data of Nepafenac Eye Drops 0.1%:

Sr. Specifica- 40° C./75% 25° C./60% 30° C./65% 40° C./75% No. Teststion Initial RH/1M RH/3M RH/3M RH/3M 1 Description Yellow Coloured ClearSolution 2 Assay 90-110% 102.18% 103.29% 103.58% 102.21% 98.64% (Glassvial) 3 Impurity Single: Single: Single: Single: Single: Single: (Glassvial) NMT 1.0%  0.11%  0.39%  0.39%  0.39%  0.39% Total Total: Total:Total: Total: Total: impurity:  0.17%  0.39%  0.39%  0.39%  0.39%

indicates data missing or illegible when filed

The formulation examples described herein and which is containingDiethylene glycol mono ethyl ether as solvent can also be used forprepare other drug delivery like preparing oral delivery systems,dermal, delivery systems by filling in as roll on gels or creams and forotic delivery systems like drops or filling in capsules for rectaldelivery or other delivery systems as stated in the description.

Oral delivery like filing the liquid directly in to Hard fill capsulewith band sealing. Eg 30 mg to 120 mg of Etoricoxib filled in HFC.

It can also be mixed with PEGs and oils or it derivatives to fill insoft gelatin capsules.

Paracetamol liquid, Dilcofeneac liquid, Acelcofenac liquid prepared inDietheyne glycol monoethyl ether can be employed for filling in softgelatin capsules for rectal deliveries.

The Liquid gels of antifungal agents like Azole derivatives, Flucanzole,Ticonazole can be prepared for vaginal deliveries.

Drugs like Lignocaine, Prilocaine can be prepared in Diethyleneglycolmonoethyl ether can be incorporated in spray delivery systems fortreating erectile dysfunction.

Drugs like Amlodipine, Nifedipine can be solubilised in Diethyleneglycolmonoethyl ether and sprayed in the granulation of tablet matrixcontaining starch, lactose, stearates and compressed in to tablets.

Dermal delivery of gels like Etoricoxib is prepared with other gelmatrices to prepare Gels for dermal application for faster onset ofpharmacological action.

Drug solutions like Aceclofenac solution prepared in Diethylene glycolmonoethyl ether can also be prepared for preparing the Roll on fordermal delivery.

The solution can further be used for preparing Tulles by appropriatelymixing the drug solution with various PEGS sprayed on waxes like woolfat, PEG 4000, 6000 etc for dermal application in pain managements.(exAceclofenac, NSAIDs, Cox 2 inhibitors etc)

Tioconazole Gel 6.5%

Qty Sr. No Ingredients Spec Rationale Gm/mg 1 Tioconazole BP Active 65.02 Carbomer-940 (Acrypol-940) USP Gelling agent 11 3 Propylene Glycol IPGel base 804 4 Di ethylene glycol mono ethyl BP Solubilser 120 ether

Spray:

  Lignocaine . . . 8.82% Prilocaine . . . 2.94% Propellent HFA . . .58.83% Diethyleneglycol monoethyl ether . . . 29.41%

Acute Eye Irritation/Corrosion Test for Diethylene Glycol MonoethylEther (Transcutol HP) in Rabbits Test Item Transcutol HP

Diluted with: Water for injection

Test System Rabbits (New Zealand White)

Total No. of Animals: 6 animals for initial test

-   -   12 animals for confirmatory test        No. of groups: 6

Study Design:

Total No. of Animals Volume Concen- For Sr. (ml/ tration For Initialconfirmatory No Group animal) Route (%) test test 1 1 0.1 Intra Occular 2% 1 2 2 2 0.1 Intra Occular 20% 1 2 3 3 0.1 Intra Occular 40% 1 2 4 40.1 Intra Occular 60% 1 2 5 5 0.1 Intra Occular 80% 1 2 6 6 0.1 IntraOccular 100%  1 2

Summary: Initial Test:

Initial test is carried out by using one animal per group. After dosinganimals were observed for irritation at 1, 24, 48, and 72 hours

There is no test item related effects were observed during first hour inall the animals of first three groups. Mild irritation was observed ingroup 4 and 5 animals. Group 6 animal showed moderate irritation andmore severity when compared to the group 4 and group 5 animals.

Irrigation was carried out after 24 hrs from the treatment and theanimals are again observed for symptoms of toxicity.

During 24 hr observation, all the animals are appeared normal exceptgroup 6 animal which was showed mild irritation including Chemosis andLacrimation. Mild conjunctivitis was also observed.

Depending up on the observations made from the initial test and therewas no corrosion effect was observed, hence we proceeded for theconfirmatory test.

Confirmatory Test:

Confirmatory test is carried out by using two animals per group. Afterdosing animals were observed at 1, 24, 48, and 72 hours for toxicity.

The dosing methodology and irrigation procedure was same as mentioned inthe initial test and the observations were found as follows:

During 1 hr observations, there is no test item related effects wereobserved in all the animals of first three groups.

Mild irritation was observed in group 4 and group 5 animals.

One animal from the group 6 was showed severe irritation when observedafter 1 hr from the dosing and the other animal also showed irritationbut the severity was less when compared with the previous animal.

During 24 hr observation, animals from group 1 to group 3 were normaland there is no irritation was observed in all the animals.

Animals from group 4 and group 5 were showed mild irritation includingChemosis, lacrimation and mild pupillary constriction.

Group 6 animals were suffered with severe irritation and the symptomsincludes Chemosis, lacrimation, conjunctivitis, pupillary constriction.The corneal reflex and Iris were normal in all the animals.

The above mentioned observations were lasts for 48 hrs.

Summary:

In summary, all the above mentioned observations, the test itemTranscutol is not showing any occular toxicity up to 80% ofconcentration. But, the test item Transcutol, may irritant but notcorrosive, at the concentration of 100% when administered intraoccularly.

Further, when performing Intramuscular, Intravenous and Intraocularstudies, Diethyelene glycol monoethyl ether was found to be safe and nontoxic.

Protocol: Pain Assessment Model Study: Measurement of Pain Sensitivity(Threshold) at Injection Site in Wistar Rats by Intravenous Route &Intramuscular Route

The pain assessment model study was carried out on two representativedrugs from each class prepared as per application. This study wasperformed to prove that the injectables prepared by this solvent arepainless and less viscous when compared to the respective marketedproducts as a reference.

The following procedure was carried out to check pain assessment of newformulation against the marketed products:

Objective:

To evaluate pain sensitivity (threshold) at injection site by Pressureapplication measurement method and comparison with control.

Test Injections Different injectable formulations (2 drugs from eachgroup of class I, II and III)Reference Injections Marketed formulations w.r.t each group of class I,II, and III.Species used for the study: Wistar ratsNo of animals used during different route I.M & I.V individually:The total number of 18 animals will be divided in to 3 groups containing6 animals (3M+3F) per group.

Study Design:

The following table are given as study design as pain assessment studythrough I.V as well I.M route

TABLE A Dosage schedule Dose Dose Duration of No. of Sr. No Group (inmg/kg) (in mL/kg) Route treatment animals 1 Negative control N1_(IV)N2_(IV) IV Single 6 (3M + 3F) (Water for dose Injection) 2 ReferenceInjection R1_(IV) R2_(IV) IV Single 6 (3M + 3F) dose 3 Test InjectionT1_(IV) T2_(IV) IV Single 6 (3M + 3F) dose

TABLE B Dosage schedule Duration Dose Dose of No. of Sr. No Group (inmg/kg) (in mL/kg) Route treatment animals 1 Negative control N1_(IM)N2_(IM) IM Single dose 6 (3M + 3F) (Water for Injection) 2 ReferenceInjection R1_(IM) R2_(IM) IM Single dose 6 (3M + 3F) 3 Test InjectionT1_(IM) T2_(IM) IM Single dose 6 (3M + 3F)

Rationale of the Study:

The Pressure Application Measurement (PAM) device is a novel,easy-to-use tool for measuring mechanical pain threshold in experimentalpain hypersensitivity models in rodents.

The PAM applies a quantifiable force for direct stimulation of theinjection site and automatic readout of the animal response.

The operator simply wears a special force sensor on thumb and measuresthe force which elicits the animal response (normally, limb withdrawal)as shown in FIG. 1.

Experimental Procedure:

After administration of Negative control, Reference item and test itemby intravenous route/intramuscular route mark will be made at injectionsite so that every time the pain sensitivity will be measure same siteby using transducer/applicator.

Transducer placed at injected site and gradually increases the pressureat peak force elicit the animal response and the Transducer/applicatormeasures the force which elicits the animal response (normally, limbwithdrawal).

Force sensor pass the signals of application force, withdrawal force andduration of highest peak force applied at injected site will be recordin compact PAM controller.

Pain sensitivity will be measure in control, reference and test groupsImmediately (within one minute after injection), 5 min, 10 min, 20 min,1 hr, 2 hr, 4 hr, 8 hr, 12 hr and 24 hrs after injection.

Pain sensitivity will be measure in control, reference and treatedgroups will be compared and difference calculated by using SAS System8.2.

Results: The following parameters are observed to evaluate the painassessment value for the test items. vs. reference item:—

-   -   body weights;    -   Nature, Severity and Duration of pain sensitivity (whether        reversible or not);    -   Pain sensitivity potentials of control, reference and test item        statistical treatment of results, where appropriate. as below    -   Alternatively other models are also adopted to assess the pain        in suitable animal model.    -   The results indicated that though not very significant        reductions in pain in the animals, the prepared injection using        diethyleneglycol monoethylether exhibits comparatively less pain        against following reference injections.    -   It may be concluded logically with prudent scientific judgements        that with a large body surface in human as compared animals, the        perception of pain will be much lesser when similar injections        are injected in human tissues and thus the injections prepared        using Diethyelene glycol monoethyl ether will be beneficial for        the parenteral purpose.

Summary:

From the studies of viscosity for various formulations prepared indiethyele glycol mono ethyl ether, it is imminent that the formulationsare easily drawable in the syringe and can be easily administered in thetissues in the required volume without causing pain at the site ofinjection.

Following injections are tested against the marketed formulation:

-   -   1. Paracetamol injection prepared in Diethyelene glycol        monoethyl ether against Fabrinil    -   2. Triamcinolone Acetonide injection in diethyelene glycol        monoethyl ether against Kenacort.    -   3. Methyl Prednisolone Acetate injection in Diethyele glycol        monoethyl ether against Depo Medrol.    -   4. Nandrolone Decanoate injection in Diethyele glycol monoethyl        ether against Deca Durabolin.    -   5. Progesterone injection in Diethyele glycol monoethyl ether        against Susten 100.    -   6. Pantaprazole Sodium injection Diethyele glycol monoethyl        ether against Pentodec.

Measurement of Pain Sensitivity (Threshold) at Triamcinolone AcetonideInjection Site in Wistar Rats by Intramuscular Route

The aim of the study is to evaluate pain sensitivity at Triamcinoloneacetonide injection site and comparison with reference

Details of Test System: Species Rat (Wistar) Animal age 6-8 weeks Numberof The total number of 8 animals divided into 2 Animals groupscontaining 4 animals (2M + 2F) per group.

Study Design:

Duration S. No Group Dose (in g/kg) Dose (in L/KG) Route of treatmentNo. of animals 1 Reference item 7.2 0.1 IM Single dose 4 (2M + 2F)(Kenacort) 2 Test item 7.2 0.1 IM Single dose 4(2M + 2F) (Triamcinoloneacetonide injection)

Experimental Procedure:

After administration of test and reference item by intramuscularroutemark will be made at injection site so that every time the painsensitivity will be observed same site.

Results:

There were no significant pain sensitivity observed at Triamcinoloneacetonide injected site compared with Kenacort at 15, 30 Min, 1, 2, 4hrs. Kenacort injected animals observed with slightly higher paincompared with Triamcinolone acetonide injection.

Measurement of Pain Sensitivity (Threshold) at Progesterone InjectionSite in Wistar Rats by Intramuscular Route

The amin of the study is to evaluate pain sensitivity at Progesteroneinjection site and comparison with reference

Details of Test System: Species Rat (Wistar) Animal age 6-8 weeks Numberof The total number of 8 animals divided into 2 Animals groupscontaining 4 animals (2M + 2F) per group.

Study Design:

Dose Dose Duration S. (in (in of No. of No Group g/kg) L/KG) Routetreatment animals 1 Reference item 0.9 0.009 IM Single dose 4 (2M + 2F)(SUSTEN100) 2 Test item 0.9 0.009 IM Single dose 4 (2M + 2F)(Progesterone injection)

Experimental Procedure:

After administration of test and reference item by intramuscular routemark will be made at injection site so that every time the painsensitivity will be observed same site.

Results:

There were no significant pain sensitivity observed at Progesteroneinjected site compared with SUSTEN100 at 15, 30 Min, 1, 2, 4 hrs.SUSTEN100 injected animals observed with slightly higher pain comparedwith Progesterone injection.

Measurement of Pain Sensitivity (Threshold) at Nandrolone DecanoateInjection Site in Wistar Rats by Intramuscular Route

The aim of the study is to evaluate pain sensitivity at NandroloneDecanoate injection site and comparison with reference

Details of Test System: Species Rat (Wistar) Animal age 6-8 weeks Numberof The total number of 8 animals divided into 2 Animals groupscontaining 4 animals (2M + 2F) per group.

Study Design:

Dose (in Dose (in Duration of No. of S. No. Group mg/kg) mL/kg) Routetreatment animals 1 Reference item (DECA- 18 0.18 IM Single dose 4 (2M +2F) DURABOLIN) 2 Test item 18 0.18 IM Single dose 4 (2M + 2F)(NandroloneDecanoate injection)

Experimental Procedure:

After administration of test and reference item by intramuscular routemark will be made at injection site so that every time the painsensitivity will be observed same site.

Results:

There were no significant pain sensitivity observed at NandroloneDecanoate injected site compared with DECA-DURABOLIN at 15, 30 Min. 1,2, 4 hrs. DECA-DURABOLIN injected animals observed with slightly higherpain compared with Progesterone injection.

Measurement of Pain Sensitivity (Threshold) at Methyl PrednisoloneInjection Site in Wistar Rats by Intramuscular Route

The aim of the study I to evaluate pain sensitivity at MethylPrednisolone injection site and comparison with reference

Details of Test System: Species Rat (Wistar) Animal age 6-8 weeks Numberof The total number of 8 animals divided into Animals 2 groupscontaining 4 animals (2M + 2F) per group.

Study Design:

Dose Dose Duration No. S. No. Group (in mg/kg) (in mL/kg) Route oftreatment of animals 1 Reference item (DEPO- 7.2 0.17 IM Single dose 4MEDROL) (2M + 2F) 2 Test item 7.2 0.17 IM Single dose 4 (MethylPrednisolone (2M + 2F) injection)

Experimental Procedure:

After administration of test and reference item by intramuscular routemark will be made at injection site so that every time the painsensitivity will be observed same site.

Results:

There were no significant pain sensitivity observed at MethylPrednisolone injected site compared with DEPO-MEDROL at 15, 30 Min. 1,2, 4 hrs. DEPO-MEDROL injected animals observed with slightly higherpain compared with Methyl Prednisolone injection.

Measurement of Pain Sensitivity at Paracetamol Injection Site in WistarRats by Intramuscular Route

The aim of the study is to evaluate pain sensitivity at paracetamolinjection site and comparison within reference

Study Design:

Details of Test system Species Rat (Wistar) Animal age 6-8 weeks NumberThe total number of 8 animals divided in to 2 of animals groupcontaining 4 animals (2M + 2F) per group S. Dose (in Dose (in Durationof No. Group mg/kg) mL/kg) Route treatment No. of animal 1 Referenceitem 27 0.18 IM Single dose 4(2m + 2F) (febtinil) 2 Test item 27 0.18 IMSingle dose 4(2m + 2F) (Paracetamol injection 150 g/ml)

Experimental Procedure:

After administration of test and reference item by intramuscular routemark all be made at injection site so that every time the painsensitivity will be observed same site

Results:

There were no significant pain sensitivity observed a paracetamolinjection 150 mg/ml injected site compared with Febrinil at 15.30 Min 1,2, 4 hrs, Febrinil injected animal observed with slightly higher paincompared with paracetamol injection 150 mg/mL injection.

Measurement of Pain Sensitivity (Threshold) at Pantoprazole InjectionSite in Wistar Rats by Intravenous Route Study Design:

Details of Test system Species Rat (Wistar) Animal age 6-8 weeks NumberThe total number of 8 animals divided in to 2 group of animalscontaining 4 animals (2M + 2F) per group S. Dose (in Dose (in Durationof No. Group mg/kg) mL/kg) Route treatment No. of animal 1 Referenceitem 3.6 0.9 IV Single dose 4(2m + 2F) (Pantrodac i.v) 2 Test item 3.60.9 IV Single dose 4(2m + 2F) (Pantoprazole injection)

Experimental Procedure:

After administration of test and reference item by intravenous routemark all be made at injection site so that every time the painsensitivity will be observed same site

Results:

There were no significant pain sensitivity observed at PantoprazoleInjected site compared with Pantodac i.v at 15.30 Min 1, 2, 4 hrs,Pantodac i.v injected animals observed with slightly higher paincompared with Pantoprazole injection.

We claim:
 1. A stable clear liquid pharmaceutical composition comprisinga pharmaceutical active and Diethylene glycol monoethyl ether or another alkyl derivative thereof.
 2. The pharmaceutical compositionaccording to claim 1, wherein the pharmaceutical active is a lipophilicactive or a hydrophilic active.
 3. The pharmaceutical compositionaccording to claim 1, for parenteral administration.
 4. Thepharmaceutical composition according to claim 3, wherein theadministration is intravenous, intramuscular, subcutaneous or ocular. 5.The pharmaceutical composition according to claim 1, further comprisinga preservative, a buffering agent, an antioxidant, a chelating agent, astabilizer or a co-solvent.
 6. The pharmaceutical composition accordingto claim 1, wherein the pharmaceutical active is selected from the groupconsisting of an Antacid; an Antireflux Agent and Antiulcerant; a GITRegulator; an Antiflatulent; an Anti-inflammatory Agent; anAntispasmodic Agent; an Antidiarrheal Agent; a Laxative; a Purgative; aCholagogue; a Cholelitholytic; a Hepatic Protector; an AnorectalPreparation; an Antiemetic Agent; a Gastrointestinal Drug; a CardiacDrug; an Anti-anginal Drug; an ACE Inhibitor/Direct Renin Inhibitor; aBeta Blocker; a Calcium Channel Blocker; an Angiotensin II Antagonist;an Antihypertensive; a Diuretic; an Antidiuretic Agent; a PeripheralVasodilator and Cerebral Activator; a Vasoconstrictor; a DyslipidaemicAgent; a Haemostatic; an Anticoagulant; an Antiasthmatic and COPDPreparation; a Cough and Cold Preparation; a Nasal Decongestant; aRespiratory System Drug; an Anxiolytic Agent; a Hypnotic and Sedative;an Antidepressant; an Antipsychotic Agent; an Anticonvulsant; anAntiparkinsonian Drug; an Analgesic (Opioid & Non-Opioid) andAntipyretic; a NSAID; a Musculo-skeletal System Drug; a Hormone; aSteroids and Contraceptive Agent; an Antibiotic; an Antifungal Agent; anAntiviral Agent; an Antimalarial Agent; an Antiamoebic; an AntiprotozoalAgent; an Anti-tubercular; an Antibacterial Combination; a Macrolides;an Anticancer Agent; a Genito-urinary Drug; An Endocrine & MetabolicSystem Drug; a Vitamin and Mineral; a Nutrition Drug belonging to Eye,Nose, Ear & Mouth/Throat; a Dermatological; an Anesthetic—Local andGeneral; a Drug belonging to Allergy and Immune System; an Antidote; anda Detoxifying Agent & Drug used in Substance Dependence.
 7. Apharmaceutical composition according to claim 6, wherein thepharmaceutical active is selected from the group consisting ofProgesterone, Nandrolone, Nandrolone Decanoate, Nandrolone PhenylPropionate, Testosterone, Testosterone Enanthate, TestesteroneCypionate, Norethisterone Enanthate, 17β Estradiol, Fulvestrant,Artemether, Arteether, Haloperidol, Vitamin D₃, Allylestrenol,Etoricoxib, Firocoxib, Mavacoxib, Robernacoxib, Cimicoxib, Tilmacoxib,Celecoxib, Boldenone Undecylanate, Drostanolone Propionate, TrenboloneAcetate, Trenbolone Enanthate, Methenolone Enanthate, MethylTestesterone, Cyclosporine, Paclitaxel, Piroxicam, Clonazepam, Diazepam,Hydrocortisone, Hydrocortisone Acetate, Carboprost, Artesunate, SodiumArtesunate, Ergotamine Maleate, Lansoprazole, Dexlansoprazole,Fluconazole, Enalapril, Methocarbamol, Lignocaine, Azithromycin,Digoxin, Dicyclomine, Dicyclomine & Diclofenac combination, Paracetamol,Pentazocine, Fenatyl, Fenatyl Citrate, Prostaglandin E₁, Omeprazole andits metallic salts, Rabeprazole and its metallic salts, Pantaprazole andits metallic salts, Lornoxicam, Etoposide, Docetaxel, Leuprolide,Clarithromycin, Voriconazole, Vecuronium, Atracurium, Cisatracurium,Doxacurium, Tubocurarine, Pipecuronium, Rocuronium, Pancuronium,Atracurium Besylate, Cisatracurium Besylate, Ibuprofen, Prednisolone,Methyl Prednisolone, Methyl Prednisolone Acetate, Medroxy ProgesteroneAcetate, Triamcinolone Acetonide, Stanozolol, Propofol, ClevidipineButyrate, Vitamin K, Vitamin K₁, Vitamin K₂, Aspirin, Choline MagnesiumTrisalicylate, Diflunisal and Salsalate, Fenoprofen, Fluriprofen,Ketoprofen, Naproxen, Oxaprozin, Aceclofenac, Indomethacin, Sulindac,Tolmetin, Meclofenamate, Mefenamic Acid, Nabumetone, Etodolac,Ketorolac, Ethinylestradiol, Terbinafine, Roxythromycin, Spironolactone,Eplerenone, Amlodipine Besylate, Barnidipine Hydrochloride, BenidipineHydrochloride, Nifedipine, Clinidipine, Darodipine, Nimodipine,Nisoldipine, Nitrendipine, Felodipine, Nicardipine, Isradipine,Captopril, Ramipril, Fosinopril, Zofenopril, Perindopril, Quinapril,Lisinopril, Isoxsuprine Hydrochloride, Brinzolamide, Difuprednate,Fluorometholone Acetate, Loteprednol, Besifloxacin, Loteprednol andTobramycin Combination, Brimonidine and Brinzolamide Combination,Rimexolone, Sulfacetamide, Sulfacetamide and Prednisolone AcetateCombination, Tobramycin and Dexamethasone Combination, Neomycin Sulphateand Dexamethasone Combination, Nepafenac, Betaxolol Hydrochloride,Ciprofloxacin, Ciprofloxacin and Dexamethasone Combination, Tadalafil,Vinpocetine, Itraconazole, Nimodipine, Ezetimibe, Valproic Acid,Bexarotene, Tretinoin, Loperamide, Melphalan, Loxapine, Amilsulpride,Tacrolimus, Doxorubicin, Olanzapine, Fluticasone Propionate, Prilocaine,and Tioconazole.
 8. The pharmaceutical composition according to claim 1,wherein the pharmaceutical active is not milled or micronized prior touse.
 9. The pharmaceutical composition according to claim 1, wherein thealkyl derivative of Diethylene glycol monoethyl ether is methyl,n-propyl, iso-propyl, n-butyl, iso-butyl or hexyl ether.
 10. Thepharmaceutical composition according to claim 1, wherein said Diethyleneglycol monoethyl ether or an other alkyl derivative thereof is presentin an amount of 1% to 100% by volume of the pharmaceutical active. 11.The pharmaceutical composition according to claim 5, wherein thebuffering agent is selected from the group consisting of 0.1 N Sodiumhydroxide, Acetic acid, Sodium citrate, Potassium chloride, Sodiumchloride, Citric acid, Sodium bicarbonate, L-Arginine, Tris buffers,Cholic acid Derivatives, and Amino acid Derivatives.
 12. Thepharmaceutical composition according to claim 5, wherein thepreservative is Benzyl alcohol, Methyl paraben, Propyl paraben,Thiomerosol, a Phenyl mercuric salt (acetate, borate, nitrate),Chlorobutanol or Meta-cresol,
 13. The pharmaceutical compositionaccording to claim 12, wherein the preservative is present in an amountof 0.001% to 2% by weight of the composition.
 14. The pharmaceuticalcomposition according to claim 5, wherein the antioxidant is selectedfrom the group consisting of Ascorbic acid, Ascorbyl palmitate,Thioglycerol and its derivatives, Sodium bisulphate, Sodiummetabisulphite, Sodium formaldehyde sulphoxylate, Thiourea, Ascorbicacid ester, Butylated hydroxyl toluene or Tocopherols.
 15. Thepharmaceutical composition according to claim 14, wherein theantioxidant is present in an amount of 0.004% to 2% by weight of thecomposition.
 16. The pharmaceutical composition according to claim 5,wherein the chelating agent is Ethylene diamine tetraacetic acid, in anamount of 0.01% to 0.075% by weight of the composition.
 17. Thepharmaceutical composition according to claim 5, wherein the stabilizeris Maleic acid or a Malate salt.
 18. The pharmaceutical compositionaccording to claim 1, for preparation of a capsule, a tablet, a nasalspray, a gargle, a gel, a cream, an ointment, an eye drop, a topical ora liquid oral dosage form.
 19. A stable clear liquid pharmaceuticalcomposition comprising a steroidal pharmaceutical active and Diethyleneglycol monoethyl ether.
 20. The pharmaceutical composition according toclaim 19, wherein the steroidal pharmaceutical active is selected fromthe group consisting of Progesterone, Nandrolone, Nandrolone Decanoate,Nandrolone Phenyl Propionate, Testosterone, Testosterone Enanthate,Testesterone Cypionate, Norethisterone Enanthate, 17β Estradiol,Fulvestrant, Boldenone Undecylanate, Drostanolone Propionate, TrenboloneAcetate, Trenbolone Enanthate, Methenolone Enanthate, MethylTestesterone, Hydrocortisone, Hydrocortisone Acetate, Prostaglandin E₁,Prednisolone, Methyl Prednisolone, Methyl Prednisolone Acetate, MedroxyProgesterone Acetate, Triamcinolone Acetonide, Stanozolol,Ethinylestradiol, Difuprednate, Fluorometholone Acetate, Loteprednol,Rimexolone, Spironolactone, Eplerenone and Fluticasone Propionate. 21.The composition of claim 1, wherein said pharmaceutical active is anon-steroidal drug.
 22. The pharmaceutical composition according toclaim 21, wherein the non-steroidal drug is selected from the groupconsisting of an analgesic, an antipyretic and an anti-inflammatoryagent.
 23. The pharmaceutical composition according to claim 22, whereinthe analgesic, antipyretic or a anti-inflammatory agent is selected fromthe group consisting of Etoricoxib, Firocoxib, Mavacoxib, Robernacoxib,Cimicoxib, Tilmacoxib, Celecoxib, Piroxicam, Paracetamol, Pentazocine,Fenatyl, Fenatyl Citrate, Lornoxicam, Aspirin, Choline MagnesiumTrisalicylate, Diflunisal and Salsalate, Ibuprofen, Fenoprofen,Fluriprofen, Ketoprofen, Naproxen, Oxaprozin, Aceclofenac, Indomethacin,Sulindac, Tolmetin, Meclofenamate, Mefenamic Acid, Nabumetone, Etodolac,Ketorolac and Nepafenac.